

University of Pennsylvania

Philadelphia, Pennsylvania

Reports on Federal Awards in

Accordance with OMB Uniform Guidance

June 30, 2021

Federal Entity Identification

Number 23-1352685

**University of Pennsylvania
Reports on Federal Awards in
Accordance with OMB Uniform Guidance
Index
June 30, 2021**

	Page(s)
I. Financial	
Report of Independent Auditors.....	i–ii
Consolidated Financial Statements	1–3
Notes to Consolidated Financial Statements	4–37
Schedule of Expenditures of Federal Awards	38–107
Notes to Schedule of Expenditures of Federal Awards	108
II. Internal Control and Compliance	
Report of Independent Auditors on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	109–110
Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control over Compliance in Accordance with the Uniform Guidance	111–113
III. Findings	
Schedule of Findings and Questioned Costs	114–121
Summary Schedule of Prior Audit Findings	122
Management's View and Corrective Action Plan	123–126

I. Financial



Report of Independent Auditors

To the Trustees of the University of Pennsylvania:

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of the University of Pennsylvania (the "University"), which comprise the consolidated statements of financial position as of June 30, 2021 and 2020, and the related consolidated statements of activities and of cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the University's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the University of Pennsylvania as of June 30, 2021 and 2020, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.



Other Matters

Other Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30, 2021 is presented for purposes of additional analysis as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and is not a required part of the consolidated financial statements. The information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated September 23, 2021 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2021. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.

A handwritten signature in cursive script that reads "PricewaterhouseCoopers LLP".

Philadelphia, Pennsylvania
September 23, 2021

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

University of Pennsylvania

(in thousands)

	June 30,	
	2021	2020
ASSETS		
Cash and cash equivalents	\$ 2,406,233	\$ 2,117,979
Accounts receivable, net	1,729,614	1,233,120
Contributions receivable, net	473,580	478,150
Loans receivable, net	60,953	63,398
Other assets	951,435	872,383
Investments, at fair value	23,039,002	16,870,116
Property, plant and equipment, net	9,176,028	8,778,085
TOTAL ASSETS	\$ 37,836,845	\$ 30,413,231
LIABILITIES		
Accounts payable	\$ 384,829	\$ 313,884
Accrued expenses and other liabilities	4,126,911	3,646,811
Deferred income	190,697	189,920
Deposits and advances	215,936	220,114
Federal student loan advances	47,039	51,822
Accrued retirement benefits	1,314,769	1,968,251
Debt obligations	4,607,594	4,456,160
TOTAL LIABILITIES	10,887,775	10,846,962
NET ASSETS		
Without donor restrictions	15,903,927	11,366,361
With donor restrictions	11,045,143	8,199,908
TOTAL NET ASSETS	26,949,070	19,566,269
TOTAL LIABILITIES AND NET ASSETS	\$ 37,836,845	\$ 30,413,231

The accompanying notes are an integral part of these consolidated financial statements.

CONSOLIDATED STATEMENTS OF ACTIVITIES

University of Pennsylvania
for the years ended June 30, 2021 and 2020
(in thousands)

	2021	2020
WITHOUT DONOR RESTRICTIONS:		
REVENUE AND OTHER SUPPORT		
Tuition and fees, net	\$ 1,105,104	\$ 1,176,737
Commonwealth appropriations	35,144	35,144
Sponsored programs	1,150,055	1,074,494
Contributions and donor support	202,184	210,894
Investment income	853,555	744,911
Net patient service revenue	7,536,453	6,803,782
Other income	1,774,703	1,264,004
TOTAL REVENUE AND OTHER SUPPORT	12,657,198	11,309,966
EXPENSES		
Compensation and benefits	6,713,886	6,313,668
Depreciation and amortization	552,935	535,003
Interest on indebtedness	88,036	87,760
Other operating expenses	4,246,611	4,008,255
TOTAL EXPENSES	11,601,468	10,944,686
INCREASE IN NET ASSETS FROM OPERATIONS	1,055,730	365,280
NONOPERATING ACTIVITIES		
Return on investments, net of amounts classified as operating revenue	2,704,552	(114,855)
Pension, OPEB and other, net	740,871	(374,803)
Contributions and donor support for capital related activities	36,413	98,487
TOTAL NONOPERATING ACTIVITIES	3,481,836	(391,171)
INCREASE (DECREASE) IN NET ASSETS WITHOUT DONOR RESTRICTIONS	4,537,566	(25,891)
WITH DONOR RESTRICTIONS:		
Contributions	460,862	478,490
Return on investments, net	2,903,720	231,372
Net assets released from restrictions	(519,347)	(542,535)
INCREASE IN NET ASSETS WITH DONOR RESTRICTIONS	2,845,235	167,327
INCREASE IN TOTAL NET ASSETS	7,382,801	141,436
Total net assets, beginning of year	19,566,269	19,424,833
TOTAL NET ASSETS, END OF YEAR	\$26,949,070	\$19,566,269

CONSOLIDATED STATEMENTS OF CASH FLOWS

University of Pennsylvania
for the years ended June 30, 2021 and 2020
(in thousands)

	2021	2020
CASH FLOWS FROM OPERATING ACTIVITIES:		
Increase in total net assets	\$ 7,382,801	\$ 141,436
Adjustments to reconcile increase in total net assets to net cash provided by operating activities:		
Depreciation and amortization	533,111	516,878
Provision for bad debts	9,793	7,925
Gain on investments, net	(5,940,709)	(372,476)
(Gain) loss on disposal of plant, property and equipment	(13,029)	1,824
Donated equipment	(318)	-
Receipt of contributed securities	(109,309)	(134,329)
Proceeds from contributed securities	28,426	26,350
Receipt of contributions designated for the acquisition of long-lived assets and long-term investment	(246,724)	(231,406)
Pension, OPEB and other, net	(740,871)	374,803
Changes in operating assets and liabilities:		
Accounts and loans receivable	(504,074)	(3,700)
Contributions receivable	4,801	10,878
Other assets	(24,912)	(49,605)
Accounts payable, accrued expenses and accrued retirement benefits	532,585	685,623
Deposits and advances	(5,880)	30,310
Deferred income	777	(2,382)
NET CASH PROVIDED BY OPERATING ACTIVITIES	906,468	1,002,129
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of investments	(16,837,731)	(16,043,267)
Proceeds from sale of investments	16,734,521	16,168,730
Purchase of property, plant and equipment	(957,675)	(1,397,560)
NET CASH USED BY INVESTING ACTIVITIES	(1,060,885)	(1,272,097)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from contributions received designated for the acquisition of long-lived assets and long-term investment	246,723	231,407
Proceeds from contributed securities received designated for the acquisition of long-lived assets and long-term investment	79,748	107,643
Federal student loan advances	(4,783)	(19,443)
Repayment of debt obligations	(234,545)	(598,091)
Proceeds from issuances of debt obligations	407,000	1,290,962
NET CASH PROVIDED BY FINANCING ACTIVITIES	494,143	1,012,478
NET INCREASE IN CASH AND CASH EQUIVALENTS	339,726	742,510
Cash and cash equivalents, beginning of year	2,117,979	1,375,469
CASH AND CASH EQUIVALENTS, END OF YEAR	\$ 2,457,705	\$ 2,117,979
RECONCILIATION TO CONSOLIDATED STATEMENTS OF FINANCIAL POSITION:		
Cash and cash equivalents, end of year	\$ 2,457,705	\$ 2,117,979
Cash included in Investments, at fair value	(51,472)	-
CASH AND CASH EQUIVALENTS, CONSOLIDATED STATEMENTS OF FINANCIAL POSITION	\$ 2,406,233	\$ 2,117,979
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:		
Cash paid for interest, net of amounts capitalized	\$ 97,375	\$ 83,526
Contributed securities received	109,309	134,329
Decrease in accrued plant, property and equipment	(6,946)	(53,778)
Operating cash flows for operating leases	72,127	61,093
Right-of-use assets obtained in exchange for lease liabilities	64,950	497,406

The accompanying notes are an integral part of these consolidated financial statements.

1. SIGNIFICANT ACCOUNTING POLICIES

Organization

The University of Pennsylvania (“University”), located in Philadelphia, Pennsylvania, is an independent, nonsectarian, not-for-profit institution of higher learning founded in 1740. The University Academic Component (“Academic Component”) provides educational services, primarily for students at the undergraduate, graduate, professional and postdoctoral levels and performs research, training and other services under grants, contracts and similar agreements with sponsoring organizations, primarily departments and agencies of the United States Government. The University also operates an integrated health care delivery system, the University of Pennsylvania Health System (“UPHS”). The University is a tax-exempt organization under Section 501(c)(3) of the Internal Revenue Code.

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include the accounts of the University and its subsidiaries over which the University has a controlling financial interest or exercises control. All material transactions between the University and its subsidiaries are eliminated in consolidation. Investments in subsidiaries over which the University has the ability to exercise significant influence are reported using the equity method of accounting. Other investments in subsidiaries are reported using the measurement alternative – at cost adjusted for impairment, if any, unless an observable transaction for an identical or similar security occurs.

The net assets of the University are classified and reported as follows:

Without donor restrictions – includes net assets that are not subject to donor-imposed restrictions.

With donor restrictions – includes net assets that are (i) subject to legal or donor-imposed restrictions that will be met by actions of the University and/or the passage of time, and (ii) the original values of donor restricted net assets, the use of which is limited to investment and can only be appropriated for expenditure by the University in accordance with the Pennsylvania Uniform Principal and Income Act (Pennsylvania Act).

Expenses are reported as a decrease in net assets without donor restrictions. Gains and losses on investments are reported as increases or decreases in net assets without donor restrictions unless their use is restricted by explicit donor stipulation or by law. Donor-restricted resources intended for the acquisition or construction of long-lived assets are initially reported as net assets with donor restrictions and released from restrictions to net assets without donor restrictions when the asset is placed in service or in accordance with donor-specified terms.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Expirations of restrictions on contributions and investment income, reported as Net assets released from restrictions, and the corresponding amounts are included in the Consolidated Statements of Activities as follows (in thousands):

Net Assets Without Donor Restrictions	2021	2020
Contributions and donor support	\$ 120,760	\$ 137,572
Investment income	362,174	306,476
Contributions and donor support for capital related activities	36,413	98,487
Net assets released from restrictions	\$ 519,347	\$ 542,535

Net Assets With Donor Restrictions	2021	2020
Net assets released from restrictions	\$ (519,347)	\$ (542,535)

Gains or losses associated with investment activities are included in Return on investments, net. Gains and losses associated with property, plant and equipment disposals are included in Other income and Other operating expenses, respectively. Gains or losses associated with all other activities, such as debt retirements and pension and postretirement plan actuarial valuation adjustments, are reported in Pension, other postretirement employee benefits (OPEB) and other, net.

Fair Value

The University values certain financial and non-financial assets and liabilities by applying the FASB pronouncement on Fair Value Measurements. The pronouncement defines fair value and establishes a framework for measuring fair value that includes a hierarchy that categorizes and prioritizes the sources used to measure and disclose fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The hierarchy is broken down into three levels based on inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the University as follows:

Level 1: Unadjusted quoted market prices in active markets for identical assets or liabilities.

Level 2: Unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable.

Level 3: Unobservable inputs for the asset or liability.

Inputs broadly refer to the assumptions that market participants use to make valuation decisions, including assumptions about risk. Inputs may include price information, volatility statistics, specific and broad credit data, liquidity statistics and other factors. The University is required by the pronouncement to maximize the use of observable inputs (Levels 1 and 2) and minimize the use of unobservable inputs (Level 3). The University considers observable data to be that market data which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary and provided by independent sources that are actively involved in the relevant market. The categorization of a financial instrument within the hierarchy is based upon the pricing transparency of the instrument and does not necessarily correspond to the University's perceived risk of that instrument.

Assets and liabilities are disclosed in the Notes to Consolidated Financial Statements within the hierarchy based on the lowest (or least observable) input that is significant to the measurement. The University's assessment of the significance of an input requires judgment, which may affect the valuation and categorization within the fair value hierarchy. The fair value of assets and liabilities using Level 3 inputs are generally determined by using

pricing models or discounted cash flow methods, which all require significant management judgment or estimation.

As a practical expedient, the University is permitted to estimate the fair value of an investment in an investment company at the measurement date using the reported net asset value (NAV). Adjustment is required if the University expects to sell the investment at a value other than NAV or if the NAV is not calculated in accordance with U.S. GAAP. The University holds investments in its portfolio which are generally valued based on the most current NAV. This amount represents fair value of these investments at June 30, 2021 and 2020. Investments reported at NAV, as a practical expedient, are not included within levels 1, 2, or 3 in the fair value hierarchy.

The University performs additional procedures, including due diligence reviews, on its investments in investment companies and other procedures with respect to the capital account or NAV provided to ensure conformity with US GAAP. The University has assessed factors including, but not limited to, managers' compliance with the *Fair Value Measurement* standard, price transparency and valuation procedures in place.

Cash and Cash Equivalents

Cash equivalents include demand deposits and liquid investments available for current operations with maturities of three months or less, which would be considered Level 1 investments under the fair value hierarchy. All short-term, highly liquid investments, otherwise qualifying as cash equivalents or restricted cash equivalents, included in the University's investments are treated as Investments, at fair value and are therefore excluded from Cash and cash equivalents in the Statements of Cash Flows.

Investments, at Fair Value

The majority of the University's investments are held in the Associated Investments Fund (AIF). The AIF is invested in accordance with the investment policies set out by an Investment Board which has been appointed by the Trustees of the University of Pennsylvania (the Trustees). The Office of Investments is responsible for the day-to-day management of the AIF including identifying, selecting and monitoring a variety of external investment managers to implement the strategic asset allocation set forth by the Investment Board. The AIF may include marketable and not readily marketable securities that it intends to hold for an indefinite period of time. The University also holds other investments which are not invested in the AIF due to various restrictions. The majority of these investments are in highly liquid short-term and equity type investments. Changes in the fair value of investments are reported in Return on investments, net in the Consolidated Statements of Activities. The following is a summary of the investments held in the AIF by asset allocation as well as investment risk:

Short-Term

Short-term investments include cash equivalents and fixed income investments with maturities of less than one year. Short-term investments are valued using observable market data and are categorized as Level 1 based on quoted market prices in active markets. The majority of these short-term investments are held in a US Treasury money market account.

Equity

Equity investments consist of direct holdings of public securities in managed accounts as well as mutual funds and private funds. The securities held in managed accounts, along with mutual funds, are generally valued based on quoted market prices in active markets obtained from exchange or dealer markets for identical assets, and are accordingly categorized as Level 1. Private funds are valued at NAV.

Debt

Debt investments consist of direct holdings of securities in managed accounts and private funds. Securities such as US Treasuries, held in managed accounts, are valued based on quoted market prices in active markets and are categorized as Level 1. Securities such as corporate and sovereign bonds, also held in managed accounts, are valued based on quoted market prices or dealer or broker quotations and are categorized as Level 2 or in the cases where inputs are unobservable as Level 3. Private funds are valued at NAV.

Absolute Return

Absolute return investments are made up of allocations to private funds. The fund managers of these private funds invest in a variety of securities, based on the strategy of the fund, which may or may not be quoted in an active market. Private funds are valued at NAV.

Real Estate

Investments in real estate are primarily in the form of private funds. The fund managers of these private funds primarily invest in investments for which there is no readily determinable market value. The fund managers may value the underlying investments based on an appraised value, discounted cash flow, industry comparables or some other method. Private funds are valued at NAV.

Private Equity

Investments in private equity are in the form of close-ended private funds. The fund managers primarily invest in investments for which there is no readily determinable market value. The fund managers may value the underlying private investments based on an appraised value, discounted cash flow, industry comparables or some other method. These private fund investments are valued at NAV.

Natural Resources

Investments in natural resources are made up of private funds and securities in managed accounts. The fund managers of these private funds primarily invest in investments for which there is no readily determinable market value. The fund managers may value the underlying investments based on an appraised value, discounted cash flow, industry comparables or some other method. Private funds are valued at NAV. The securities held in managed accounts are generally valued based on quoted market prices in active markets obtained from exchange or dealer markets for identical assets, and are accordingly categorized as Level 1.

Derivatives

The University, in the normal course of business, utilizes derivative financial instruments in connection with its investment activity. Derivatives utilized by the University include futures, options, swaps and forward currency contracts and are reflected at fair value following the definition of Level 1 and 2 assets and liabilities as previously described. Investments in derivative contracts are subject to foreign exchange and equity price risks that can result in a loss of all or part of an investment. In addition, the University is also subject to additional counterparty risk should its counterparties fail to meet the terms of their contracts.

Investment Risks

The University's investing activities expose it to a variety of risks including market, credit and liquidity risks. The University attempts to identify, measure and monitor risk through various mechanisms including risk management strategies and credit policies.

Market risk is the potential for changes in the fair value of the University's investment portfolio. Commonly used categories of market risk include currency risk (exposure to exchange rate differences between functional currency relative to other foreign currencies), interest rate risk (changes to prevailing interest rates or changes in expectations of futures rates) and price risk (changes in market value other than those related to currency or interest rate risk, including the use of NAV provided).

Credit risk is the risk that one party to a financial investment will cause a financial loss for the other party by failing to discharge an obligation (counterparty risk).

Liquidity risk is the risk that the University will not be able to meet its obligations associated with financial liabilities.

Endowment

The University's endowment consists of 7,196 donor-restricted endowment funds and 944 quasi-endowment funds established by management for a variety of purposes. The University reports all endowment investments at fair value. Most of the endowment funds of the University have been pooled in the University's AIF. The endowment funds not pooled in the AIF are primarily invested in equities and bonds.

The Commonwealth of Pennsylvania has not adopted the Uniform Management of Institutional Funds Act (UMIFA) or the Uniform Prudent Management of Institutional Funds Act (UPMIFA). Rather, the Pennsylvania Act governs the investment, use and management of the University's endowment funds.

The Pennsylvania Act does not require the preservation of the fair value of a donor's original gift as of the gift date of a donor-restricted endowment fund, absent explicit donor stipulations to the contrary. However, based on its interpretation of the Pennsylvania Act and relevant accounting literature, the University classifies the following as net assets with donor restrictions for reporting purposes: (i) the original value of donated assets required to be invested in perpetuity; (ii) the original value of subsequent donated assets required to be invested in perpetuity; (iii) accumulations to the donated assets invested in perpetuity made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund; and (iv) donated assets and accumulations that are subject to legal or donor-imposed restrictions that will be met by actions of the University and/or the passage of time. The Pennsylvania Act allows a nonprofit to elect to appropriate for expenditure between 2% and 7% (increased to 10% for fiscal years 2020 through 2022) of the endowment fair value, determined at least annually and averaged over a period of three or more preceding years, including funds whose fair value is less than the original donated value.

In accordance with the Pennsylvania Act, the University has elected to adopt and follow an investment policy seeking a total return for the investments held by the AIF, whether the return is derived from appreciation of capital or earnings and distributions with respect to capital or both. The endowment spending policy which the Board of Trustees has elected to govern the expenditure of funds invested in the AIF, including funds whose fair value is less than the original donated value, is designed to manage annual spending levels and is independent of the cash yield and appreciation of investments for the year. For fiscal year 2021, the spending rule payout is based on the sum of: (i) 70% of the prior fiscal year distribution adjusted by an inflation factor; and (ii) 30% of the prior fiscal year-end fair value of the AIF, lagged one year, multiplied by a 7% target spending rate for all funds. The payout or allocation to operations exceeded actual income, net of expenses, by \$797,492,000 and \$654,691,000 in 2021 and 2020, respectively.

Property, Plant and Equipment

Property, plant and equipment (PPE) is reported net of related depreciation. Donated PPE is reported based on estimated fair value at the date of acquisition. All other PPE is reported at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the assets, or the shorter of the lease term or estimated useful life for leased assets. Contributions of library materials, as well as rare books and other collectibles, are not recorded for financial statement presentation, while purchases are recorded as Other operating expenses on the Consolidated Statement of Activities in the period acquired.

Split-Interest Agreements

The University's split-interest agreements with donors consist of irrevocable charitable remainder trusts, charitable gift annuities, pooled income funds, perpetual trusts and charitable lead trusts. Assets are invested and payments are made to donors and/or other beneficiaries in accordance with the respective agreements.

The University recognizes assets contributed to charitable remainder trusts, charitable gift annuities and pooled income funds, where it serves as trustee, at fair value, recognizes a liability to the beneficiaries based on the present value of the estimated future payments to beneficiaries to be made over the estimated remaining life of those beneficiaries using current market rates at the date of the contribution, and recognizes the difference as contribution revenue. Subsequently, the trust assets, invested in equity and debt securities, are measured at fair value at quoted market prices, and are categorized as Level 1, with the changes reported as an adjustment to Investments, at fair value on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities. Liabilities to beneficiaries are revalued based on current market rates, and are categorized as Level 2, with the changes reported as an adjustment to Accrued expense and other liabilities on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities.

Charitable remainder trust assets, where the University does not serve as trustee, are initially valued using the current fair value of the underlying assets, using observable market inputs based on its beneficial interest in the trust, discounted to a single present value using current market rates at the date of the contribution. The initially contributed assets are categorized as Level 3, and reported as Investments, at fair value on the Consolidated Statements of Financial Position and Contribution revenue on the Consolidated Statements of Activities. Subsequent valuation follows this same approach with changes in fair value reported as an adjustment to Investments, at fair value on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities. The primary unobservable input used in the fair value measurement of the charitable remainder trust assets is the discount rate.

Perpetual trust assets are initially valued at the current fair value of the underlying assets using observable market inputs based on its beneficial interest in the trust. The initially contributed assets are categorized as Level 3 and are reported as Investments, at fair value on the Consolidated Statements of Financial Position and as Contribution revenue on the Consolidated Statements of Activities. Subsequent valuation follows this same approach with changes in fair value reported as an adjustment to Investments, at fair value on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities. The primary unobservable inputs used in the fair value measurement of the perpetual trust assets are the underlying securities held by the trust.

The University reports charitable lead trust assets by discounting future cash flows using current market rates at the measurement date, matched to the payment period of the agreement. The initially contributed assets are categorized as Level 3, and reported as Investments, at fair value on the Consolidated Statements of Financial Position and as Contribution revenue on the Consolidated Statements of Activities. Subsequent valuation follows this same approach with changes in fair value reported as an adjustment to Investments, at fair value on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities. The primary unobservable input used in the fair value measurement of the charitable lead trust assets is the discount rate.

Income Taxes

The University is a tax-exempt organization under Section 501(c)(3) of the Internal Revenue Code. Most of its activities and income are related to its exempt purposes and are exempt from federal and state income taxes. None of its activities and income is subject to Pennsylvania income tax. Unrelated activities and income are subject to federal "Unrelated Business Income Tax."

The University regularly evaluates its tax position and does not believe it has any uncertain tax positions that require disclosure or adjustment to the consolidated financial statements.

Tuition and Fees

Tuition and fees includes tuition, room and board, and other student fees which are recognized as revenue over time during the fiscal year in which the related academic services are rendered. Tuition and fees received in advance of services to be rendered are reported as Deferred income on the Consolidated Statements of Financial Position. The University maintains a policy of offering qualified applicants admission to the University without regard to financial circumstance, as well as meeting in full the demonstrated financial need of those admitted. Tuition and fees have been reduced by certain grants and scholarships in the amount of \$349,592,000 and \$360,863,000 in 2021 and 2020, respectively.

Sponsored Programs

Sponsored programs includes revenue from exchange and conditional non-exchange agreements with governments, foundations and private sources, generally for research activities. Revenue from exchange agreements is generally recognized at a point in time when performance obligations are met, and revenue from conditional non-exchange agreements is generally recognized as the related costs are incurred. Non-exchange agreements are considered conditional if the terms of the agreement include both a right of return/release of assets received/promised and a barrier. These agreements become unconditional as barriers are met. At June 30, 2021, the University has unrecorded conditional agreements of \$2,437,286,000. In 2021 and 2020, sponsored programs revenue earned from governmental sources totaled \$833,004,000 and \$753,901,000, respectively. Indirect costs recovered on federally-sponsored programs are generally based on predetermined reimbursement rates which are stated as a percentage and distributed based on the modified total direct costs incurred. The University negotiates its federal indirect rates with its cognizant federal agency. Indirect costs recovered on all other grants and contracts are based on rates negotiated with the respective sponsors. Funds received for sponsored research activity are subject to audit. Based upon information currently available, management believes that any liability resulting from such audits will not materially affect the financial position or operations of the University.

Contributions

Contributions are revenues from unconditional non-exchange agreements with private sources and foundations. Contributions are recognized in the period received and reported as increases in the appropriate net asset category based on the presence or absence of donor-imposed restrictions. Non-exchange agreements are considered conditional if the terms of the agreement include both a right of return/release of assets received/promised and a barrier. These agreements become unconditional as barriers are met. Contributions and donor support without donor restrictions also includes net assets released as a result of corresponding expenditures which met donor-imposed restrictions. Contributions designated for the acquisition of long-lived assets and long-term investment are reported in Nonoperating activities.

The University reports unconditional pledges at fair value by discounting future cash flows using current market rates at the measurement date, ranging from 0.32% to 2.26%, matched to the payment period of the agreement, and accordingly categorizes these assets as Level 3. The primary unobservable input used in the fair value measurement of the University's Contributions receivable is the discount rate. Changes in the fair value of the University's Contributions receivable due to fluctuations in the discount rate are reported as Contributions revenue on the Consolidated Statements of Activities.

Net Patient Service Revenue

Net patient service revenue is derived from contracts with patients of UPHS in which its performance obligation is to provide health care services. Net patient service revenue is recorded over time during the period these performance obligations are satisfied and at the determined transaction price, which represents the estimated net realizable amounts due from patients, third-party payers and others for health care services rendered. Estimated net realizable amounts represent amounts due, net of implicit and explicit price concessions. Implicit price concessions are based on management's assessment of expected net collections considering economic conditions, historical experience, trends in health care coverage and other collection indicators. After satisfaction of amounts due from insurance and reasonable efforts to collect from patients have been exhausted, UPHS follows established guidelines for placing certain past-due patient balances with collection agencies, subject to terms of certain restrictions on collection efforts as determined by UPHS. Patient receivables are written off after collection efforts have been followed in accordance with UPHS' policy. Certain revenue received from third-party payers is subject to audit and retroactive adjustment. Any changes in estimates under these contracts are recorded in operations currently.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

COVID-19

In January 2020, the World Health Organization declared the novel strain of coronavirus ("COVID-19") a Public Health Emergency of International Concern. During fiscal year 2020, the COVID-19 pandemic caused disruptions to our nation's healthcare and higher education systems, including the University's. Such disruptions included reductions in availability of staffing and in the availability of personal protective equipment to prevent spread of the disease during patient treatment. Generally, elective procedures were postponed by physicians and acute care facilities to prepare for the expected volume of COVID-19 patients and reduce the risk of exposure to COVID-19. Other negatively impacted areas in fiscal year 2020 included but were not limited to, student enrollment, housing and dining revenues, research, faculty, staff & student travel, investment performance, philanthropy and increased

financial need of students, with some impacts carrying over into fiscal year 2021. The University continues to monitor legislative developments, including future relief funding opportunities, and directives from federal, state, and local officials to determine additional precautions and procedures that may need to be implemented.

In response, on March 27, 2020, the Federal Government passed the Coronavirus Aid, Relief, and Economic Stimulus Act (CARES Act) which made funds available to UPHS and the Academic Component through various provisions of the legislation, including provider relief funding and advanced payments from the Centers for Medicare and Medicaid Services (CMS) Accelerated and Advanced Payments Program. Furthermore, the CARES Act allowed employers to defer the deposits and payments of the employer’s share of the Social Security taxes. The following table summarizes the related impact on the Consolidated Financial Statements as of June 30, 2021 and 2020, and for the years then ended (in thousands):

	Line Item	2021	2020
Consolidated Statements of Activities:			
UPHS Provider relief funding	Other Income	\$ 201,281	\$ 213,160
Consolidated Statements of Financial Position:			
UPHS CMS Accelerated and Advanced Payments Program	Accrued expenses and other liabilities	\$ 535,787	\$ 599,498
Deferral of Social Security taxes	Accrued expenses and other liabilities	180,763	62,045

UPHS recognized revenue related to the CARES Act funding based on information available at June 30, 2021 and 2020, respectively, based upon laws and regulations governing the funding as well as interpretations issued by the Department of Health and Human Services. Due to the volatility of the reporting requirements, there is at least a reasonable possibility that amounts recorded under CARES Act funding may change in future periods.

Recent Authoritative Pronouncements

Periodically, the Financial Accounting Standards Board (FASB) issues updates to the Accounting Standards Codification (ASC) which impacts the University’s financial reporting and related disclosures. The paragraphs which follow summarize a number of relevant updates.

In February 2016, the FASB issued a standard on Leases. This standard requires lessees to recognize assets and liabilities for the rights and obligations created by leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily depends on its classification as a finance or operating lease. The University adopted this standard for fiscal year 2020 on a modified retrospective basis.

In November 2016, the FASB issued a standard on Restricted Cash. This standard requires the Consolidated Statements of Cash Flows explain the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents during a fiscal year. It is also required that this total be reconciled to the amounts reported on the Consolidated Statements of Financial Position and that the nature of the restrictions be disclosed. The University adopted this standard for fiscal year 2020 on a retrospective basis.

2. UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM - SUMMARIZED FINANCIAL AND RELATED INFORMATION

The Trustees formed Penn Medicine, the governance structure which oversees the activities of UPHS and the University of Pennsylvania Perelman School of Medicine (PSOM) in order to operate, oversee and coordinate its academic, research and clinical missions.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UPHS is comprised of the following operating entities: Clinical Practices of the University of Pennsylvania; Clinical Care Associates; Hospital of the University of Pennsylvania; Penn Presbyterian Medical Center; Pennsylvania Hospital of the University of Pennsylvania Health System; Chester County Hospital and Health System; Lancaster General Health (LGH); Wissahickon Hospice of the University of Pennsylvania Health System; Princeton HealthCare System (PHCS); Franklin Casualty Insurance Company, a wholly owned Risk Retention Group; and, Quaker Insurance Company Ltd., a wholly owned offshore captive insurance company, (collectively referred to as RRG/Captive).

Throughout the year, certain transactions (primarily billings for allocations of common costs, physicians' salaries and benefits, certain purchased services and support for PSOM) are conducted between UPHS and the University. Nonoperating, net, as shown below, includes transfers from UPHS to the University of \$181,414,000 and \$207,085,000 in 2021 and 2020, respectively, to further the research and educational activities of PSOM, and \$61,008,000 and \$6,581,000 in 2021 and 2020, respectively, for other activities. In addition, UPHS recognized operating expenses of \$21,583,000 and \$19,618,000 in 2021 and 2020, respectively, to support academic operating activities in the clinical departments of PSOM.

The effect of all these transactions is included in the following summarized financial information of UPHS as of and for the years ended June 30, 2021 and 2020 (in thousands):

	2021	2020
Net patient service revenue	\$ 7,545,629	\$ 6,813,226
Other revenue and support	1,132,479	994,662
Total expenses	(8,067,225)	(7,565,166)
Excess of revenue over expenses from operations	610,883	242,722
Nonoperating, net	1,725,343	(393,237)
Increase (decrease) in net assets	\$ 2,336,226	\$ (150,515)
Total current assets	\$ 2,478,737	\$ 2,554,537
Assets whose use is limited:		
Held by trustees	186,258	139,028
RRG/ Captive	283,865	243,622
Donor restricted and other	867,329	657,776
Designated	3,946,161	2,833,871
Property and equipment, net	5,700,083	5,369,409
Investments and other assets	1,580,799	1,361,266
Total assets	\$ 15,043,232	\$ 13,159,509
Total current liabilities	\$ 1,977,367	\$ 1,973,427
Long-term debt, net of current portion	2,617,838	2,692,254
Other liabilities	2,340,540	2,722,567
Total liabilities	\$ 6,935,745	\$ 7,388,248
Net assets		
Without donor restrictions	\$ 7,217,776	\$ 5,098,229
With donor restrictions	889,711	673,032
Total net assets	\$ 8,107,487	\$ 5,771,261
Total liabilities and net assets	\$ 15,043,232	\$ 13,159,509

Net Patient Service Revenue

Net Patient Service Revenue (NPSR) for the years ended June 30, 2021 and 2020 is derived from the following payers:

	2021	2020
Medicare (including Managed Medicare)	32%	32%
Medicaid (including Managed Medicaid)	12%	12%
Managed care	35%	36%
Independence Blue Cross (IBC)	16%	15%
Commercial	4%	4%
Self pay	1%	1%
	100%	100%

Third-party payers

UPHS has agreements with the following third-party payers that provide for payments at amounts that differ from its established rates:

Medicare and Medicaid

Inpatient acute care services and outpatient services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors. Inpatient psychiatric services and medical education costs related to Medicare beneficiaries are paid based on a cost reimbursement methodology. UPHS is reimbursed for cost reimbursable items at a tentative rate with final settlement determined after submission of annual cost reports by each hospital and audits thereof by the Medicare fiscal intermediary.

Inpatient and outpatient services rendered to Medicaid program beneficiaries are paid at prospectively determined rates. Additional amounts are allocated to each hospital for training residents and serving a disproportionate indigent population.

Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term.

IBC and Commercial

During 2017, UPHS and IBC reached agreement on terms of a five-year agreement. Payments made for inpatient services provided to IBC traditional and managed care subscribers are effected on a per case rate basis for most services. Payment for outpatient services is principally based upon negotiated fee schedules. Hospital and physician rates also provide for annual inflationary increases. In addition, incentives are paid for high performance with regard to clinical outcomes and patient quality. On September 10, 2021, this agreement was extended from June 30, 2022 to June 30, 2025.

During 2015, UPHS and Aetna reached agreement on terms of a five-year agreement. A one-year bridge agreement, effective July 1, 2020, remains in effect until a new agreement is reached. The terms of the agreement provide payments for inpatient hospital services on a per case rate basis. Payments for outpatient services continue to be predominantly based upon negotiated fee schedules.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UPHS also has reimbursement agreements with other commercial insurance carriers, health maintenance organizations and preferred provider organizations. The basis for reimbursement under these agreements includes prospectively determined rates per discharge, discounts from established charges and prospectively determined per diem rates.

Charity Care

UPHS provides services to patients who meet certain criteria under its charity care policy without charge or at amounts less than UPHS' established rates. Because UPHS does not pursue collections for these patients, such amounts have been excluded from NPSR. UPHS estimates the costs of providing charity care services based on data derived from a combination of UPHS' cost accounting system and the ratio of costs to charges. Of the Total expenses reported above by UPHS, an estimated \$27,335,000 and \$29,793,000 were incurred as a result of providing services to charity patients for the years ended June 30, 2021 and 2020, respectively.

Medical Professional Liability Claims

The University is insured for medical professional liability claims through the combination of the Medical Care Availability and Reduction of Error Fund (Mcare), various commercial insurance companies and risk retention programs.

Mcare levies health care provider surcharges, as a percentage of the Pennsylvania Joint Underwriters Association rates for basic coverage, to pay claims and pay administrative expenses of Mcare participants. These surcharges are recognized as expenses in the period incurred. Mcare operates on a pay-as-you-go basis and no provision has been made for any future Mcare assessments in the accompanying financial statements, as the University's portion of the unfunded Mcare liability cannot be estimated.

Anticipated insurance recoveries and estimated liabilities for medical malpractice claims or similar contingent liabilities are presented separately on the Consolidated Statement of Financial Position in Accounts receivable, net and Accrued expenses and other liabilities, respectively. The University accrues for estimated risks arising from both asserted and unasserted medical professional liability claims. The estimate of the gross liability and corresponding receivable for unasserted claims arising from unreported incidents is based on analysis of historical claims data by an independent actuary, which is recorded utilizing a 2.25% to 3.50% discount rate as of June 30, 2021 and 2020. The gross liability recorded under this program is \$765,755,000 and \$750,633,000 at June 30, 2021 and 2020, respectively, with a corresponding receivable of \$113,343,000 and \$119,255,000 at June 30, 2021 and 2020, respectively.

3. ACCOUNTS RECEIVABLE

Accounts receivable are reported at their net realizable value. The major components of receivables, net of allowances for doubtful accounts of \$29,040,000 and \$22,771,000 at June 30, 2021 and 2020, respectively, are as follows (in thousands):

	2021	2020
Patient	\$ 927,009	\$ 726,081
Intellectual property	321,287	14,186
Sponsored research	149,303	159,528
Malpractice	113,343	119,255
Trade	44,884	49,047
Student	29,150	26,450
Other	144,638	138,573
TOTAL ACCOUNTS RECEIVABLE, NET	\$ 1,729,614	\$ 1,233,120

4. LOANS RECEIVABLE

Loans receivable, and related allowances for doubtful accounts, consist of the following at June 30, 2021 and 2020 (in thousands):

2021			
	Receivable	Allowance	Net
Student Loans:			
Federally-sponsored	\$ 36,974		\$ 36,974
Other	12,547	\$ 2,902	9,645
Total Student loans	\$ 49,521	\$ 2,902	\$ 46,619
Other	15,001	667	14,334
TOTAL	\$ 64,522	\$ 3,569	\$ 60,953

2020			
	Receivable	Allowance	Net
Student Loans:			
Federally-sponsored	\$ 42,410		\$ 42,410
Other	13,748	\$ 2,994	10,754
Total Student loans	\$ 56,158	\$ 2,994	\$ 53,164
Other	10,658	424	10,234
TOTAL	\$ 66,816	\$ 3,418	\$ 63,398

Loans receivable primarily consists of student loans. Student loans include federally-sponsored student loans and donor-restricted student loans with mandated interest rates and repayment terms. The federally-sponsored student loans represent amounts due from current and former students under various Federal Government funded loan programs offered to graduate and undergraduate students. Loans disbursed under these programs are able to be assigned to the Federal Government upon default by the borrower; therefore, no related allowance is considered necessary. Funding received under these programs is ultimately refundable to the Federal Government in the event the University no longer participates and accordingly is reported as a liability in Federal student loan advances in the Consolidated Statements of Financial Position. Determination of the fair value of student loans receivable is not practicable.

Loans receivable are reported at their net realizable value. The University regularly assesses the adequacy of the allowances for credit losses of its loans by performing ongoing evaluations, including such factors as aging, differing economic risks associated with each loan category, financial condition of specific borrowers, economic environment in which the borrowers operate, level of delinquent loans, value of collateral and existence of guarantees or indemnifications.

5. CONTRIBUTIONS RECEIVABLE

A summary of contributions receivable at June 30, 2021 and 2020, is as follows (in thousands):

	2021	2020
Unconditional promises expected to be collected in:		
Less than one year	\$ 164,432	\$ 169,979
One year to five years	232,207	249,791
Over five years	138,684	120,726
	535,323	540,496
Less: Discount	(31,618)	(27,699)
Less: Allowances for doubtful amounts	(30,125)	(34,647)
TOTAL CONTRIBUTIONS RECEIVABLE, NET	\$ 473,580	\$ 478,150

At June 30, 2021 and 2020, the University has outstanding unrecorded conditional promises to give, including non-legally binding bequests, of \$512,434,000 and \$467,797,000, respectively. When conditional promises to give become unconditional or non-legally binding bequests cash payments are received, they are recorded and are generally restricted for operations, endowment and capital projects as stipulated by the donors.

6. INVESTMENTS, AT FAIR VALUE

A summary of investments, including the AIF, as of June 30, 2021 and 2020, categorized in accordance with the fair value hierarchy, is as follows (in thousands):

2021	Level 1	Level 2	Level 3	Investments at NAV	Total
Short-term:	\$ 1,237,141				\$ 1,237,141
Equity:					
US equities	1,193,240			\$ 1,803,025	2,996,265
International equities	225,447			1,240,442	1,465,889
Emerging market equities	178,608			1,524,253	1,702,861
Total Equity	1,597,295			4,567,720	6,165,015
Debt:					
US treasuries	1,378,651	\$ 23,746			1,402,397
Corporate bonds	87,678	236,088			323,766
Total Debt	1,466,329	259,834			1,726,163
Split-interest agreements	103,128		\$ 395,694		498,822
Absolute return				4,423,435	4,423,435
Real estate		2,059		1,042,564	1,044,623
Private equity			21,754	6,995,732	7,017,486
Natural resources	175,758			747,025	922,783
Derivative instruments		667			667
Other			2,867		2,867
TOTAL INVESTMENTS, AT FAIR VALUE	\$ 4,579,651	\$ 262,560	\$ 420,315	\$ 17,776,476	\$ 23,039,002

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

2020	Investments at				
	Level 1	Level 2	Level 3	NAV	Total
Short-term	\$ 594,126				\$ 594,126
Equity:					
US equities	719,227			\$ 1,299,712	2,018,939
International equities	141,939			1,111,548	1,253,487
Emerging market equities	175,705			1,087,617	1,263,322
Total Equity	1,036,871			3,498,877	4,535,748
Debt:					
US treasuries	1,642,721	\$ 19,999			1,662,720
Corporate bonds	1,449	114,512			115,961
High yield				119	119
Total Debt	1,644,170	134,511		119	1,778,800
Split-interest agreements	87,085		\$ 325,701		412,786
Absolute return				3,893,852	3,893,852
Real estate		59		978,372	978,431
Private equity			14,473	4,110,984	4,125,457
Natural resources	86,075			445,171	531,246
Derivative instruments		17,132			17,132
Other				2,538	2,538
TOTAL INVESTMENTS, AT FAIR VALUE	\$ 3,448,327	\$ 151,702	\$ 342,712	\$ 12,927,375	\$ 16,870,116

Included in Short-term investments is \$23,259,000 and \$20,947,000 of amounts held by trustees under indenture and escrow agreements at June 30, 2021 and 2020, respectively.

At June 30, 2021 and 2020, Short-term investments include \$284,569,000 and \$40,915,000, respectively, of outstanding receivables from trading activities. At June 30, 2021 and 2020, Short-term investments also include \$64,517,000 and \$64,542,000, respectively, of outstanding payables from trading activities.

Liabilities related to equity short positions of \$389,222,000 and \$329,955,000 at June 30, 2021 and 2020, respectively, are reported in Accrued expenses and other liabilities on the Consolidated Statements of Financial Position. These liabilities are valued using observable market data and are categorized as Level 1 based on quoted market prices in active markets.

Split-interest agreement investments included in Level 1 above are readily marketable assets invested by the University separately from the AIF where the University serves as trustee. These amounts include assets related to the University Academic Component charitable gift annuities totaling \$49,757,000 and \$43,979,000 at June 30, 2021 and 2020, respectively. Included in these split-interest agreement investments are amounts held to meet legally mandated annuity reserves of \$28,009,000 and \$29,006,000 as of June 30, 2021 and 2020, respectively, as required by the laws of the following states where certain individual donors reside: California, Maryland, New Jersey and New York. Level 3 split-interest agreement investments are managed and invested outside of the University by external trustees.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

A summary of Level 3 assets included in split-interest agreement investments, where the University is not trustee, measured at fair value, as of June 30, 2021 and 2020 is as follows (in thousands):

	2021	2020
Charitable remainder trusts	\$ 18,874	\$ 19,487
Charitable lead trusts	6,523	5,763
Perpetual trusts	370,297	300,451
Total	\$ 395,694	\$ 325,701

Changes to the reported amounts of split-interest agreement investments measured at fair value using unobservable (Level 3) inputs as of June 30, 2021 and 2020 are as follows (in thousands):

	Charitable Remainder Trusts	Charitable Lead Trusts	Perpetual Trusts	Total
June 30, 2020	\$ 19,487	\$ 5,763	\$ 300,451	\$ 325,701
Net realized gains			10,170	10,170
Net unrealized gains/(losses)	(571)	812	59,647	59,888
Acquisitions			29	29
Liquidations	(42)	(52)		(94)
June 30, 2021	\$ 18,874	\$ 6,523	\$ 370,297	\$ 395,694

	Charitable Remainder Trusts	Charitable Lead Trusts	Perpetual Trusts	Total
June 30, 2019	\$ 18,511	\$ 4,568	\$ 299,552	\$ 322,631
Net realized gains			2,974	2,974
Net unrealized gains/(losses)	976	1,225	(2,610)	(409)
Acquisitions			535	535
Liquidations		(30)		(30)
June 30, 2020	\$ 19,487	\$ 5,763	\$ 300,451	\$ 325,701

The following tables set forth the fair value, related gains (losses) and notional amounts of the University's derivative instruments by contract type as of June 30, 2021 and 2020 (in thousands):

2021	Notional Amount	Gross Derivative Assets	Gross Derivative Liabilities	Derivative Gains (Losses)
Foreign currency contracts	\$ 132,341	\$ 309	\$ 723	\$ (5,078)
Futures contracts	(431,857)	166		(225,995)
Options contracts	(101,311)	192	333	4,553
Total	\$ (400,827)	\$ 667	\$ 1,056	\$ (226,520)

2020	Notional Amount	Gross Derivative Assets	Gross Derivative Liabilities	Derivative Losses
Foreign currency contracts	\$ 112,672	\$ 301	\$ 916	\$ (2,442)
Futures contracts	(542,830)	16,403		(17,423)
Options contracts	(125,284)	428	1,306	(7,606)
Total	\$ (555,442)	\$ 17,132	\$ 2,222	\$ (27,471)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The notional amount is representative of the volume and activity of the respective derivative type during the years ended June 30, 2021 and 2020.

Gross derivatives assets and liabilities are shown on the Consolidated Statements of Financial Position in Investments, at fair value and Accrued expenses and other liabilities, respectively. Derivative gains (losses) are shown in Return on investments, net on the Consolidated Statements of Activities, in the appropriate net asset classification.

Details on the fair value, remaining estimated life, outstanding commitments, current redemption terms and restrictions by strategy and type of investment are provided below (in thousands):

Strategy	Fair Value at June 30,		Outstanding Commitments	Redemption Terms	Redemption Restrictions
	2021	2020			
Short-term	\$ 1,237,141	\$ 594,126		Daily	None
Equity:					
Managed accounts	1,259,520	761,773		Daily and semi-annually with varying notice periods	None
Mutual funds	337,776	275,098		Daily	None
Private funds (1)	4,567,719	3,498,877	\$ 55,050	Weekly to annually with varying notice periods	Lock-up provisions ranging from 0 to 5 years and side pocket investments (2)
Total Equity	6,165,015	4,535,748	55,050		
Debt:					
Managed accounts	1,726,163	1,778,681		Daily	None
Private funds (1)		119		Daily	None; side pocket investments (2)
Total Debt	1,726,163	1,778,800			
Absolute return	4,423,435	3,893,852	341,836	Range from monthly to annually and close- ended funds not available for redemption	Lock-up provisions ranging from 0 to 5 years with earlier redemptions subject to redemption fee, close-ended funds not available for redemption, and side pocket investments (2)
Real estate	1,044,623	978,431	934,876	Close-ended funds not available for redemption	Close-ended funds not available for redemption
Private equity	7,017,486	4,125,457	2,646,161	Close-ended funds not available for redemption	Close-ended funds not available for redemption
Natural Resources:					
Managed accounts	175,758	86,075		Daily	None
Private funds (1)	747,025	445,171	170,320	Close-ended funds not available for redemption	Close-ended funds not available for redemption
Total Natural Resources	922,783	531,246	170,320		
Total	\$ 22,536,646	\$ 16,437,660	\$ 4,148,243		

(1) Private funds consist of close-ended and open-ended funds generally in the form of limited partnerships. Close-ended funds have varying remaining fund terms between 1 to 15 years.

(2) Side pocket investments represent investments designated by a manager that are not available for liquidity in an otherwise liquid fund vehicle.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Invested in the AIF with an aggregate fair value of \$226,422,000 and \$168,792,000 at June 30, 2021 and 2020, respectively, is a perpetual trust managed by an external trustee who has delegated investment decisions to the University. The University invests the assets of this trust in accordance with its endowment policy.

The University has made investments in various long-lived partnerships and, in other cases, has entered into contractual agreements that may limit its ability to initiate redemptions due to notice periods, lock-ups and gates. The University has also made commitments to various limited partnerships. The University expects these funds to be called over the next 5 years. The total amount of unfunded commitments is \$4,148,243,000 which represents 20.7% of the AIF value as of June 30, 2021.

A summary of the University's total investment return, net of external and direct internal investment expenses, for the years ended June 30, 2021 and 2020 is presented below (in thousands):

	2021	2020
AIF investment income	\$ 55,780	\$ 59,105
AIF realized and unrealized gains	5,781,692	457,907
Total return on AIF	5,837,472	517,012
Other investment gains	262,182	37,940
Total return on investments, net	\$ 6,099,654	\$ 554,952

7. ENDOWMENT

The composition and changes to the amount of the University's endowment at June 30, 2021 are as follows (in thousands):

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted endowment funds		\$ 10,186,280	\$ 10,186,280
Quasi-endowment funds	\$ 10,337,266		10,337,266
June 30, 2021	\$ 10,337,266	\$ 10,186,280	\$ 20,523,546

	Without Donor Restrictions	With Donor Restrictions	Total
Net assets, June 30, 2020	\$ 7,363,736	\$ 7,513,627	\$ 14,877,363
Investment return	2,974,220	2,848,798	5,823,018
New gifts	7,385	209,055	216,440
Allocation of endowment assets for expenditure	(797,492)		(797,492)
Other investment allocation	(4,239)		(4,239)
Transfers to create board designated funds	380,634		380,634
Donor-imposed income reinvestments		11,371	11,371
Other transfers	50,007	(33,556)	16,451
Released from restriction	363,015	(363,015)	-
Net assets, June 30, 2021	\$ 10,337,266	\$ 10,186,280	\$ 20,523,546

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The composition and changes to the amount of the University's endowment as of June 30, 2020 are as follows (in thousands):

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted endowment funds		\$ 7,513,627	\$ 7,513,627
Quasi-endowment funds	\$ 7,363,736		7,363,736
June 30, 2020	\$ 7,363,736	\$ 7,513,627	\$ 14,877,363

	Without Donor Restrictions	With Donor Restrictions	Total
Net assets, June 30, 2019	\$ 7,252,228	\$ 7,397,533	\$ 14,649,761
Investment return	123,658	216,502	340,160
New gifts	11,219	236,657	247,876
Allocation of endowment assets for expenditure	(654,691)		(654,691)
Other investment allocation	(6,918)		(6,918)
Transfers to create board designated funds	302,623		302,623
Donor-imposed income reinvestments		955	955
Other transfers	21,940	(24,343)	(2,403)
Released from restriction	313,677	(313,677)	-
Net assets, June 30, 2020	\$ 7,363,736	\$ 7,513,627	\$ 14,877,363

At June 30, 2021 and 2020, the aggregate amount of funds reported in Net assets with donor restrictions for which the fair value was below historic value was \$0 and \$1,265,000, respectively.

8. PROPERTY, PLANT AND EQUIPMENT, NET

The components of PPE at June 30, 2021 and 2020 are as follows (in thousands):

	Estimated Useful	2021	2020
	Life in years		
Land and land improvements	N/A to 20	\$ 446,746	\$ 423,467
Buildings and fixed equipment	5 to 50	11,100,395	10,475,473
Moveable equipment and other	4 to 20	2,294,762	2,136,837
Construction-in-progress		2,043,096	2,046,652
		15,884,999	15,082,429
Less: Accumulated depreciation		(6,708,971)	(6,304,344)
TOTAL PROPERTY, PLANT AND EQUIPMENT, NET		\$ 9,176,028	\$ 8,778,085

The University recorded \$552,221,000 and \$533,289,000 of depreciation expense for the years ended June 30, 2021 and 2020, respectively.

The University capitalized \$65,649,000 and \$55,940,000 of interest costs for the years ended June 30, 2021 and 2020, respectively.

9. SPLIT-INTEREST AGREEMENTS

Changes in the value of assets, liabilities and net assets pursuant to split-interest agreements as of June 30, 2021 and 2020 are as follows (in thousands):

2021	Assets	Liabilities	Net Assets
June 30, 2020	\$ 412,786	\$ (50,836)	\$ 361,950
New contributions	2,505	(4,385)	(1,880)
Investment income	1,984	(1,446)	538
Realized and unrealized gain, net	89,903	-	89,903
Payments and settlements	(8,356)	9,124	768
Actuarial adjustment		(5,474)	(5,474)
Net change	86,036	(2,181)	83,855
June 30, 2021	\$ 498,822	\$ (53,017)	\$ 445,805
2020	Assets	Liabilities	Net Assets
June 30, 2019	\$ 409,123	\$ (50,311)	\$ 358,812
New contributions	7,418	(3,951)	3,467
Investment income	2,038	(1,673)	365
Realized and unrealized gain, net	2,515		2,515
Payments and settlements	(8,308)	7,517	(791)
Actuarial adjustment		(2,418)	(2,418)
Net change	3,663	(525)	3,138
June 30, 2020	\$ 412,786	\$ (50,836)	\$ 361,950

10. CONTINGENCIES, GUARANTEES, AND COMMITMENTS

The University offers various loan programs for students and families to pay tuition, fees and other costs. Certain loans issued by private lending institutions are guaranteed by the University totaling \$15,341,000 and \$20,644,000 at June 30, 2021 and 2020, respectively. Upon default by the borrower, the University is required to pay all or a portion of the outstanding loan balance. The University recognizes a liability for the greater of the fair value of the guarantee or defaults in the portfolio of guaranteed loans. The recognized liability is \$2,826,000 and \$3,005,000 at June 30, 2021 and 2020, respectively and reflects the fair value of the guarantee on these outstanding loan balances.

Various lawsuits, claims and other contingent liabilities arise in the ordinary course of the University's education and health care activities. Based upon information currently available, management believes that any liability resulting therefrom will not materially affect the financial position or operations of the University.

The University is currently involved in various projects that have resulted in capital and property acquisition commitments from the University. As of June 30, 2021, approximately \$405,963,000 has been committed by the University.

11. PENSION AND OTHER POSTRETIREMENT BENEFITS COSTS

Retirement benefits are principally provided to employees through contributory defined contribution plans. The Academic Component's policy with respect to its contribution is to provide up to 9% of eligible employees' salaries, while the UPHS contribution can be up to 6.5%. The University's contributions to these plans amounted to \$247,158,000 and \$231,054,000 as of June 30, 2021 and 2020, respectively.

The University also has non-contributory defined benefit pension plans. Benefits under the plans generally are based on the employee's years of service and compensation during the years preceding retirement. Contributions to the plans are made in amounts necessary to at least satisfy the minimum required contributions as specified in the Internal Revenue Service Code and related regulations. The Academic Component's plan was frozen to new full-time entrants effective July 1, 2000 and part-time entrants effective July 1, 2018. UPHS' primary plan was frozen to new entrants effective July 1, 2010; the benefit accruals for all participants of the LGH and PHCS plans were frozen effective June 30, 2013 and December 31, 2011, respectively. During the years ended June 30, 2021 and 2020, UPHS paid \$25,814,000 and \$78,879,000, respectively, from plan assets to insurance companies to buy out the total pension benefit for a portion of its retired participants.

The University also has faculty retirement incentive plans which are included in Other retirement programs shown below. The net liability under these plans is \$95,139,000 and \$8,279,000 as of June 30, 2021 and 2020, respectively, with the increase primarily attributable to the University's offering of a special one-time faculty retirement plan during the year ended June 30, 2021.

Additionally, the University provides certain healthcare and life insurance benefits (OPEB) for retired employees. Only a limited number of employees may become eligible for such benefits if they reach retirement age while working for the University. These and similar benefits for active and certain retired employees are provided through insurance contracts.

The University uses a measurement date of June 30 for its defined benefit pension and OPEB plans.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Change in Plan Assets/Obligation and Funded Status

The funded status of the plans is measured as the difference between the plan assets at fair value and the projected benefit obligation (PBO) for Pension Benefits or accumulated postretirement benefit obligation (APBO) for Other Postretirement Benefits. The resulting net liability is recorded in Accrued retirement benefits on the Statements of Financial Position. The following shows changes in the benefit obligation, plan assets and funded status for the years ended June 30, 2021 and June 30, 2020 (in thousands):

2021	Pension Benefits	Other Postretirement Benefits	Total
Change in Benefit Obligation:			
Benefit obligation, beginning of year (PBO/APBO)	\$ 4,121,716	\$ 1,090,300	\$ 5,212,016
Service cost	79,683	41,638	121,321
Interest cost	122,483	35,292	157,775
Plan participants' contributions	144	9,133	9,277
Settlements	(13,366)		(13,366)
Net actuarial (gain)/loss	(12,159)	(38,799)	(50,958)
Benefits paid	(120,546)	(41,422)	(161,968)
Benefit obligation, end of year (PBO/APBO)	\$ 4,177,955	\$ 1,096,142	\$ 5,274,097
Change in Plan Assets:			
Fair value of plan assets, beginning of year	\$ 2,792,335	\$ 554,951	\$ 3,347,286
University contributions	143,707	30,875	174,582
Plan participants' contributions	144	9,133	9,277
Settlements	(13,366)		(13,366)
Actual return on plan assets	684,259	163,798	848,057
Benefits paid	(120,546)	(41,422)	(161,968)
Fair value of plan assets, end of year	\$ 3,486,533	\$ 717,335	\$ 4,203,868
Funded status, end of year	\$ 691,422	\$ 378,807	\$ 1,070,229
Other retirement programs			227,551
			1,297,780
Plans with fair value of plan assets in excess of PBOs*			16,989
ACCRUED RETIREMENT BENEFITS			\$ 1,314,769

* Included in Other assets on the Consolidated Statements of Financial Position

2020	Pension Benefits	Other Postretirement Benefits	Total
Change in Benefit Obligation:			
Benefit obligation, beginning of year (PBO/APBO)	\$ 3,750,476	\$ 1,014,328	\$ 4,764,804
Service cost	77,085	35,476	112,561
Interest cost	136,674	38,148	174,822
Plan participants' contributions	151	8,729	8,880
Net actuarial (gain)/loss	342,211	30,238	372,449
Benefits paid	(184,881)	(36,619)	(221,500)
Benefit obligation, end of year (PBO/APBO)	\$ 4,121,716	\$ 1,090,300	\$ 5,212,016
Change in Plan Assets:			
Fair value of plan assets, beginning of year	\$ 2,696,740	\$ 522,365	\$ 3,219,105
University contributions	130,008	42,698	172,706
Plan participants' contributions	151	8,729	8,880
Actual return on plan assets	150,317	17,778	168,095
Benefits paid	(184,881)	(36,619)	(221,500)
Fair value of plan assets, end of year	\$ 2,792,335	\$ 554,951	\$ 3,347,286
Funded status, end of year	\$ 1,329,381	\$ 535,349	\$ 1,864,730
Other retirement programs			103,521
ACCRUED RETIREMENT BENEFITS			\$ 1,968,251

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Accumulated Benefit Obligation for the Pension Benefits was \$3,827,175,000 and \$3,766,340,000 at June 30, 2021 and 2020, respectively.

For the year ended June 30, 2021, the net actuarial gain in the Benefit Obligation for the Pension Benefits was principally driven by a change in mortality assumptions. For the year ended June 30, 2020, the net actuarial loss in the Benefit Obligation for the Pension Benefits was primarily attributable to a reduction in the weighted average discount rate from 3.72% to 3.05%.

Net Periodic Benefit Cost

The components of net periodic benefit cost for pension benefits and other postretirement benefits are detailed below (in thousands). In the Consolidated Statements of Activities, service cost is reported as Compensation and benefits while the remaining components of net periodic benefit cost are reported as Pension, OPEB and other, net.

	Pension Benefits	Other Postretirement Benefits	Total
2021			
Service cost	\$ 79,683	\$ 41,638	\$ 121,321
Interest cost	122,483	35,292	157,775
Expected return on plan assets	(173,940)	(41,671)	(215,611)
Amortization of:			
Net prior service cost		(387)	(387)
Net losses	77,169	9,765	86,934
Settlement/Curtailment Expense	1,000		1,000
Net periodic benefit cost	\$ 106,395	\$ 44,637	\$ 151,032

	Pension Benefits	Other Postretirement Benefits	Total
2020			
Service cost	\$ 77,085	\$ 35,476	\$ 112,561
Interest cost	136,674	38,148	174,822
Expected return on plan assets	(184,845)	(39,251)	(224,096)
Amortization of:			
Net prior service cost		(387)	(387)
Net losses	53,500	6,992	60,492
Net periodic benefit cost	\$ 82,414	\$ 40,978	\$ 123,392

Net Assets Without Donor Restrictions

The University recorded the following year-end valuation adjustments to its Pension and Other Postretirement Benefit Plans in Pension, OPEB and other, net in the Consolidated Statements of Activities (in thousands):

	Pension Benefits	Other Postretirement Benefits	Total
2021			
Net Assets Without Donor Restrictions:			
Net actuarial loss	\$ 651,333	\$ 69,196	\$ 720,529
Net prior service cost/(credit)		(1,986)	(1,986)
Total	\$ 651,333	\$ 67,210	\$ 718,543
Adjustment to net assets without donor restrictions (gain)/loss	\$ (600,589)	\$ (170,303)	\$ (770,892)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

2020	Pension Benefits	Other Postretirement Benefits	Total
Net Assets Without Donor Restrictions:			
Net actuarial loss	\$ 1,251,922	\$ 239,885	\$ 1,491,807
Net prior service cost/(credit)		(2,372)	(2,372)
Total	\$ 1,251,922	\$ 237,513	\$ 1,489,435
Adjustment to net assets without donor restrictions (gain)/loss	\$ 323,237	\$ 45,107	\$ 368,344

Actuarial Assumptions

The expected long-term rate of return on plan assets is management's best estimate of the average investment return expected to be received on the assets invested in the plan over the benefit period. The expected long-term rate of return on plan assets has been established by considering historical and future expected returns of the asset classes invested in by the pension trust, and the allocation strategy currently in place among those classes.

	Pension Benefits	Other Postretirement Benefits		
Weighted-Average Assumptions Used to Determine Benefit Obligations at Year End	2021	2020	2021	2020
Discount rate	3.04%	3.05%	3.29%	3.28%
Salary increase	3.20%	3.22%	N/A	N/A
Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost				
Discount rate	3.05%	3.72%	3.27%	3.81%
Expected long-term return on plan assets	7.14%	7.26%	7.50%	7.50%
Salary increase	3.23%	4.03%	N/A	N/A
Assumed Health Care Cost Trend Rates				
Initial trend rate	N/A	N/A	6.20%	6.24%
Ultimate trend rate	N/A	N/A	4.72%	4.72%
Fiscal year end that ultimate trend rate is reached	N/A	N/A	2037	2037

Expected Contributions

The University expects to contribute \$34,082,000 and \$31,528,000 for pension benefits and other postretirement benefits, respectively, during the fiscal year ending June 30, 2022.

Expected Benefits Payments (in thousands):

Expected benefit payments for the year ending:	Pension Benefits	Other Postretirement Benefits before Medicare Part D Subsidy	Medicare Part D Subsidy
June 30, 2022	\$ 137,170	\$ 28,499	\$ 75
June 30, 2023	142,130	30,388	77
June 30, 2024	150,866	32,644	79
June 30, 2025	159,320	34,611	81
June 30, 2026	167,879	36,399	84
June 30, 2027 to June 30, 2031	955,325	211,640	438

Plan Assets and Allocations

The principal investment objectives for the pension and other postretirement benefits plans are to ensure the availability of funds to pay pension benefits as they become due under a broad range of future economic scenarios, to maximize long-term investment returns with an acceptable level of risk based on the pension obligations, and to invest the pension trust in a diversified manner.

The University's Office of Investments is responsible for the day-to-day management of the majority of the investments of the pension and other postretirement benefits. The investments are made in accordance with policies set out by the Investment Board which has been appointed by the Trustees. The pension and other postretirement benefit investments are similar in nature to those investments discussed in Notes 1 and 6 – Investments, at Fair Value. However, the actual allocations to specific investments within each asset class may vary due to certain restrictions imposed by investment managers and ERISA regulations.

A summary of plan assets, measured at fair value, as of June 30, 2021 and 2020, is as follows (in thousands):

Pension Benefits:

2021	Level 1	Level 2	Level 3	Investments at NAV	Total
Assets:					
Short-term	\$ 155,966				\$ 155,966
Equity:					
US equities	288,098	\$ 564		\$ 224,600	513,262
International equities	159,911			246,411	406,322
Emerging market equities	1,373			224,024	225,397
Debt:					
US treasuries	329,630	7,923			337,553
Corporate bonds	131,152	125,821		230,796	487,769
Absolute return				764,295	764,295
Real estate				88,727	88,727
Private equity	438			382,274	382,712
Natural resources	94,163			30,502	124,665
Total assets	\$ 1,160,731	\$ 134,308	\$ -	\$ 2,191,629	\$ 3,486,668
Liabilities:					
Derivative instruments		\$ 135			\$ 135
Total liabilities	\$ -	\$ 135	\$ -	\$ -	\$ 135
Fair value of plan assets, end of year	\$ 1,160,731	\$ 134,173	\$ -	\$ 2,191,629	\$ 3,486,533

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

2020	Level 1	Level 2	Level 3	Investments at NAV	Total
Assets:					
Short-term	\$ 49,251				\$ 49,251
Equity:					
US equities	197,651	\$ 949		\$ 195,134	393,734
International equities	143,448			225,478	368,926
Emerging market equities	135			158,366	158,501
Debt:					
US treasuries	250,287	10,160		1,944	262,391
Corporate bonds	121,245	114,848		211,629	447,722
Absolute return				660,490	660,490
Real estate				76,464	76,464
Private equity	2,016			261,780	263,796
Natural resources	51,196			60,232	111,428
Total assets	\$ 815,229	\$ 125,957	\$ -	\$ 1,851,517	\$ 2,792,703
Liabilities:					
Derivative instruments		\$ 368			\$ 368
Total liabilities	\$ -	\$ 368	\$ -	\$ -	\$ 368
Fair value of plan assets, end of year	\$ 815,229	\$ 125,589	\$ -	\$ 1,851,517	\$ 2,792,335

Other Postretirement Benefits:

2021	Level 1	Level 2	Level 3	Investments at NAV	Total
Assets:					
Short-term	\$ 44,598				\$ 44,598
Equity:					
US equities	12,503			\$ 81,196	93,699
International equities				92,334	92,334
Emerging market equities				65,903	65,903
Debt:					
US treasuries	19,821				19,821
Corporate bonds				11,514	11,514
Absolute return				215,675	215,675
Real estate				38,665	38,665
Private equity				95,435	95,435
Natural resources	31,284			8,452	39,736
Total assets	\$ 108,206	\$ -	\$ -	\$ 609,174	\$ 717,380
Liabilities:					
Derivative instruments		\$ 45			45
Total liabilities	\$ -	\$ 45	\$ -	\$ -	\$ 45
Fair value of plan assets, end of year	\$ 108,206	\$ (45)	\$ -	\$ 609,174	\$ 717,335

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

2020	Level 1	Level 2	Level 3	Investments at NAV	2020
Assets:					
Short-term	\$ 28,467				\$ 28,467
Equity:					
US equities	4,685			\$ 67,369	72,054
International equities				82,376	82,376
Emerging market equities	70			43,251	43,321
Debt:					
US treasuries	20,692				20,692
Corporate bonds				11,077	11,077
Absolute return				185,917	185,917
Real estate				33,203	33,203
Private equity				59,059	59,059
Natural resources	12,122			6,781	18,903
Total assets	\$ 66,036	\$ -	\$ -	\$ 489,033	\$ 555,069
Liabilities:					
Derivative instruments		\$ 118			\$ 118
Total liabilities	\$ -	\$ 118	\$ -	\$ -	\$ 118
Fair value of plan assets, end of year	\$ 66,036	\$ (118)	\$ -	\$ 489,033	\$ 554,951

As of June 30, 2021, the University has unfunded commitments to limited partnerships totaling \$447,051,000, which are expected to be called over the next 5 years.

Plan asset allocations by category are as follows:

2021 Allocation of Plan Assets	Pension Benefits		Other Postretirement Benefits	
	Target	Actual	Target	Actual
Short-term	0.0%	4.4%	0.0%	6.1%
Equity:				
US equities	12.3%	14.7%	11.0%	13.1%
International equities	12.4%	11.7%	13.0%	12.9%
Emerging markets equities	6.4%	6.5%	10.0%	9.2%
Debt:				
US treasuries	26.4%	9.7%	6.0%	2.8%
Corporate bonds	0.1%	14.0%	0.0%	1.6%
Absolute return	23.9%	21.9%	34.0%	30.1%
Real estate	3.4%	2.5%	6.5%	5.4%
Private equity	11.7%	11.0%	13.0%	13.3%
Natural resources	3.4%	3.6%	6.5%	5.5%
Total	100.0%	100.0%	100.0%	100.0%

12. DEBT OBLIGATIONS

Debt obligations at June 30, 2021 and 2020 are as follows (in thousands):

	Final Maturity	Effective Interest Rate at June 30, 2021	2021	2020
Academic Component:				
<u>Fixed rate debt obligations:</u>				
The Trustees of the University of Pennsylvania				
Series A of 2020 Taxable Bonds	10/2050	2.40%	\$ 300,000	
Series A of 2019 revenue bonds	02/2119	3.610%	300,000	\$ 300,000
Series 2012 Taxable Bonds	09/2112	4.670%	300,000	300,000
Pennsylvania Higher Educational Facilities Authority (PHEFA)				
Series B of 2019 revenue bonds	02/2045	2.40% - 2.97%	213,585	213,585
Series A of 2018 revenue bonds	08/2048	2.08% - 4.70%	183,145	183,145
Series A of 2017 revenue bonds	08/2046	2.26% - 3.72%	178,395	178,395
Series A of 2016 revenue bonds	08/2041	1.27% - 2.93%	119,435	120,680
Series A of 2015 revenue bonds	10/2045	1.59% - 2.63%	43,640	49,125
Series B of 2015 revenue bonds	10/2038	1.59% - 3.38%	153,595	159,460
Series C of 2015 revenue bonds	10/2035	3.680%	8,020	8,020
Series A of 2011 revenue bonds	09/2021	3.68%	3,885	7,590
Series B of 2009 revenue bonds	09/2020	N/A	-	2,245
Other loans	05/2031	3.00% - 5.53%	20,703	21,468
<u>Variable rate debt obligations:</u>				
PHEFA Series of 1990 revenue bonds	12/2020	N/A	-	6,500
Washington County Authority Series of 2004	07/2034	0.02%	46,500	48,900
Total Academic Component outstanding bonds payable			1,870,903	1,599,113
Unamortized issuance costs, premiums and discounts, net			58,518	66,130
Total Academic Component debt obligations			\$ 1,929,421	\$ 1,665,243
UPHS:				
<u>Fixed rate debt obligations:</u>				
Lancaster County Hospital Authority (LCHA)				
Series A of 2016 revenue bonds	08/2042	1.45% - 3.52%	\$ 152,150	\$ 156,455
Series B of 2016 revenue bonds	08/2046	1.43% - 3.58%	128,050	128,050
PHEFA				
Series A of 2021 revenue bonds	08/2044	1.61% - 2.11%	79,810	-
Series A of 2019 revenue bonds	08/2049	1.67% - 3.22%	534,870	534,870
Series A of 2017 revenue bonds	08/2047	2.60% - 3.68%	400,000	400,000
Series C of 2016 revenue bonds	08/2041	1.10% - 3.08%	128,125	128,435
Series A of 2015 revenue bonds	08/2045	1.80% - 4.00%	235,055	257,495
Series A of 2012 revenue bonds	08/2042	2.50% - 4.08%	132,140	134,650
Series A of 2009 revenue bonds	08/2021	4.67%	1,545	12,115
New Jersey Health Care Facilities Financing Authority (NJHCFFA)				
Princeton Healthcare System Series A of 2016	07/2039	1.86% - 3.875%	168,400	173,660
University of Pennsylvania Health System Taxable Note	08/2047	4.01%	200,000	200,000
Lancaster General Hospital 2015 Taxable Note	08/2022	2.66%	65,193	67,798
Mortgages, notes and other	Various	Various	110,429	160,914
<u>Variable rate debt obligations:</u>				
PHEFA Series A of 2014 revenue bonds	08/2044	N/A	-	100,000
PHEFA Series A of 2008 revenue bonds	01/2038	0.02%	69,995	69,995
NJHCFFA Princeton Healthcare System Series B of 2016	07/2045	0.61%	65,000	65,000
NJHCFFA Princeton Healthcare System Series C of 2016	07/2045	0.62%	20,000	20,000
Total UPHS outstanding bonds payable			2,490,762	2,609,437
Unamortized issuance costs, premiums and discounts, net			187,411	181,480
Total UPHS debt obligations			2,678,173	2,790,917
TOTAL DEBT OBLIGATIONS			\$ 4,607,594	\$ 4,456,160

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Contractual maturities of debt obligations are as follows (in thousands):

Fiscal Year	Academic		Total
	Component	UPHS	
2022	\$ 26,086	\$ 60,335	\$ 86,421
2023	26,520	116,642	143,162
2024	35,151	58,741	93,892
2025	29,128	62,262	91,390
2026	44,545	64,453	108,998
Thereafter	1,709,473	2,128,329	3,837,802
Total Principal	1,870,903	2,490,762	4,361,665
Unamortized issuance costs, premiums & discounts	58,518	187,411	245,929
TOTAL DEBT OBLIGATIONS	\$ 1,929,421	\$ 2,678,173	\$ 4,607,594

The University has letters of credit with various financial institutions to secure certain self-insured liabilities totaling \$12,535,000 and \$19,096,000 at June 30, 2021 and 2020, respectively, of which \$3,065,000 and \$8,843,000 and were issued under a line of credit. The letters of credit have evergreen provisions for automatic renewal. There have been no draws under the letters of credit.

Academic Component

On July 14, 2020, the Trustees of the University of Pennsylvania (the "University") issued Taxable Bonds, Series A of 2020 in the aggregate principal amount of \$300,000,000. The proceeds of the sale of the Series A of 2020 Bonds will be used by the University for its general corporate purposes, including the financing or refinancing of capital projects and the payment of the cost of issuing the Series A of 2020 Bonds. Interest on the Series A of 2020 is fixed with coupons of 2.396%.

On August 6, 2019, the Trustees of the University of Pennsylvania (the "University") issued Taxable Bonds, Series A of 2019 in the aggregate principal amount of \$300,000,000. The proceeds of the sale of the Series A of 2019 Bonds will be used by the University for its general corporate purposes, including the financing or refinancing of capital projects and the payment of the cost of issuing the Series A of 2019 Bonds. Interest on the Series A of 2019 is fixed with coupons of 3.61%.

On August 14, 2019, Pennsylvania Higher Educational Facilities Authority (PHEFA) issued Series B of 2019 Taxable Refunding Revenue Bonds (PHEFA 2019B bonds) with an aggregate principal amount of \$213,585,000. The proceeds were used to fund an escrow which will be used to refund \$16,935,000 from the PHEFA Series 2010 revenue bonds, \$136,745,000 PHEFA Series A of 2015, and \$45,570,000 from the PHEFA Series A of 2016. The refunded bonds were legally defeased, and as such are no longer included among the University's reported liabilities. Interest on the PHEFA 2019B bonds is fixed with coupons ranging between 2.40% and 2.97%.

As a result of the legal defeasance of debt associated with the issuance of PHEFA 2019B bonds, the University reported a loss on early extinguishment of debt in Pension, OPEB and other, net on the Consolidated Statements of Activities in the amount of \$3,618,000 for the year ended June 30, 2020.

The University has variable rate debt in the amount of \$46,500,000 which is subject to optional tender by the holders upon seven days' notice. These bonds are reflected in the table above based on original scheduled maturities. In the event that the University receives notice of any optional tender on its variable rate demand bonds, the purchase price will be repaid from the remarketing of the bonds. However, in the event that the entire remarketing effort were to fail, the University would have the general obligation to purchase the bonds.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

On June 14, 2016, the University entered into a five-year agreement with a financial institution, whereby the institution has agreed to provide a line of credit in the amount of \$100,000,000 for general purposes of the University. The agreement ended on June 13, 2021. On June 14, 2021, the University entered into a new five-year agreement with a financial institution to provide a line of credit in the amount of \$100,000,000 for general purposes of the University. The University pays a fee annually on the unused amount of the line of credit. As of June 30, 2021 and 2020, amounts drawn under these agreements total \$0 and \$1,000,000, respectively.

UPHS

The PHEFA Revenue Bonds, Lancaster County Hospital Authority (LCHA) Revenue Bonds and New Jersey Health Care Facilities Financing Authority (NJHCFFA) Revenue Bonds are secured by master notes issued under the UPHS Master Trust Indenture (MTI). The MTI and related agreements contain certain restrictive covenants which limit the issuance of additional indebtedness, and among other things, require UPHS to meet an annual debt service coverage requirement of "income available for debt service" (excess of revenue over expenses plus depreciation, amortization, interest expense and extraordinary items) at an amount equal to 110% of the annual debt service requirements. If the coverage requirement for a particular year is not met, within six months of the close of that fiscal year, UPHS must retain the services of a consultant to make recommendations to improve the coverage requirement. UPHS must also implement the recommendations of the consultant to the extent that they can be feasibly implemented. UPHS will not be considered to be in default of the provisions of the MTI so long as UPHS has sufficient cash flow to pay total operating expenses and debt service for the fiscal year. In both 2021 and 2020, UPHS met its debt service coverage requirement under the MTI. Additionally, UPHS has pledged its gross revenues to secure its obligation under the MTI.

On April 13, 2021, Pennsylvania Higher Educational Facilities Authority (PHEFA) issued Series A of 2021 Refunding Revenue Bonds (PHEFA 2021A bonds) with an aggregate principal amount of \$79,810,000. The proceeds were immediately used to fully redeem \$100,000,000 from the PHEFA Series A of 2014 revenue bonds. The redeemed bonds are no longer included among UPHS' reported liabilities. Interest on the PHEFA 2021A bonds is fixed with coupons ranging between 1.61% and 2.11%.

As a result of the redemption of debt associated with the issuance of PHEFA 2021A bonds, UPHS reported a loss on early extinguishment of debt in Pension, OPEB and other, net on the Consolidated Statements of Activities in the amount of \$310,000 for the year ended June 30, 2021.

On May 18, 2022, Pennsylvania Higher Educational Facilities Authority (PHEFA) will issue Series B of 2021 Refunding Revenue Bonds (PHEFA 2021B bonds), which will be a forward delivery, with an aggregate principal amount of \$109,735,000. The proceeds will be used to fund an escrow which will be used to refund \$122,275,000 from the PHEFA Series A of 2012 revenue bonds. The refunded bonds will be legally defeased and will no longer be included among UPHS' reported liabilities. Interest on the PHEFA 2021B bonds is fixed with coupons ranging between 0.82% and 2.70%.

On December 5, 2019, Pennsylvania Higher Educational Facilities Authority (PHEFA) issued UPHS Series A of 2019 revenue bonds in an aggregate principal amount of \$534,870,000. The proceeds were used to reimburse UPHS for \$484,738,000 incurred in relation to various capital projects, and \$112,276,000 of the remaining proceeds, including the issued premium, were deposited in a capital project fund held by trustee to be drawn upon for future capital expenditures. This portion of the financing is reflected as a noncash transaction in the Statement of Cash Flows. Future reimbursements from the capital project fund will be accounted for as a cash inflow from investing activities in the Statement of Cash Flows. The bonds have stated interest rates that range between 3.00% and 5.00%.

UPHS has variable rate debt in the amount of \$69,995,000 which is subject to optional tender by the holders upon seven days' notice. These bonds are reflected in the debt obligations maturity table above based on original

scheduled maturities. In the event that UPHS receives notice of any optional tender on its variable rate demand bonds, the purchase price will be repaid from the remarketing of the bonds. However, in the event that the entire remarketing effort were to fail, UPHS has in place a renewable direct pay letter of credit issued by Bank of America with an expiration date of April 15, 2023. In the event that the letter of credit cannot be drawn upon, UPHS would have the general obligation to purchase the bonds.

UPHS secured an \$82,132,000 loan on December 21, 2018 for the sole purpose of funding the development of a new ambulatory building. As of June 30, 2020, the entire balance has been drawn down to reimburse construction costs incurred by UPHS and is accounted for as a cash inflow from investing activities in the Statement of Cash Flows.

UPHS maintains a \$100,000,000 line of credit with a maturity date of April 13, 2022 to supplement liquidity and issue letters of credit to cover balances due on construction projects and reinsurance agreements. There were no outstanding balances as of June 30, 2021 and 2020.

Interest Rate Swap Agreements

The University enters into interest rate swap agreements to synthetically modify the interest rate terms of its long-term debt portfolio. These agreements are not entered into for trading or speculative purposes. Fair value of these agreements is determined by obtaining quotes from Goldman Sachs Mitsui Marine Derivative Products, L.P. (GSMMDP) and Merrill Lynch, respectively, which are based on the income approach, using observable market data to discount future net payment streams and accordingly considers this to be a Level 2 measurement. The quotes provided also represent the amount the University would accept or be required to pay to transfer the agreement to GSMMDP and Merrill Lynch, respectively, or exit price as defined by the Fair Value Measurements standard. The University also takes into account the risk of nonperformance.

The following table summarizes the terms of the University’s remaining interest rate swap agreements (in thousands):

	Academic Component		UPHS		
Notional Amounts	\$ 101,950	\$ 10,790	\$ 10,790	\$ 20,900	
Trade Date	11/6/2007	7/15/2009	1/7/2010	7/28/2006	
Maturity Date	7/1/2034	8/15/2023	8/15/2023	7/1/2041	
Rates:					
Receive	67% of 1-Month LIBOR	3.184%	2.902%	70% of 1-Month LIBOR	
Pay	3.573%	SIFMA Index	SIFMA Index	3.980%	

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The following table summarizes the fair value of the interest rate swap agreements, not designated as hedging instruments, as of June 30, 2021 and 2020, and the related gains/(losses) on the interest rate swap agreements, both realized and unrealized, for the years ended June 30, 2021 and 2020 (in thousands):

Line Item	2021	2020
Consolidated Statements of Financial Position:		
Asset interest rate swaps:		
UPHS	\$ 757	\$ 1,425
Other assets		
Total asset interest rate swaps	\$ 757	\$ 1,425
Liability interest rate swaps:		
Academic Component	\$ 21,372	\$ 28,801
UPHS	6,517	8,854
Total liability interest rate swaps	\$ 27,889	\$ 37,655
Consolidated Statements of Activities:		
Academic Component	\$ 3,583	\$ (9,772)
UPHS	2,334	511
Total	\$ 5,917	\$ (9,261)

13. NET ASSETS

The major components of net assets at June 30, 2021 and 2020 are as follows (in thousands):

2021	Without donor restrictions	With donor restrictions	Total
General operating	\$ 5,489,628	\$ 612,678	\$ 6,102,306
Sponsored programs	69,896		69,896
Capital		179,635	179,635
Student loans	7,137		7,137
Planned giving agreements		66,550	66,550
Quasi-endowment	10,337,266		10,337,266
Endowment, subject to spending rule		5,552,009	5,552,009
Endowment, held in perpetuity		4,634,271	4,634,271
TOTAL NET ASSETS	\$ 15,903,927	\$ 11,045,143	\$ 26,949,070

2020	Without donor restrictions	With donor restrictions	Total
General operating	\$ 3,931,320	\$ 503,062	\$ 4,434,382
Sponsored programs	63,592		63,592
Capital		130,462	130,462
Student loans	7,713		7,713
Planned giving agreements		52,757	52,757
Quasi-endowment	7,363,736		7,363,736
Endowment, subject to spending rule		3,109,738	3,109,738
Endowment, held in perpetuity		4,403,889	4,403,889
TOTAL NET ASSETS	\$ 11,366,361	\$ 8,199,908	\$ 19,566,269

14. LEASES

The University leases research labs and office space under operating leases expiring through December 2043. On the Consolidated Statements of Financial Position, lessees are required to record Right-of-Use assets, representing the right to use the underlying assets for the lease term, and Lease liabilities, representing the obligation to make lease payments arising from the lease based on the present value of lease payments over the lease term. The University has made the following elections: (1) to adopt a package of practical expedients relating to reassessment, (2) to exclude leases with a term of less than one year, and (3) to use an incremental borrowing rate for discounting leases, as applicable. At June 30, 2021, Right-of-Use assets recorded in Other assets were \$482,065,000 and Lease liabilities recorded in Accrued expenses and other liabilities were \$488,329,000. At June 30, 2021, the weighted average remaining lease term was 10.0 years and the weighted average discount rate was 2.72%. Rental expense, for the years ended June 30, 2021 and 2020, totaled \$137,693,000 and \$136,529,000 (including amortizations related to Right-of-Use assets and Lease liabilities of \$35,931,000 and \$68,189,000), respectively. Rental expense is included in Other operating expenses on the Consolidated Statements of Activities.

Future maturities of lease liabilities at June 30, 2021 are as follows (in thousands):

Year ending June 30,	
2022	\$ 86,434
2023	73,136
2024	69,201
2025	63,704
2026	49,282
Thereafter	242,104
Total lease payments	\$ 583,861
Less imputed interest	(95,532)
Total Future lease payments	\$ 488,329

15. FUNCTIONAL CLASSIFICATION OF EXPENDITURES

Expenses for the years ended June 30, 2021 and 2020 are categorized on a functional basis as follows (in thousands):

2021	Instruction, student services & academic support	Hospital & physician practices	Research	Institutional support	Enterprises & independent operations	Total
Compensation and benefits	\$ 1,194,366	\$ 4,526,333	\$ 519,767	\$ 282,531	\$ 190,889	\$ 6,713,886
Depreciation and amortization	91,631	333,710	46,595	21,546	59,453	552,935
Interest on indebtedness	15,844	35,597	23,912	184	12,499	88,036
Other operating expense	532,615	3,155,502	390,292	26,623	141,579	4,246,611
Total operating expense	1,834,456	8,051,142	980,566	330,884	404,420	11,601,468
Non-service net periodic benefit cost	5,285	20,031	2,300	1,251	844	29,711
Total	\$ 1,839,741	\$ 8,071,173	\$ 982,866	\$ 332,135	\$ 405,264	\$ 11,631,179

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

2020	Instruction, student services & academic support	Hospital & physician practices	Research	Institutional support	Enterprises & independent operations	Total
Compensation and benefits	\$ 1,095,779	\$ 4,256,950	\$ 490,783	\$ 266,324	\$ 203,832	\$ 6,313,668
Depreciation and amortization	88,149	324,642	44,648	20,510	57,054	535,003
Interest on indebtedness	16,027	36,741	23,637	207	11,148	87,760
Other operating expense	532,648	2,929,459	332,312	42,231	171,605	4,008,255
Total operating expense	1,732,603	7,547,792	891,380	329,272	443,639	10,944,686
Non-service net periodic benefit cost	1,880	7,302	842	457	350	10,831
Total	\$ 1,734,483	\$ 7,555,094	\$ 892,222	\$ 329,729	\$ 443,989	\$ 10,955,517

Operation and maintenance of PPE and depreciation are allocated to functional classifications based on square footage. Interest expense is generally allocated to functional classifications of the activity that directly benefited from the proceeds of the debt. Non-service net periodic benefit cost is allocated to functional classifications based on compensation and benefits.

16. LIQUIDITY AND AVAILABILITY

As of June 30, 2021 and 2020, respectively, financial assets and liquidity resources available within one year for general expenditure, such as operating expenses, scheduled principal payments on debt and capital construction costs not financed with debt, were as follows (in thousands):

	2021	2020
Financial assets:		
Cash & cash equivalents	\$ 2,406,233	\$ 2,117,979
Receivables, net	1,591,996	1,213,513
Pledge payments available for operations	65,743	65,559
Investments	8,823,927	7,103,005
Total financial assets available within one year	12,887,899	10,500,056
Liquidity resources:		
Bank lines of credit	196,935	340,157
Total financial assets and liquidity resources available within one year	\$ 13,084,834	\$ 10,840,213

The University's cash flows have seasonal variations during the year attributable to tuition billing, patient service reimbursement and a concentration of contributions received at calendar and fiscal year-end. To manage liquidity, the University maintains lines of credit with several banks that are drawn upon as needed during the year to manage cash flows. Management has the discretion to utilize the full amount of quasi-endowment funds for general expenditures.

17. SUBSEQUENT EVENTS

The University has evaluated subsequent events for the period from June 30, 2021 through September 23, 2021, the date the consolidated financial statements were issued.

Schedule of Expenditures of Federal Awards

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2020 - 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DEPARTMENT OF AGRICULTURE									
AGRICULTURAL RESEARCH BASIC AND APPLIED RESEARCH	10.001		CRDF GLOBAL	59-0210-8-184	\$26,159	\$145,007		RESEARCH AND DEVELOPMENT	\$780,703,439
AGRICULTURAL RESEARCH BASIC AND APPLIED RESEARCH	10.001	58-8072-0-016			\$40,941	\$145,007		RESEARCH AND DEVELOPMENT	\$780,703,439
AGRICULTURAL RESEARCH BASIC AND APPLIED RESEARCH	10.001		CRDF GLOBAL	59-0210-6-004	\$77,907	\$145,007		RESEARCH AND DEVELOPMENT	\$780,703,439
PLANT AND ANIMAL DISEASE, PEST CONTROL, AND ANIMAL CARE	10.025	AP19VNSVLS00C030			\$11	\$382,646		RESEARCH AND DEVELOPMENT	\$780,703,439
PLANT AND ANIMAL DISEASE, PEST CONTROL, AND ANIMAL CARE	10.025	AP21VSD&B000C049			\$455	\$382,646		RESEARCH AND DEVELOPMENT	\$780,703,439
PLANT AND ANIMAL DISEASE, PEST CONTROL, AND ANIMAL CARE	10.025	AP19PPQS&T00C206			\$3,768	\$382,646		RESEARCH AND DEVELOPMENT	\$780,703,439
COMMONWEALTH OF PENNSYLVANIA									
PLANT AND ANIMAL DISEASE, PEST CONTROL, AND ANIMAL CARE	10.025			4420908	\$112,577	\$382,646		RESEARCH AND DEVELOPMENT	\$780,703,439
PLANT AND ANIMAL DISEASE, PEST CONTROL, AND ANIMAL CARE	10.025	AP20VSD&B000C048			\$121,779	\$382,646		RESEARCH AND DEVELOPMENT	\$780,703,439
PLANT AND ANIMAL DISEASE, PEST CONTROL, AND ANIMAL CARE	10.025	AP20VSD&B000C012			\$144,056	\$382,646		RESEARCH AND DEVELOPMENT	\$780,703,439
ANIMAL HEALTH AND DISEASE RESEARCH	10.207	NI19AHDRXXXG046			\$5,164	\$44,821		RESEARCH AND DEVELOPMENT	\$780,703,439
ANIMAL HEALTH AND DISEASE RESEARCH	10.207	NI20AHDRXXXG015			\$39,657	\$44,821		RESEARCH AND DEVELOPMENT	\$780,703,439
AGRICULTURAL AND RURAL ECONOMIC RESEARCH, COOPERATIVE AGREEMENTS AND COLLABORATIONS	10.250	58-4000-5-0092			\$24,466	\$24,466		RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2017-67015-26910			\$150	\$403,745		RESEARCH AND DEVELOPMENT	\$780,703,439
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2021-67015-34830			\$9,395	\$403,745		RESEARCH AND DEVELOPMENT	\$780,703,439
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2021-67015-33385			\$44,292	\$403,745		RESEARCH AND DEVELOPMENT	\$780,703,439
TEXAS A&M UNIVERSITY									
COVID-19 - AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310			M2003104	\$50,556	\$403,745		RESEARCH AND DEVELOPMENT	\$780,703,439
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2017-67015-26910			\$111,877	\$403,745		RESEARCH AND DEVELOPMENT	\$780,703,439
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2017-67021-26601			\$1,473	\$51,786		RESEARCH AND DEVELOPMENT	\$780,703,439
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2018-67015-27494			\$20,568	\$135,689		RESEARCH AND DEVELOPMENT	\$780,703,439
STATE ADMINISTRATIVE MATCHING GRANTS FOR THE SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM	10.561		PENNSYLVANIA STATE UNIVERSITY	5541-TUP-COP-9151	-\$5,953	\$921,852		SNAP CLUSTER	\$921,852
COVID-19 - STATE ADMINISTRATIVE MATCHING GRANTS FOR THE SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM	10.561		PENNSYLVANIA STATE UNIVERSITY	S000426-COP-UN	\$41	\$921,852		SNAP CLUSTER	\$921,852
COVID-19 - STATE ADMINISTRATIVE MATCHING GRANTS FOR THE SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM	10.561		PENNSYLVANIA STATE UNIVERSITY	S000426-COP-UN	\$193	\$921,852		SNAP CLUSTER	\$921,852
STATE ADMINISTRATIVE MATCHING GRANTS FOR THE SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM	10.561		PENNSYLVANIA STATE UNIVERSITY	S000426-COP-UN	\$235,544	\$921,852		SNAP CLUSTER	\$921,852
STATE ADMINISTRATIVE MATCHING GRANTS FOR THE SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM	10.561		PENNSYLVANIA STATE UNIVERSITY	S000426-COP-UN	\$692,027	\$921,852		SNAP CLUSTER	\$921,852
NATURE AND HUMAN HEALTH	10.RD	19-JV-11242308-090			\$14,998	\$14,998		RESEARCH AND DEVELOPMENT	\$780,703,439
TOTAL DEPARTMENT OF AGRICULTURE					\$22,041	\$1,937,535			
DEPARTMENT OF COMMERCE									
MEASUREMENT AND ENGINEERING RESEARCH AND STANDARDS	11.609		IOWA STATE UNIVERSITY	022284H	\$32,359	\$32,359		RESEARCH AND DEVELOPMENT	\$780,703,439
ARRANGEMENTS FOR INTERDISCIPLINARY RESEARCH INFRASTRUCTURE	11.619		UNIVERSITY OF DELAWARE	SUB TO 70NANB17H002	\$6,931	\$19,765		RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL INSTITUTE FOR INNOVATION IN MANUFACTURING BIOPHARMACEUTICALS									
ARRANGEMENTS FOR INTERDISCIPLINARY RESEARCH INFRASTRUCTURE	11.619			PC3.L-121	\$12,834	\$19,765		RESEARCH AND DEVELOPMENT	\$780,703,439
TOTAL DEPARTMENT OF COMMERCE						\$52,124			
DEPARTMENT OF DEFENSE									
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-16-1-2539			-\$29,664	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439
GEORGIA INSTITUTE OF TECHNOLOGY									
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300			RF228-G2	-\$18,509	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-16-1-2195			-\$1,207	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-01-2076			-\$1,149	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-1-2690			-\$863	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-18-1-2021			\$98	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-10-1-0942			\$506	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-14-1-0761			\$514	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300		DUKE UNIVERSITY	SUB TO ONR ADV ACCT	\$3,561	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	ADVANCE ACCOUNT			\$5,676	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-16-1-2350			\$20,587	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	W9126G-20-2-0033			\$26,478	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-20-1-2635			\$75,737	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-20-1-2701			\$78,566	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-1-2248			\$89,405	\$10,504,627		RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-1-2574				\$101,140	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-1-2093				\$103,177	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-1-2620				\$144,603	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-18-1-2580				\$146,262	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	FA8750-20-20-0501				\$168,210	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300		STANFORD UNIVERSITY	62145214-107484		\$179,769	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-1-2353				\$182,166	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-16-1-2817				\$183,634	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300		UNIVERSITY OF MASSACHUSETTS-AMHERST	17-009730 A 00		\$195,885	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-20-1-2822				\$213,951	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00015-16-1-2010				\$285,345	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-20-1-2744				\$287,714	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-15-1-2029				\$298,667	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-1-2253				\$305,767	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-18-1-2618				\$324,535	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-18-1-2557				\$408,527	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-20-1-2372				\$422,954	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300		UNIVERSITY OF ILLINOIS RENSSELAER POLYTECHNIC INSTITUTE	099963-17889		\$446,551	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300			A20-0047-5002		\$638,222	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-18-1-2021				\$669,449	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-1-2690				\$6,285	\$10,504,627	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	FA8750-19-2-3334				\$14,615	\$202,796	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-1-2012				\$96,429	\$331,239	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-1-2930				\$128,660	\$171,700	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-20-1-2115				\$147,125	\$381,373	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-1-2643				\$375,951	\$391,703	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-1-2661				\$779,558	\$1,033,299	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-18-1-2497				\$1,171,347	\$2,029,968	RESEARCH AND DEVELOPMENT	\$780,703,439
SCIENTIFIC RESEARCH - COMBATING WEAPONS OF MASS DESTRUCTION	12.351		UNIVERSITY OF MICHIGAN	SUBK00009972		\$196,413	\$196,413	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0264				-\$10,698	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0404				-\$8,049	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0399				-\$5,756	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	8901940917		-\$4,335	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	102255C		-\$3,735	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810503				\$471	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		NATIONAL TRAUMA INSTITUTE	NTI-CLOTT17-04		\$510	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF CINCINNATI	010376-003		\$530	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF WASHINGTON	UWSC9138		\$3,164	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		CASE WESTERN RESERVE UNIVERSITY	RES515708		\$3,316	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		FOX CHASE CANCER CENTER	27799-01		\$4,337	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1820067				\$5,629	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0796				\$7,530	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF MASSACHUSETTS VANDERBILT UNIVERSITY MEDICAL CENTER	19-010887-A 00		\$10,018	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420			VUMC86814		\$14,290	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF MARYLAND-BALTIMORE COUNTY	D0000006-01		\$15,218	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		GEORGE WASHINGTON UNIVERSITY	20-M20		\$19,304	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		DANA-FARBER CANCER INSTITUTE	3086701		\$19,338	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF MARYLAND	F302347-17		\$20,515	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION	1820		\$21,313	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		FOX CHASE CANCER CENTER	22782-01		\$26,779	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		GEORGETOWN UNIVERSITY	413814_GRA13762-UPENN		\$27,994	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810274				\$29,668	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		THOMAS JEFFERSON UNIVERSITY	08004000X16001		\$30,579	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0595				\$38,497	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	8901940917		\$38,872	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000404		\$44,391	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		MICHIGAN STATE UNIVERSITY	RC110291UP		\$52,789	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810734				\$57,677	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		MOFFITT CANCER CTR	12-18717-99-1-G2		\$60,736	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000254		\$76,545	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0594				\$82,942	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810635				\$83,716	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	11330SC		\$85,182	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		UNIVERSITY OF ILLINOIS AT CHICAGO	17094		\$93,828	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010531				\$101,934	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010009				\$106,939	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810289				\$111,194	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010417				\$112,315	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010838				\$117,526	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-14-1-0060				\$119,302	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010901				\$122,002	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2020022				\$127,749	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1910137				\$150,775	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0404				\$180,983	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010025				\$208,495	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010856				\$209,406	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0082				\$209,555	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010490				\$243,045	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0092				\$248,168	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010206				\$257,603	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810503				\$597,437	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010008				\$724,259	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1920002				\$824,566	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0447				\$70	\$87,778	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		CITIZENS UNITED FOR RESEARCH IN EPILEPSY	CURE	\$21,019	\$207,434	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010242				\$47,249	\$279,644	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1910461				\$54,530	\$367,405	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH18C0163				\$54,697	\$244,151	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1910861				\$76,344	\$336,790	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1910829				\$124,360	\$268,849	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		DENVER RESEARCH INSTITUTE	MSRC-FY19-02	\$145,302	\$325,274	\$8,348,771	RESEARCH AND DEVELOPMENT	\$780,703,439
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0555				\$430,788	\$515,088	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431		GOOD JUDGMENT	N/A			\$5,703,591	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-17-1-0083					\$5,703,591	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-11-1-0403					\$18	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910458					\$5,571	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910155					\$6,099	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF2110148					\$9,180	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431		UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN	0078446-16767			\$22,201	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF2110076					\$26,890	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431		NORTHEASTERN UNIV CALIFORNIA INSTITUTE OF TECHNOLOGY	504139-78050			\$40,523	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431			52-1097908			\$41,794	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-17-1-0438					\$43,296	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1810224					\$48,062	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910350					\$49,124	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431		JOHNS HOPKINS UNIVERSITY	2004717370			\$74,646	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-17-1-0436					\$91,873	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431		UNIVERSITY OF ROCHESTER	417358 / URFAO: GR510801			\$131,146	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910342					\$131,539	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431		UNIVERSITY OF CALIFORNIA, SANTA BARBARA	KK1711			\$132,094	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910109					\$134,592	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910087					\$152,678	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910503					\$163,679	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910249					\$192,232	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF2010113					\$206,551	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF2010080					\$76,717	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-17-1-0229					\$119,406	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1810244					\$184,044	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910263					\$223,716	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1810327					\$684,215	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC, APPLIED, AND ADVANCED RESEARCH IN SCIENCE AND ENGINEERING	12.630		AUBURN UNIVERSITY	21-ARCPAL-203229-UPENN			\$1,763	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC, APPLIED, AND ADVANCED RESEARCH IN SCIENCE AND ENGINEERING	12.630	HQ00342110001					\$15,066	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC, APPLIED, AND ADVANCED RESEARCH IN SCIENCE AND ENGINEERING	12.630		UNIVERSITY OF MASSACHUSETTS	S51330000044313			\$30,862	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC, APPLIED, AND ADVANCED RESEARCH IN SCIENCE AND ENGINEERING	12.630	FA9550-18-1-0194					\$117,374	RESEARCH AND DEVELOPMENT	\$780,703,439
BASIC, APPLIED, AND ADVANCED RESEARCH IN SCIENCE AND ENGINEERING	12.630	W911NF-17-2-0181					\$4,055,171	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA2386-18-1-4083					\$12,702	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA2386-17-1-4656				\$12,286	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA-9550-21-1-0035				\$15,438	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-20-1-0092				\$20,740	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-20-1-0345				\$57,381	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA2386-20-1-4074				\$57,577	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-18-1-0133				\$65,791	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800		TULANE UNIVERSITY	TUL-SCC-553957-15/16		\$85,154	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-20-1-0060				\$95,020	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-18-1-0497				\$116,853	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800		WRIGHT STATE UNIVERSITY	669737-1		\$121,510	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9950-19-1-0285				\$145,164	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-20-1-0111				\$204,181	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-19-1-0326				\$211,483	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-19-1-0265				\$235,772	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800		UNIVERSITY OF TEXAS AT AUSTIN	UTA16-001254		\$305,060	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800		EMORY UNIVERSITY	A007760		\$312,580	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA2386-18-1-4083				\$41,077	\$2,090,365	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011623730 & HR0011623730-1							
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910		RUTGERS UNIVERSITY	5911		-\$1	\$5,311,173	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	FA8650-18-1-7828				\$46,965	\$5,311,173	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910		WISTAR INSTITUTE	36000-01-374-UPENN		\$59,882	\$5,311,173	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910		CENTER FOR OPEN SCIENCE	SUB TO N660011924015		\$65,812	\$5,311,173	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR00111820056				\$67,240	\$5,311,173	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	FA8620-21-1-7010				\$74,064	\$5,311,173	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	FA8650-21-1-7011				\$99,998	\$5,311,173	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-19-2-0013				\$118,407	\$5,311,173	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-19-2-0013				\$121,055	\$5,311,173	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	W911NF2010278				\$122,876	\$5,311,173	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910		NEW YORK UNIVERSITY	F1400-03		\$310,782	\$5,311,173	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	FA8750-19-2-0201				\$156,508	\$886,507	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-16-C-0056				\$453,770	\$5,311,173	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	FA8750-18-2-0117				\$694,557	\$5,311,173	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-19-2-0016				\$797,846	\$1,424,685	RESEARCH AND DEVELOPMENT	\$780,703,439
INSIGHT: A SILICON NEURAL PROBE VISUAL PROSTHESIS SYSTEM SECURITY INTEGRATED THROUGH HARDWARE AND FIRMWARE (SSITH)	12.RD	2017-606-001	SCIENTIFIC AND BIOMEDICAL MICROSYSTEMS, LLC	2017-PENN-001		-\$17,558	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
TAMBA: TESTING AND MODELING OF BRANDEIS ARTIFACTS	12.RD	HR001118C0011	DRAPER LABORATORY	SUB TO HR001118C0011		-\$3,315	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
FUEL-EFFICIENT NANO FLUID GEAR OIL	12.RD	BAA-15-29	GALOIS, INC.	2015-016		-\$158	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - US ARMY COMBAT CAPABILITIES DEVELOPMENT	12.RD	W56HZ-18-C-0025	PIXELLIGENT TECHNOLOGIES	10053480		\$641	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
COMMAND - CHEMICAL BIOLOGICAL EXPLOITING LANGUAGE INFORMATION FOR SITUATIONAL AWARENESS (ELISA)	12.RD	(BLANK)	EXCET, INC	9638		\$5,847	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
REAL-TIME COMPUTER VISION	12.RD	HR0011-15-C-0115	UNIVERSITY OF SOUTHERN CALIFORNIA	67104157		\$11,041	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
DEVELOPMENT OF THERAPEUTIC STRATEGIES FOR NF1-ASSOCIATED OPTIC PATHWAY	12.RD	(BLANK)	NOVATEUR RESEARCH SOLUTIONS	SUB TO FA9550-18-C-0050		\$13,440	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
ALUMINUM SCANDIUM NITRIDE MEMS PDK	12.RD	W81XWH-18-1-0685	CHILDREN'S RESEARCH INSTITUTE	30004908-01		\$14,208	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
HYPERSONIC VEHICLE ELECTRICAL POWER GENERATION THROUGH EFFICIENT THERM	12.RD	HR0011-21-9-0004	AKOUSTIS	SUB TO HR0011-21-9-0004		\$14,231	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
WARETOWN WIND TUNNEL IMPROVEMENTS FOR DUNE ECOGEOGRAPHY RESEARCH & NEURAL SIGNALS OF MESSAGE EFFECTIVENESS	12.RD	FA864920P0325	SPARK THERMIONICS	SUB TO FA864920P0325		\$14,984	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
TOP GATED 2D/ALSCN/SIC STRUCTURES FOR SURFACE ACOUSTIC WAVE AMPLIFIERS	12.RD	W912HZ 18P0090				\$15,034	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
REGULATION OF MYELOMA PROGRESSION BY PROTEIN CITRULLINATION	12.RD	FA8650-17-C-7712	NEXT CENTURY CORPORATION	POINT-1001		\$24,021	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
ARMY SBIR A20-018 NOVEL ENERGY HARVESTING TECHNOLOGY FOR UNATTENDED SE	12.RD	HR0011-21-9-0055				\$29,201	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
UNO: UNDERACTUATED NATURALLY-STABILIZED ONE-MOTOR ROBOT SOLUTION-BASED RECEPTORS FOR LARGE SURFACE OPIOIDS CONTAMINATION IDENT	12.RD	W81XWH1910630	WISTAR INSTITUTE	35611-02-370		\$29,652	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
IBIS: IMPLANTABLE BIOLUMINESCENCE INTERFACE SYSTEM FOR AN ALL-OPTICAL	12.RD	W911QX-20-P-0175	LYNNTech	SUB TO W911QX-20-P-0175		\$30,132	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
AUTOMATED RAPID CERTIFICATION OF SOFTWARE (ARCOS) - ARGUMENT COMPREHEN	12.RD	HR001119C0052	ZYMERON CORPORATION	Z116/UPENN		\$38,202	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANSFORMING RESEARCH AND CLINICAL KNOWLEDGE IN TRAUMATIC BRAIN INJURY	12.RD	N66001-17-C-4012	PIERCE (JOHN B.) LABORATORY	275-F		\$39,410	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
INTEGRATED HIGH VOLTAGE BATTERY AND MAGNETIC CONVERSION MICROPOWER SYS	12.RD	FA875020C0515 (AF44)	JOHNS HOPKINS APPLIED PHYSICS LABORATORY	163906		\$44,137	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING QUANTUM FLUCTUATIONS WITH EPSILON-NEAR-ZERO MATERIALS	12.RD	(BLANK)	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	111845C		\$45,726	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
DISTINGUISHING BRAIN STATES AND RESOLVING STATE TRANSITIONS	12.RD	HR001119C0039				\$47,760	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
	12.RD	HR00112090084	UNIVERSITY OF CALIFORNIA, DAVIS	A20-3862-S001		\$50,000	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
	12.RD	W911NF-10-2-0022	DCS CORPORATION	APX02-0006 - TASK ORDER 001		\$52,224	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned by Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DESIGNER OPTICAL SUPERLATTICES FROM EXCITRON MATERIALS	12.RD	FA8650-15-D-5405	UES, INC.	S-111-06G-001		\$67,468	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
APPLYING NOVEL MATERIALS AND FABRICATION TECHNIQUES TO HIGH EFFICIENCY	12.RD	W911NF18C0057	SPARK THERMIONICS	SUB TO W911NF18C0057		\$87,081	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
SELF-RECONFIGURABLE MODULAR GROUND ROBOTS	12.RD	1400D42C0049	TRITON SYSTEMS, INC	TSI-2650-20-20201255		\$90,820	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
BIO-FABRICATED NERVE-MUSCLE COMPLEXES TO AUGMENT REGENERATION AND FACI	12.RD	(BLANK)	PHILADELPHIA RESEARCH AND EDUCATION FOUNDATION	JPA		\$96,150	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
ELECTROMECHANICAL COMPONENTS FOR EFFICIENT, SMALL SCALE POWER CONVERSI	12.RD	2019-19090900002				\$98,809	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
STARKPEPPER	12.RD	H98230-21-D-0013				\$110,810	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
SECURE HANDLING OF ISOLATED EXECUTABLES WITHOUT LEAKING (CLOSURE).	12.RD	HR001119S0017	PERSPECTA LABS INC	PO-0018618		\$124,921	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
CIRCULATING CFDNA FRAGMENTS FOR THE DETECTION AND DIAGNOSIS OF TRAUMAT	12.RD	W81XWH-15-9-0001	CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000206		\$125,737	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
HYPOTHESIS-GUIDED MODEL REVISION OVER MULTIPLE ALIGNED REPRESENTATIONS	12.RD	HR001120C0040	PALO ALTO RESEARCH CENTER	P315541		\$130,450	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
SYSTEMIC GENERATIVE ENGINEERING	12.RD	FA8750-20-C-0542	SIEMENS CORP RES, INC	198-01		\$148,779	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
LINKING INVESTIGATIONS IN TRAUMA AND EMERGENCY SERVICES (LITES)	12.RD	W81XWH-16-D-0024-0002	UNIVERSITY OF PITTSBURGH	0058514-2		\$154,567	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTCAT: AUTONOMIC RESPONSE TO DISRUPTIVE CYBER-ATTACKS	12.RD	N68335-19-C-0200	GRAMMATECH	GT 519-01		\$160,979	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
DOD PHASE II STTR 12.A, TOPIC NO. A12A-T009	12.RD	1400D419C0093	CHARLES RIVER ANALYTICS, INC.	SC1906402		\$214,720	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
BETTER EXTRACTION FROM TEXT TOWARDS ENHANCED RETRIEVAL (BETTER)	12.RD	2019-19051600006	BBN SYSTEMS AND TECHNOLOGIES	SUB TO 2019-19051600006		\$255,818	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
TASK-AND-USER AWARE REPRESENTATION LEARNING FOR FINE GRAINED CROSSLING	12.RD	2019-19051600004	BROWN UNIVERSITY	00001475		\$272,206	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
BEHAVIORAL CHARACTERIZATION OF ODOR DETECTION DOGS FOR SELECTION OF PO	12.RD	70RSAT19CB0000014	BATTELLE MEMORIAL INSTITUTE	769331		\$284,233	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
ROBOTIC PERCEPTION, INTELLIGENCE, AND DEXTEROUS MANIPULATION & UNIQUE	12.RD	W911NF-10-2-0016	GENERAL DYNAMICS ROBOTIC SYSTEMS	PO #40228149		\$359,869	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
DCOMP	12.RD	HR00111-17-C-0047	PERSPECTA LABS INC	PO-0011396		\$400,959	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
POST-CMOS COMPATIBLE ALUMINUM SCANDIUM NITRIDE FERROELECTRIC FIELD EFF	12.RD	HR00112090046				\$410,500	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
MULTIFERROIC VECTOR MAGNETOMETER (MFVM)	12.RD	HR001120C0098	LEIDOS, INC.	P010242159		\$445,390	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
SONICVIPER	12.RD	H98230-15-C-0825				\$1,271,144	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
FOCUS - FORECASTING COUNTERFACTUALS IN UNCONTROLLED SETTINGS	12.RD	140D0419C0049				\$2,074,700	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
ELECTROCHEMICAL DEPOSITION OF THICK AND CONTINUOUS ELECTRODES FOR HIGH	12.RD	HR001119C0056			\$18,412	\$20,098	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
INTEGRATED STATIC AND DYNAMIC APPROACHES TO HIGH-ASSURANCE FOR LEARNIN	12.RD	FA8750-18-C-0090			\$87,929	\$1,233,097	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
CORPORA OF ANNOTATED EVENTS REPRESENTED UNDER SCHEMAS (CAERUS)	12.RD	FA8750-19-C-0203			\$144,143	\$1,240,021	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
RESTORING MEMORY WITH TASK-INDEPENDENT SEMI-CHRONIC CLOSED-LOOP DIRECT	12.RD	W81XWH-20-9-0020	MEDICAL TECHNOLOGY ENTERPRISE CONSORTIUM (MTEC)	2020-639	\$337,053	\$835,960	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
CAIRO-MS: CONFLICTING ACCOUNT INFORMATION RESOURCES IN OMNIVOROUS MEDI	12.RD	FA8750-18-C-0013			\$409,561	\$1,637,523	\$12,883,168	RESEARCH AND DEVELOPMENT	\$780,703,439
DARPA JPA #0246 J.M. SMITH	12.U01	JPA 0246				\$296,164	\$296,164	OTHER PROGRAMS	\$233,218,639
TOTAL DEPARTMENT OF DEFENSE						\$12,261,821	\$51,811,503		
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT									
COVID-19 - COMMUNITY DEVELOPMENT BLOCK GRANTS/ENTITLEMENT GRANTS	14.218		COUNTY OF LANCASTER REDEVELOPMENT AUTHORITY OF	CDBG-CV PROGRAM FUNDS		\$15,855	\$15,855	OTHER PROGRAMS	\$233,218,639
COVID-19 - EMERGENCY SOLUTIONS GRANT PROGRAM	14.231		COUNTY OF LANCASTER	ESG CV COUNTY		\$116,983	\$257,074	OTHER PROGRAMS	\$233,218,639
COVID-19 - EMERGENCY SOLUTIONS GRANT PROGRAM	14.231		CITY OF LANCASTER	ESG CV CITY		\$140,091	\$257,074	OTHER PROGRAMS	\$233,218,639
HOMELESS MANAGEMENT INFORMATION SYSTEMS TECHNICAL ASSISTANCE	14.261		ABT ASSOCIATES INC.	50001		-\$19,667	-\$19,667	RESEARCH AND DEVELOPMENT	\$780,703,439
CONTINUUM OF CARE PROGRAM	14.267	N/A				\$763,781		OTHER PROGRAMS	\$233,218,639
HUD COMMUNITY COMPASS TECHNICAL ASSISTANCE AND CAPACITY BUILDING PROGR	14.RD	H-18-TA-MD-0001	ABT ASSOCIATES INC.	51536		\$31,469	\$31,469	RESEARCH AND DEVELOPMENT	\$780,703,439
TOTAL DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT							\$1,048,512		
DEPARTMENT OF THE INTERIOR									
YOUTH ENGAGEMENT, EDUCATION, AND EMPLOYMENT	15.676	F19AC00830				\$37,566	\$37,566	OTHER PROGRAMS	\$233,218,639
U.S. GEOLOGICAL SURVEY RESEARCH AND DATA COLLECTION	15.808	G16AC00332				-\$585	-\$585	RESEARCH AND DEVELOPMENT	\$780,703,439
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P16AC01266				-\$305	\$342,592	RESEARCH AND DEVELOPMENT	\$780,703,439
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P18AC00782				\$2,774	\$342,592	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total	
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P19AC00896				\$4,233	\$342,592	RESEARCH AND DEVELOPMENT	\$780,703,439	
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P18AC01009				\$7,939	\$342,592	RESEARCH AND DEVELOPMENT	\$780,703,439	
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P20AC01060				\$9,166	\$342,592	RESEARCH AND DEVELOPMENT	\$780,703,439	
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P19AC01183				\$15,760	\$342,592	RESEARCH AND DEVELOPMENT	\$780,703,439	
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P18AC00737				\$19,118	\$342,592	RESEARCH AND DEVELOPMENT	\$780,703,439	
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P19AC01226				\$25,697	\$342,592	RESEARCH AND DEVELOPMENT	\$780,703,439	
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P18AC00723				\$35,130	\$342,592	RESEARCH AND DEVELOPMENT	\$780,703,439	
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P19AC01178				\$36,436	\$342,592	RESEARCH AND DEVELOPMENT	\$780,703,439	
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P20AC00859				\$37,318	\$342,592	RESEARCH AND DEVELOPMENT	\$780,703,439	
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P20AC01062				\$59,618	\$342,592	RESEARCH AND DEVELOPMENT	\$780,703,439	
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P18AC00666				\$64,117	\$342,592	RESEARCH AND DEVELOPMENT	\$780,703,439	
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P20AC00850				\$25,591	\$342,592	RESEARCH AND DEVELOPMENT	\$780,703,439	
NATIONAL PARK SERVICE CONSERVATION, PROTECTION, OUTREACH, AND EDUCATION	15.954		NATIONAL WRITING PROJECT	92-PA06-NPS2019		-\$14	\$3,486	OTHER PROGRAMS	\$233,218,639	
NATIONAL PARK SERVICE CONSERVATION, PROTECTION, OUTREACH, AND EDUCATION	15.954		NATIONAL WRITING PROJECT	92-PA06-NPS2020		\$3,500	\$3,486	OTHER PROGRAMS	\$233,218,639	
PROJECT WRITE ONLINE (JULY 15, 2020 - AUGUST 31, 2020)	15.U10	N/A				\$900	\$900	OTHER PROGRAMS	\$233,218,639	
TOTAL DEPARTMENT OF THE INTERIOR						\$383,959				
DEPARTMENT OF JUSTICE										
NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	16.560	2014-CK-BX-0008				\$11,676	\$1,032,183	RESEARCH AND DEVELOPMENT	\$780,703,439	
NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	16.560	2017-MU-MU-K021				\$200,821	\$1,032,183	RESEARCH AND DEVELOPMENT	\$780,703,439	
NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	16.560	2017-CK-BX-0016			\$642,875	\$819,686	\$1,032,183	RESEARCH AND DEVELOPMENT	\$780,703,439	
CRIME VICTIM ASSISTANCE	16.575		COUNTY OF LANCASTER	2017-VF-05-28107		\$39,084	\$133,915	OTHER PROGRAMS	\$233,218,639	
CRIME VICTIM ASSISTANCE	16.575		COUNTY OF LANCASTER	2018/2019/2020-VF-05-33169		\$94,831	\$133,915	OTHER PROGRAMS	\$233,218,639	
CRIME VICTIM ASSISTANCE/DISCRETIONARY GRANTS	16.582	2019-V3-GX-0036				\$236,096	\$236,096	OTHER PROGRAMS	\$233,218,639	
EDWARD BYRNE MEMORIAL JUSTICE ASSISTANCE GRANT PROGRAM	16.738		INTERNATIONAL ASSOCIATION OF CHIEFS OF POLICE	SUB TO 2017-VI-BX-K001		\$431,837	\$431,837	JAG PROGRAM CLUSTER	\$431,837	
CAPITAL CASE LITIGATION INITIATIVE	16.746	2018-FA-BX-K003				\$280,302	\$280,302	RESEARCH AND DEVELOPMENT	\$780,703,439	
IMPROVING THE INVESTIGATION AND PROSECUTION OF CHILD ABUSE AND THE REGIONAL AND LOCAL CHILDREN'S ADVOCACY Y CENTERS	16.758		NATIONAL CHILDREN'S ALLIANCE	LANC-PA-CORE21		\$20,041	\$20,041	OTHER PROGRAMS	\$233,218,639	
COMPREHENSIVE OPIOID, STIMULANT, AND SUBSTANCE ABUSE PROGRAM	16.838		COUNTY OF LANCASTER	2018-CO-01-30255		\$212,213	\$212,213	OTHER PROGRAMS	\$233,218,639	
TOTAL DEPARTMENT OF JUSTICE						\$642,875	\$2,346,587			
DEPARTMENT OF STATE										
INVESTING IN PEOPLE IN THE MIDDLE EAST AND NORTH AFRICA	19.021	SIZ-100-19-GR0021				\$112,539	\$178,672	\$649,292	RESEARCH AND DEVELOPMENT	\$780,703,439
INVESTING IN PEOPLE IN THE MIDDLE EAST AND NORTH AFRICA	19.021	SIZ10019GR0033				\$340,816	\$470,620	\$649,292	RESEARCH AND DEVELOPMENT	\$780,703,439
U.S. AMBASSADORS FUND FOR CULTURAL PRESERVATION	19.025	SNEAAC18CA0043				\$32,221	\$707,581	OTHER PROGRAMS	\$233,218,639	
INTERNATIONAL PROGRAMS TO SUPPORT DEMOCRACY, HUMAN RIGHTS AND LABOR	19.345		INTERNATIONAL ORGANIZATION FOR MIGRATION	IOM/CM-CPC2019		\$41,591	\$41,591	RESEARCH AND DEVELOPMENT	\$780,703,439	
FULBRIGHT FOREIGN LANGUAGE TEACHING ASSISTANTS SUMMER ORIENTATION 2020	19.U12	S-ECAGD-20-CA-0009	INSTITUTE OF INTERNATIONAL EDUCATION	FST2001_UPENN_FLTA_7.2.20		\$26,900	\$26,900	OTHER PROGRAMS	\$233,218,639	
TOTAL DEPARTMENT OF STATE						\$485,576	\$1,425,364			
DEPARTMENT OF TRANSPORTATION										
AIR TRANSPORTATION CENTERS OF EXCELLENCE	20.109	13-C-AJFE-UPENN				\$4,918	\$4,918	RESEARCH AND DEVELOPMENT	\$780,703,439	
HIGHWAY RESEARCH AND DEVELOPMENT PROGRAM	20.200	693JJ31750012			\$30,148	\$481,709	\$481,709	RESEARCH AND DEVELOPMENT	\$780,703,439	
HIGHWAY TRAINING AND EDUCATION	20.215	693JJ32045052				\$4,000	\$40,851	RESEARCH AND DEVELOPMENT	\$780,703,439	
COVID-19 - HIGHWAY TRAINING AND EDUCATION	20.215	693JJ32145024				\$9,867	\$40,851	RESEARCH AND DEVELOPMENT	\$780,703,439	
HIGHWAY TRAINING AND EDUCATION	20.215	693JJ32145004				\$26,984	\$40,851	RESEARCH AND DEVELOPMENT	\$780,703,439	
NATIONAL HIGHWAY TRAFFIC SAFETY ADMINISTRATION (NHTSA) DISCRETIONARY SAFETY GRANTS AND COOPERATIVE AGREEMENTS	20.614		AMERICAN COLLEGE OF EMERGENCY PHYSICIANS	SUB TO 693JJ91850017		\$104,577	\$104,577	RESEARCH AND DEVELOPMENT	\$780,703,439	

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
UNIVERSITY TRANSPORTATION CENTERS PROGRAM	20.701		UNIVERSITY OF TEXAS AT AUSTIN	UTA17-000185		\$133,935	\$503,043	RESEARCH AND DEVELOPMENT	\$780,703,439
UNIVERSITY TRANSPORTATION CENTERS PROGRAM	20.701		CARNEGIE MELLON UNIVERSITY	1080376-379208		\$369,108	\$503,043	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - NATIONAL SLEEP STUDY TECHNICAL SUPPORT	20.RD	692M15-19-T-00020				\$790	\$680,448	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL SLEEP STUDY TECHNICAL SUPPORT	20.RD	692M15-19-T-00020				\$679,658	\$680,448	RESEARCH AND DEVELOPMENT	\$780,703,439
TOTAL DEPARTMENT OF TRANSPORTATION						\$30,148	\$1,815,546		
DEPARTMENT OF TREASURY									
COVID-19 - CORONAVIRUS RELIEF FUND	21.019		CARING PEOPLE ALLIANCE	ACT 24/ROUND 3 CARES ACT		\$48,600	\$48,600	OTHER PROGRAMS	\$233,218,639
COVID-19 - CORONA VIRUS HEALTH COMMUNICATION SUPPORT	21.RD	(BLANK)	DELAWARE, STATE OF	DMS-21-004		\$144,406	\$144,406	RESEARCH AND DEVELOPMENT	\$780,703,439
TOTAL DEPARTMENT OF TREASURY							\$193,006		
LIBRARY OF CONGRESS									
THE LIFE OF FREE AFRICAN AMERICANS IN 19TH CENTURY PHILADELPHIA: USING SUPPORTING AND SUSTAINING TEACHERS' WRITING, LEARNING, AND LEADING THR	42.007		WAYNESBURG UNIVERSITY	GA GA08C0016		\$153	\$153	OTHER PROGRAMS	\$233,218,639
THE LIFE OF FREE AFRICAN AMERICANS IN 19TH CENTURY PHILADELPHIA: USING SUPPORTING AND SUSTAINING TEACHERS' WRITING, LEARNING, AND LEADING THR	42.U06	GA08C0016	WAYNESBURG UNIVERSITY	SUB TO GA08C0016		\$20,000	\$20,000	OTHER PROGRAMS	\$233,218,639
TOTAL LIBRARY OF CONGRESS							\$20,153		
NATIONAL AERONAUTICS & SPACE ADMINISTRATION									
SCIENCE	43.001	NNX13AE50G			\$-9,089	\$-9,089	\$1,451,317	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - SCIENCE	43.001	80NSSC18K0765				\$136	\$1,451,317	RESEARCH AND DEVELOPMENT	\$780,703,439
SCIENCE	43.001		GEORGIA INSTITUTE OF TECHNOLOGY	RH809-G1		\$14,447	\$1,451,317	RESEARCH AND DEVELOPMENT	\$780,703,439
SCIENCE	43.001	NNX13AI79G				\$19,142	\$1,451,317	RESEARCH AND DEVELOPMENT	\$780,703,439
SCIENCE	43.001	80NSSC20K0497				\$31,914	\$1,451,317	RESEARCH AND DEVELOPMENT	\$780,703,439
SCIENCE	43.001	1650195				\$32,758	\$1,451,317	RESEARCH AND DEVELOPMENT	\$780,703,439
SCIENCE	43.001		PLANETARY SCIENCE INSTITUTE	1565 UNIV OF PA		\$49,070	\$1,451,317	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - SCIENCE	43.001	1650126				\$83,729	\$1,451,317	RESEARCH AND DEVELOPMENT	\$780,703,439
SCIENCE	43.001	80NSSC18K0694				\$128,314	\$1,451,317	RESEARCH AND DEVELOPMENT	\$780,703,439
SCIENCE	43.001		UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN	097657-17658		\$133,052	\$1,451,317	RESEARCH AND DEVELOPMENT	\$780,703,439
SCIENCE	43.001	80NSSC18K0765				\$166,931	\$1,451,317	RESEARCH AND DEVELOPMENT	\$780,703,439
SCIENCE	43.001	80NSSC18K0481			\$513,808	\$800,913	\$1,451,317	RESEARCH AND DEVELOPMENT	\$780,703,439
AERONAUTICS	43.002	80NSSC18M0155				\$180,935	\$1,451,317	RESEARCH AND DEVELOPMENT	\$780,703,439
EXPLORATION	43.003	NNX16AI53G				-\$349	\$1,574,748	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - EXPLORATION	43.003		BAYLOR COLLEGE OF MEDICINE	T0408		\$1,739	\$1,574,748	RESEARCH AND DEVELOPMENT	\$780,703,439
EXPLORATION	43.003	80NSSC17K0644				\$1,877	\$1,574,748	RESEARCH AND DEVELOPMENT	\$780,703,439
EXPLORATION	43.003		BAYLOR COLLEGE OF MEDICINE	7000000801		\$12,629	\$1,574,748	RESEARCH AND DEVELOPMENT	\$780,703,439
EXPLORATION	43.003		BAYLOR COLLEGE OF MEDICINE	7000001348		\$19,351	\$1,574,748	RESEARCH AND DEVELOPMENT	\$780,703,439
EXPLORATION	43.003	80NSSC19K1046				\$72,599	\$1,574,748	RESEARCH AND DEVELOPMENT	\$780,703,439
EXPLORATION	43.003		BAYLOR COLLEGE OF MEDICINE	7000000839		\$173,459	\$1,574,748	RESEARCH AND DEVELOPMENT	\$780,703,439
EXPLORATION	43.003		BAYLOR COLLEGE OF MEDICINE	T0408		\$191,550	\$1,574,748	RESEARCH AND DEVELOPMENT	\$780,703,439
EXPLORATION	43.003	80NSSC17K0644				\$887,239	\$1,574,748	RESEARCH AND DEVELOPMENT	\$780,703,439
EXPLORATION	43.003	NNX15AK76A			\$90,144	\$214,654	\$1,574,748	RESEARCH AND DEVELOPMENT	\$780,703,439
SPACE OPERATIONS	43.007	80NSSC19K0599				\$37,380	\$465,691	RESEARCH AND DEVELOPMENT	\$780,703,439
SPACE OPERATIONS	43.007	80NSSC20K0513				\$86,542	\$465,691	RESEARCH AND DEVELOPMENT	\$780,703,439
SPACE OPERATIONS	43.007	80NSSC19K0348				\$154,606	\$465,691	RESEARCH AND DEVELOPMENT	\$780,703,439
SPACE OPERATIONS	43.007	80NSSC19K1602				\$187,163	\$465,691	RESEARCH AND DEVELOPMENT	\$780,703,439
SPACE TECHNOLOGY	43.012	80NSSC20K1191				\$59,113	\$180,276	RESEARCH AND DEVELOPMENT	\$780,703,439
SPACE TECHNOLOGY	43.012	80NSSC19K1179				\$59,925	\$180,276	RESEARCH AND DEVELOPMENT	\$780,703,439
SPACE TECHNOLOGY	43.012	80NSSC19K0214				\$61,238	\$180,276	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH SPONSORED AGREEMENT: CONSTRAINING DARK ENERGY AND MODIFIED GR	43.RD	1479009				\$141	\$80,033	RESEARCH AND DEVELOPMENT	\$780,703,439
AN EXTREME PRECISION DOPPLER SPECTROMETER FOR THE US O/IR SYSTEM	43.RD	1547612	PENNSYLVANIA STATE UNIVERSITY	5405-UP-JPL-7612		\$26,800	\$80,033	RESEARCH AND DEVELOPMENT	\$780,703,439
FOAM OPTICS AND MECHANICS	43.RD	80NSSC21K0898				\$53,092	\$80,033	RESEARCH AND DEVELOPMENT	\$780,703,439
TOTAL NATIONAL AERONAUTICS & SPACE ADMINISTRATION						\$594,863	\$3,933,000		
INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL ENDOWMENT FOR THE ARTS OR NATIONAL ENDOWMENT FOR THE HUMANITIES									
PROMOTION OF THE ARTS GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1849823-31-19				-\$98	\$148,912	OTHER PROGRAMS	\$233,218,639
PROMOTION OF THE ARTS GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1854917-44-19				\$424	\$148,912	OTHER PROGRAMS	\$233,218,639
PROMOTION OF THE ARTS GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1807815-34-18				\$8,500	\$148,912	OTHER PROGRAMS	\$233,218,639

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
PROMOTION OF THE ARTS GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1861920-34-20				\$20,000	\$148,912	OTHER PROGRAMS	\$233,218,639
PROMOTION OF THE ARTS GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1865735-32				\$40,000	\$148,912	OTHER PROGRAMS	\$233,218,639
PROMOTION OF THE ARTS GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1862782-38-C-20				\$80,086	\$148,912	OTHER PROGRAMS	\$233,218,639
PROMOTION OF THE HUMANITIES DIVISION OF PRESERVATION AND ACCESS	45.149	PW-253771-17				\$1,378	\$1,378	RESEARCH AND DEVELOPMENT	\$780,703,439
PROMOTION OF THE HUMANITIES RESEARCH	45.161	RZ-266202-19				-\$1,613	\$116,627	RESEARCH AND DEVELOPMENT	\$780,703,439
PROMOTION OF THE HUMANITIES RESEARCH	45.161	RZ-266063-19				\$535	\$116,627	RESEARCH AND DEVELOPMENT	\$780,703,439
PROMOTION OF THE HUMANITIES RESEARCH	45.161	RZ-266119-19				\$117,705	\$116,627	RESEARCH AND DEVELOPMENT	\$780,703,439
PROMOTION OF THE HUMANITIES PUBLIC PROGRAMS	45.164	GA-274783-20				\$144,051	\$144,051	OTHER PROGRAMS	\$233,218,639
MUSEUMS FOR AMERICA	45.301	MA-245681-OMS-20				\$43,708	\$136,809	OTHER PROGRAMS	\$233,218,639
MUSEUMS FOR AMERICA	45.301	MA-30-19-0708-19				\$93,101	\$136,809	OTHER PROGRAMS	\$233,218,639
NATIONAL LEADERSHIP GRANTS	45.312	LG-00-17-0102-17				\$762	\$71,052	OTHER PROGRAMS	\$233,218,639
NATIONAL LEADERSHIP GRANTS	45.312	LG-246396-OLS-20				\$70,290	\$71,052	OTHER PROGRAMS	\$233,218,639
CENTER FOR ADVANCED STUDY IN THE VISUAL ARTS FELLOWSHIP	45.RD	PAUL MELLON SR. FELLOW 2020-2021				\$49,202	\$49,202	RESEARCH AND DEVELOPMENT	\$780,703,439
TOTAL INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL ENDOWMENT FOR THE ARTS OR NATIONAL ENDOWMENT FOR THE HUMANITIES							\$668,031		
NATIONAL SCIENCE FOUNDATION									
CIF: SMALL: COLLABORATIVE RESEARCH: COMMUNICATIONS IN ULTRA-LOW-RATE R									
ENGINEERING	47.041	1910056				\$20,970	\$20,970	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CMMI-1840672				-\$13,232	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	ECSS-1651433				-\$6,775	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CMMI-1745912				-\$904	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1840457				-\$607	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	COVID-19 - ENGINEERING	COGWEAR	SUB TO 2110037		\$399	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CMMI-2047506				\$967	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1937031				\$1,948	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1944248				\$7,040	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	EFMA-1542879				\$8,586	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CBET-2010890				\$10,674	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041		UNIVERSITY OF BUFFALO	R1106709		\$11,351	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041		RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (BUFFALO)	R1107943		\$12,298	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1903673				\$12,429	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1943243				\$13,208	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1728360				\$15,049	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	EFMA-1542707				\$17,310	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CBET-1604536				\$22,259	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CBET-1706014				\$26,904	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CBET-1704833				\$30,759	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041		UNIVERSITY OF HOUSTON	R-19-0095		\$31,338	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CBET-1554200				\$32,741	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1804523				\$39,505	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CMMI-2047851				\$41,313	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	2026906				\$52,423	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CMMI-1760369				\$58,597	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	2036881				\$59,682	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	EEC-1950720				\$61,249	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1932803				\$62,252	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CBET-1705891				\$64,400	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CBET-1803215				\$65,734	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	EFRI-1331583				\$68,319	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	2002477				\$70,517	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	ECSS-1846766				\$73,953	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1663037				\$77,142	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CMMI-1662695				\$77,457	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	2023780				\$78,329	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CBET-1652646				\$83,345	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1839535				\$87,602	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CMMI-1653216				\$88,395	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1804145				\$89,769	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1662101				\$91,964	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1830475				\$93,155	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041		NORTH CAROLINA STATE UNIVERSITY	2017-1-718-02		\$95,155	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1933704				\$97,913	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041		CARNEGIE MELLON UNIVERSITY	1122380-424804		\$98,769	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1945841				\$99,247	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ENGINEERING	47.041		GEORGIA INSTITUTE OF TECHNOLOGY	RJ375-G1		\$101,229	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1944691				\$102,267	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CMMI-1548571				\$103,186	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	ECSS-1553511				\$106,400	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041		UNIVERSITY OF MICHIGAN	3004604526		\$109,751	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CBET-1845933				\$111,937	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CMMI-1761874				\$115,571	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1943394				\$117,362	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1761726				\$122,151	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	2038873				\$146,840	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1727717				\$155,187	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CBET-1943945				\$172,985	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1830218				\$212,497	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1734355				\$232,006	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	CBET-1920156				\$292,515	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1837253				\$410,104	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1933400				\$630,615	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	ECSS-2025608			\$3,816	\$603,711	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1661858			\$7,234	\$65,978	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	ECSS-1542153			\$13,907	\$190,684	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1827673			\$25,025	\$76,555	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	ECSS-1842655			\$35,481	\$203,878	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	ECSS-1842612			\$49,409	\$181,830	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	2037097			\$96,396	\$244,054	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	1935294			\$208,493	\$412,466	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
ENGINEERING	47.041	EEC-1941529			\$265,181	\$1,153,117	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ENGINEERING	47.041	CMMI-1548571			\$1,492,231	\$3,962,780	\$12,447,584	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1838412				-\$2,281	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1609784				-\$20,581	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1609267				-\$2,383	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1607878				-\$254	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1601438				-\$57	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1506148				-\$2	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1262047				\$27	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1309053				\$81	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049		UNIVERSITY OF PUERTO RICO	DMR-1523463		\$336	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1709827				\$391	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - MATHEMATICAL AND PHYSICAL SCIENCES	47.049	PHY-1554887				\$418	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1709763				\$1,136	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1805439				\$1,191	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1665291				\$3,575	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049		PRINCETON UNIVERSITY	SUB0000223		\$4,025	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1764177				\$5,469	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	2009210				\$6,139	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1941318				\$6,788	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1664928				\$10,135	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049		STONY BROOK	76749/1136652/2/2R7D		\$13,677	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1709518				\$15,146	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1610525				\$15,462	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	AST-2007232				\$16,502	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1507713				\$24,622	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1953572				\$25,623	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1945966				\$26,073	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-2005749				\$27,594	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1659512				\$28,305	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1506625				\$30,464	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-2031895				\$30,893	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1953848				\$31,671	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1808202				\$34,663	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	PHY-1915174				\$37,272	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	AST-1907610				\$37,859	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	2055271				\$38,355	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1943925				\$40,389	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1916245				\$42,026	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1851640				\$45,718	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	AST-1615555				\$45,844	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	2027986				\$45,900	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-2102402				\$46,470	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	2104554				\$47,318	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1664818				\$48,353	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1910496				\$50,284	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1904767				\$54,569	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1854148				\$55,666	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	AST-1615604				\$60,472	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1719353				\$62,296	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1807127				\$63,552	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	2015259				\$63,567	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1764143				\$63,918	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1757479				\$65,017	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1664572				\$66,411	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1665339				\$70,336	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1847415				\$70,774	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1609525				\$71,982	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049		UNIVERSITY OF DELAWARE	58081		\$73,646	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1554130				\$74,225	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1708759				\$74,236	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1764329				\$75,671	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1808065				\$77,955	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1904776				\$78,639	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1905045				\$79,793	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	AST-1455151				\$89,818	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1805439				\$90,905	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1838456				\$94,609	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1952877				\$99,637	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-2003659				\$112,076	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1844514				\$122,547	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1607378				\$123,339	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1809398				\$125,485	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1764365				\$125,538	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1905912				\$130,503	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	2042144				\$132,935	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1905853				\$133,620	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	AST-1816330				\$134,593	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1562665				\$135,059	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1603526				\$138,839	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1952583				\$142,113	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049		PRINCETON UNIVERSITY	SUB0000032		\$153,445	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1953701				\$154,415	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	PHY-1554488				\$164,571	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1902509				\$203,309	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1945265				\$215,549	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1856547				\$232,099	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1955724				\$236,394	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1922278				\$240,466	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049		TEXAS A&M UNIVERSITY	M2002925		\$244,857	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1905203				\$254,675	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1955068				\$268,956	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1764298				\$294,379	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	PHY-1554887				\$304,812	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1838412			\$7,660	\$7,660	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1720530			\$31,309	\$3,558,698	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1916859			\$75,259	\$75,259	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1925708			\$208,026	\$466,113	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	OMA-1936276			\$280,742	\$492,301	\$11,641,935	RESEARCH AND DEVELOPMENT	\$780,703,439
GEOSCIENCES	47.050	1554134				\$8	\$695,608	RESEARCH AND DEVELOPMENT	\$780,703,439
GEOSCIENCES	47.050	OCE-1756808				\$24,901	\$695,608	RESEARCH AND DEVELOPMENT	\$780,703,439
GEOSCIENCES	47.050	1624504				\$30,563	\$695,608	RESEARCH AND DEVELOPMENT	\$780,703,439
GEOSCIENCES	47.050		PRINCETON UNIVERSITY	SUB0000091		\$32,911	\$695,608	RESEARCH AND DEVELOPMENT	\$780,703,439
GEOSCIENCES	47.050	1951462				\$118,793	\$695,608	RESEARCH AND DEVELOPMENT	\$780,703,439
GEOSCIENCES	47.050	1846777				\$132,536	\$695,608	RESEARCH AND DEVELOPMENT	\$780,703,439
GEOSCIENCES	47.050	1939913				\$137,795	\$695,608	RESEARCH AND DEVELOPMENT	\$780,703,439
GEOSCIENCES	47.050	1923743				\$218,101	\$695,608	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-19555670				\$243	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1955565				\$3,560	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	2006535				\$4,792	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1253345				\$7,362	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1813624				\$10,579	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070		VANDERBILT UNIVERSITY	3834-019899		\$11,217	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	2008284				\$11,266	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1829197				\$17,415	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1939132				\$18,707	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	2039382				\$20,000	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CCF-1733794				\$28,971	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-2045861				\$29,035	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1513108				\$29,336	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CCF-1525296				\$29,549	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1910534				\$29,882	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	2031244				\$31,743	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1717120				\$33,601	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	2016943				\$34,266	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	IIS-1910108				\$35,528	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	2011168				\$35,707	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COVID-19 - COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	2035101				\$36,452	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COVID-19 - COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-2043858				\$38,705	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1837964				\$39,331	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1836936				\$44,575	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	2024692				\$53,307	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070		COMPUTING RESEARCH ASSOCIATION	CIF2020-UP-35		\$56,786	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070		PURDUE UNIVERSITY	10001171-018		\$65,232	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1850356				\$65,275	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1925587				\$65,731	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1837210				\$67,361	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1943064				\$67,478	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1917545				\$73,973	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1703791				\$77,083	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1910308				\$77,264	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1763314				\$83,864	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1845339				\$89,639	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1703835				\$94,959	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	IIS-1910864				\$99,986	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CCF-1917852				\$104,767	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1703319				\$110,610	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1845749				\$111,131	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	IIS-1717290				\$116,466	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1926872				\$118,255	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1931419				\$126,707	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CCF-1617851				\$131,978	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1912232				\$132,221	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	IIS-1812319				\$142,770	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1915398				\$148,511	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1513679				\$169,480	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CCF-1910769				\$170,171	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1910594				\$171,275	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1730377				\$177,515	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CCF-1934876				\$182,142	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1763307				\$193,732	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1703541				\$219,681	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070		UNIVERSITY OF MEMPHIS	1640813		\$223,848	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070		UNIVERSITY OF WISCONSIN-MADISON	0000000973		\$231,860	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	IIS-1926757				\$246,216	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	2008456				\$248,902	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1513854				\$259,873	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1446664				\$295,863	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1513694				\$296,462	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1934960				\$354,949	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1763514				\$379,345	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1563873				\$444,158	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CCF-1521539				\$574,489	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-2042216			\$5,000	\$31,233	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	IIS-2020312				\$32,325	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1513671				\$47,483	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1739012				\$55,099	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	IIS-1827472				\$236,507	\$248,988	\$8,296,065	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	MCB-1614355					-\$17,168	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	1557499					-\$376	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	DBI-1458390					-\$116	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	MCB-1413158					-\$96	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BIOLOGICAL SCIENCES	47.074	MCB-1856292					\$199	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	MCB-1614191					\$1,416	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	DEB-1926114					\$3,821	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	MCB-2044613					\$14,483	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074		UNIVERSITY CORPORATION, THE	A16-0018-5001		\$15,893	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439	
BIOLOGICAL SCIENCES	47.074	MCB-1652003					\$39,287	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	IOS-1953279					\$44,909	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	DBI-2016487					\$64,540	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074		BOYCE THOMPSON INSTITUTE	20-01		\$153,196	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439	
BIOLOGICAL SCIENCES	47.074	IOS-1452520					\$169,479	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	1856587					\$211,931	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	MCB-1856292					\$222,416	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	1905062					\$226,562	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	1929671					\$228,104	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	IOS-1853719					\$273,742	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	MCB-1916431					\$275,381	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
BIOLOGICAL SCIENCES	47.074	1817518				\$299,520	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	IOS-1343159			\$7,625	\$89,717	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	IOS-1444490			\$96,663	\$99,237	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOLOGICAL SCIENCES	47.074	IOS-1849708			\$244,598	\$556,233	\$2,972,310	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075		CARNEGIE MELLON UNIVERSITY	1122598-38829		-\$9,027	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075		EMORY UNIVERSITY	A140427		-\$5,215	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1825583				-\$3,327	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1747642				\$86	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-2041171				\$130	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-2029098				\$297	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1917900				\$1,668	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1755237				\$1,818	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1852987				\$2,281	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1729412				\$4,846	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1751863				\$6,541	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1827876				\$7,193	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1529586				\$7,877	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1919029				\$9,819	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1459353				\$11,324	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1749397				\$12,208	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-2017086				\$14,007	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1729469				\$21,131	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1921325				\$23,492	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1726976				\$26,062	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1851634				\$26,062	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1631550				\$27,366	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-2017655				\$30,646	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1758653				\$31,690	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1851707				\$34,324	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1823521				\$38,232	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1946882				\$42,152	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1824826				\$46,153	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075		COLUMBIA UNIVERSITY	1(GG008689)		\$49,062	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075		SYRACUSE UNIV	30158-05060-501		\$51,457	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1265480				\$61,622	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SMA-2050803				\$61,686	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1824520				\$66,063	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1729185				\$88,327	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1941006				\$91,813	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1948943				\$100,853	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-2026850				\$116,516	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1851879				\$125,304	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1851629				\$131,683	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1851449				\$157,010	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1942917				\$161,466	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1847794				\$162,264	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1847598				\$189,192	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1947096				\$145	\$118,039	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SMA-1917608			\$8,216	\$136,086	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	2032598			\$9,606	\$100,014	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1917573			\$72,128	\$92,798	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1918173			\$263,729	\$279,229	\$2,750,320	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	1946150				-\$1,021	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076		DREXEL UNIVERSITY	235920		\$9,276	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	1840933				\$15,918	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5119693		\$16,747	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	DGE-1937490				\$16,896	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	1721003			-\$12,971	\$35,031	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	1928474				\$37,447	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	DRL-1621333				\$48,971	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	2000405				\$58,457	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	DRL-1907437				\$70,432	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	1839686				\$95,160	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	1661153				\$108,759	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	DRL-1742140				\$132,009	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	DRL-1812738				\$204,022	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	DUE-1760867				\$321,022	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	DRL-1813048				\$697,620	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	DGE-1845298				\$4,696,017	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	DRL-2009803			\$28,261	\$64,747	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION AND HUMAN RESOURCES	47.076	DUE-1665216			\$41,198	\$156,462	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - EDUCATION AND HUMAN RESOURCES	47.076	2031748			\$58,803	\$164,652	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - EDUCATION AND HUMAN RESOURCES	47.076	DUE-2038507			\$81,333	\$130,719	\$7,079,343	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	OISE-1545884			\$34,545	\$583,119	\$583,119	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
SINGLE WEARABLE PATCH FOR COST-EFFECTIVE, RELIABLE, AND ACCURATE HOME MULTIPLEXED CRISPR EDITING OF T CELLS THROUGH LARGE CARGO DELIVERY VIA	47.RD	2016158	HUXLEY MEDICAL, INC. GEORGIA INSTITUTE OF TECHNOLOGY	SUB TO 2016158		\$14,194	\$130,385	RESEARCH AND DEVELOPMENT	\$780,703,439
HARNESSING EVOLUTION TO REVEAL THE MOLECULAR LOGIC OF KINETOCHORE WIRI	47.RD	(BLANK)	WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH	SUB TO NSF ADV ACCT		\$15,391	\$130,385	RESEARCH AND DEVELOPMENT	\$780,703,439
ROBOTIC FOREST INVENTORY AND MAPPING	47.RD	1938565	TREFO, LLC	SUB TO 1938565		\$25,800	\$130,385	RESEARCH AND DEVELOPMENT	\$780,703,439
TOTAL NATIONAL SCIENCE FOUNDATION						\$4,110,462	\$46,617,639		
SMALL BUSINESS ADMINISTRATION									
SMALL BUSINESS DEVELOPMENT CENTERS	59.037	SBAHQ-14-B-0055				\$10,713	\$10,713	OTHER PROGRAMS	\$233,218,639
TOTAL SMALL BUSINESS ADMINISTRATION							\$10,713		
DEPARTMENT OF VETERANS AFFAIRS									
TRANSPLANTABLE MICRO-TISSUE ENGINEERED NEURAL NETWORKS TO RESTORE THE	64.000	IPA CASSIDY FETTERMAN				\$45	\$95,289	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA SHIMRIT KEDDEM	64.000	IPA AGREEMENT				\$95,244	\$95,289	RESEARCH AND DEVELOPMENT	\$780,703,439
MRI IMAGE ANALYSIS FOR THE GERIATRIC RESEARCH EDUCATION CLINICAL CENTE	64.RD	36C24519C0130				\$31,200	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL ILLNESS RESEARCH, EDUCATION AND CLINICAL CENTER COGNITIVE BEHAVIORAL THERAPY (CBT-I) AUGMENTATION OF TOPIRAMATE IN PRO	64.RD	IPA WADE H BERRETTINI				-\$6,668	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
OSLIN TOP IPA-PETRO	64.RD	IPA KNASHAWN MORALES				\$457	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
ACCELERATED AGING AS A CAUSE OF CHRONIC LUNG ALLOGRAFT DYSFUNCTION	64.RD	IPA CHRISTOPHER PETRO				\$862	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - LEA WILLIAMS COVID-19 IPA	64.RD	IPA AGREEMENT				\$1,047	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA CHALANDA EVANS	64.RD	IPA AGREEMENT				\$3,071	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
TISSUE ENGINEERED NIGROSTRIATAL PATHWAY AS A TESTBED FOR EVALUATING AX	64.RD	IPA CHALANDA EVANS				\$3,501	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
PREFERENCES ELICITED AND RESPECTED FOR SERIOUSLY ILL VETERANS THROUGH	64.RD	IPA AGREEMENT				\$3,860	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
DIANE LIM'S VA MERIT GRANT: EFFECT OF CYCLICAL INTERMITTENT HYPOXIA ON	64.RD	ADVANCE ACCOUNT				\$4,190	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
LYNCH IPA - TOP	64.RD	IPA AGREEMENT				\$5,000	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
NEUROMODULATION AS A THERAPY FOR PTSD FOLLOWING CHRONIC TBI	64.RD	IPA AGREEMENT				\$5,449	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
CHHATRE IPA- SCHAPIRA PROJECT	64.RD	IPA AGREEMENT				\$5,851	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
LIZBETH NOVELO STRIDE GO IPA	64.RD	IPA SUMEDHA CHHATRE				\$6,016	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
CHHATRE IPA- DICHTER PROJECT	64.RD	IPA LIZBETH NOVELO				\$6,177	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA - LEONARD PPO 15-143	64.RD	IPA SUMEDHA CHHATRE				\$8,021	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA AILEEN OON	64.RD	IPA CHARLES E LEONARD				\$8,492	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
PHENOTYPIC AND GENOMIC ARCHITECTURE OF CARDIOVASCULAR DISEASE SUBTYPES	64.RD	IPA AGREEMENT				\$8,598	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA: SHIMRIT KEDDEM (PROJECT: CHERP)	64.RD	IPA GABRIELLE SHAKT				\$9,445	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA - REBECCA HUBBARD PPO 15-143	64.RD	IPA AGREEMENT				\$9,673	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
CHHATRE IPA- NAVATHE PROJECT	64.RD	IPA AGREEMENT				\$9,719	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA-SHIMRIT KEDDEM (PROJECT: SAGE)	64.RD	IPA SUMEDHA CHHATRE				\$10,026	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA ANDREA SEGAL	64.RD	N/A				\$10,831	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
THE ROLE OF DISC NUTRITION IN THE ETIOLOGY AND CLINICAL TREATMENT OF D	64.RD	VA ADV ACCT				\$11,364	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
TAMMY XU IPA	64.RD	IPA AGREEMENT				\$11,707	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
NEUROMODULATION AS A THERAPY FOR PTSD FOLLOWING CHRONIC TBI	64.RD	IPA AGREEMENT				\$11,817	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
DESIGNING NEURONAL TISSUE CONSTRUCTS THAT MIMIC BRAIN-SPECIFIC ARCHITE	64.RD	IPA AGREEMENT				\$11,988	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
GORDON IPA- GABRIELA KHAZANOV PROJECT	64.RD	IPA AGREEMENT				\$12,518	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
THE INTRA-INDIVIDUAL CHANGES IN AMBULATION AND FUNCTIONAL OUTCOMES AMO	64.RD	IPA AGREEMENT				\$12,875	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA LYNCH MIRECC	64.RD	IPA PAMELA CACCHIONE				\$13,239	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
SDR: GENOMIC ANALYSIS OF BLAST TUBE INDUCED TBI IN MICE	64.RD	IPA - KEVIN LYNCH				\$13,352	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA FOR DAWEI XIE	64.RD	IPA AGREEMENT-GEORGES				\$13,703	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
OPTIMIZATION OF ENGINEERED ENDPLATES TO IMPROVE IN VIVO INTEGRATION OF	64.RD	IPA DAWEI XIE				\$16,230	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
LYNCH PRIME IPA	64.RD	IPA - SARAH GULLBRAND ADV ACCT				\$16,782	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA-TIMOTHY POND	64.RD	IPA KEVIN LYNCH				\$16,923	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
VA IPA - MOLLY KNOWLES	64.RD	IPA AGREEMENT				\$16,954	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA - RICHARD CRIST (GAMMA)	64.RD	IPA AGREEMENT				\$17,162	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA	64.RD	IPA - RICHARD CRIST				\$17,173	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
REMOTE AMBULATORY MANAGEMENT OF VETERANS WITH SLEEP APNEA (REVAMP)	64.RD	IPA - MARY VALIGA				\$17,461	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANSPLANTABLE MICRO-TISSUE ENGINEERED NEURAL NETWORKS TO RESTORE THE	64.RD	(BLANK)				\$18,156	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
		IPA JUSIN BURRELL				\$18,796	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
VA IPA - ALEXANDER GERALNICK	64.RD	IPA AGREEMENT				\$19,247	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
DESIGNING NEURONAL TISSUE CONSTRUCTS THAT MIMIC BRAIN-SPECIFIC ARCHITE	64.RD	IPA AGREEMENT				\$19,425	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
DESIGNING NEURONAL TISSUE CONSTRUCTS THAT MIMIC BRAIN-SPECIFIC ARCHITE	64.RD	IPA JAMES LIM				\$20,361	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
PATHOGENESIS OF CHRONIC RHINOSINUSITIS	64.RD	IPA MICHAEL DODSON				\$20,472	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
INVESTIGATING MULTI-LEVEL DETERMINANTS OF RACIAL/ETHNIC DISPARITIES IN	64.RD	IPA AGREEMENT				\$22,009	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANSPLANTABLE MICRO-TISSUE ENGINEERED NEURAL NETWORKS TO RESTORE THE	64.RD	IPA AGREEMENT				\$22,690	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
CHRONIC FOCAL AND DIFFUSE TRAUMATIC BRAIN INJURY: MECHANISMS UNDERLYIN	64.RD	IPA AGREEMENT				\$23,751	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA # 3 DAMRAUER DOE (M. VUJKOVIC)	64.RD	IPA MARIJANA VUJKOVIC				\$24,796	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
DOWNING IPA-TOP	64.RD	IPA - LAURIE DOWNING				\$27,432	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA KEMBER	64.RD	IPA - RACHEL KEMBER				\$28,295	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
LIVING ELECTRODES FOR AUDITORY REHABILITATION	64.RD	IPA AGREEMENT				\$29,990	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
NEUROMODULATION AS A THERAPY FOR PTSD FOLLOWING CHRONIC TBI	64.RD	IPA OCEANE FRUCHET				\$32,190	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA AGREEMENT FOR MELISSA NASCHEK	64.RD	IPA AGREEMENT				\$32,976	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
YEAR 1 IPAS FOR MAUCK/BURDICK VA SPIRE PROJECT: "HYDROGEL DELIVERY OF	64.RD	IPA - BURDICK AND HENNING				\$34,420	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
INCORPORATING VETERANS' PREFERENCES INTO LUNG CANCER SCREENING DECISIO	64.RD	IPA AGREEMENT				\$34,528	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA AGREEMENT FOR DANIEL TRAUM	64.RD	IPA DANIEL TRAUM				\$36,503	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - COVID-19: ELUCIDATING THE ROLE OF THE NASAL EPITHELIUM IN SARS-COV-2 I	64.RD	IPA AGREEMENT				\$37,587	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
VA MERIT AWARD: IMMUNE AND GENETIC CONTROLS OF TISSUE REGENERATION IN	64.RD	IPA AGREEMENT				\$37,660	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
VA IPA - ANEEZA AGHA	64.RD	IPA AGREEMENT				\$39,283	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
CRISWELL LAVERY FY21 IPA	64.RD	IPA AGREEMENT				\$42,842	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IMMUNOLOGIC MECHANISMS FOR HETEROGENEITY OF CUTANEOUS LUPUS ERYTHEMATO	64.RD	JPA AGREEMENT				\$43,818	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA #1, CHANG-MVP (M. VUJKOVIC)NO RESTRICTS NON-U.S. ENTITY PARTICIPAT	64.RD	IPA AGREEMENT				\$44,555	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
VA IPA - DENERALE JONES	64.RD	IPA AGREEMENT				\$46,290	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
EVIDENCE BASED PSYCHOTHERAPY PROGRAM	64.RD	IPA GREGORY K BROWN				\$46,632	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
LIZBETH NOVELO SPIRE IPA	64.RD	IPA LIZBETH NOVELO				\$47,799	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA AGREEMENTS FOR ALEX BURDZY AND PATRIK GARREN	64.RD	IPA ALEXANDER E BURDZY				\$48,182	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - COVID-19: UNDERSTANDING THE ROLE OF CORONA VIRUS INDUCED DISRUPTION OF	64.RD	IPA AGREEMENT				\$48,702	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
RESURFACING OF THE THUMB JOINT WITH A BIOLOGIC TISSUE ENGINEERED IMPLA	64.RD	IPA AGREEMENT				\$49,122	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA KEMBER-MVP004	64.RD	IPA - RACHEL KEMBER				\$49,210	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
NEUROMODULATION AS A THERAPY FOR PTSD FOLLOWING CHRONIC TBI	64.RD	IPA EMMA HALTER				\$51,800	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
SDR: GENOMIC ANALYSIS OF BLAST TUBE INDUCED TBI IN MICE	64.RD	IPA AGREEMENT				\$53,043	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA ANEEZA AGHA	64.RD	IPA ANEEZA AGHA				\$54,996	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
PRECISION CARDIO-METABOLIC PHENOTYPING FOR GENETIC DISCOVERY AND RISK	64.RD	IPA AGREEMENT				\$55,827	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
VA IPA - ANTHONY DAVIS	64.RD	IPA AGREEMENT				\$60,151	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
VA IPA - RANDY HASTINGS	64.RD	IPA AGREEMENT				\$60,151	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
BEERS - VA MERIT AWARD	64.RD	IPA SURAFEL MULLUGETA				\$61,211	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
PROBLEM SOLVING THERAPY PROGRAM IPA: GREGORY BROWN AND KELLY GREEN	64.RD	IPA KELLY L. GREEN				\$63,186	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
TISSUE ENGINEERED NIGROSTRIATAL PATHWAY AS A TESTBED FOR EVALUATING AX	64.RD	IPA JUSIN BURRELL				\$63,731	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
VA COMPREHENSIVE END-OF-LIFE CARE'S PROMISE CENTER	64.RD	IPA AGREEMENT				\$63,958	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA FOR K. LINN AND J. YAN	64.RD	IPA AGREEMENT				\$64,399	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
IMPLEMENTING GOALS OF CARE CONVERSATIONS WITH VETERANS IN VA LTC SETTI	64.RD	IPA				\$66,493	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
CHRONIC FOCAL AND DIFFUSE TRAUMATIC BRAIN INJURY: MECHANISMS UNDERLYIN	64.RD	IPA AGREEMENT				\$87,174	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
TISSUE-ENGINEERED CONSTRUCTS FOR TREATMENT OF INTERVERTEBRAL DISC DEGE	64.RD	IPA AGREEMENT				\$90,038	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
GROUP (PROJECT LIFE FORCE) VS. INDIVIDUAL SUICIDE SAFETY PLANNING RC	64.RD	IPA AGREEMENT				\$113,469	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
THE ROLE OF FUNCTIONAL IRON DEFICIENCY IN SYSTEMIC COMPLICATIONS OF CK	64.RD	36C24E19P0068				\$116,144	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
KNEE JOINT RESURFACING WITH ANATOMIC TISSUE ENGINEERED OSTEOCHONDRAL I	64.RD	IPA AGREEMENT				\$121,384	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
PHENOTYPIC AND GENOMIC ARCHITECTURE OF CARDIOVASCULAR DISEASE SUBTYPES	64.RD	IPA AGREEMENT				\$144,015	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOACTIVE INJECTABLE IMPLANTS FOR FUNCTIONAL INTERVERTEBRAL DISC REGE	64.RD	IPA AGREEMENT				\$209,781	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
VA MERIT AWARD: IMMUNE AND GENETIC CONTROLS OF TISSUE REGENERATION IN	64.RD	IPA AGREEMENT				\$224,594	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
TISSUE ENGINEERED TOTAL DISC REPLACEMENT IN A LARGE ANIMAL MODEL	64.RD	IPA J LACHLAN SMITH				\$238,251	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
COGNITIVE BEHAVIORAL THERAPY (CBT-I) AUGMENTATION OF TOPIRAMATE IN PRO	64.RD	IPA AGREEMENT				\$2,666	\$3,490,247	RESEARCH AND DEVELOPMENT	\$780,703,439
INTENSIVE TRAINING IN COGNITIVE BEHAVIORAL THERAPY FOR VETERANS EXPERI	64.U02	IPA AGREEMENT				\$10,964	\$10,964	OTHER PROGRAMS	\$233,218,639
CBT-SP TELE-HUB PROJECT	64.U03	IPA GREGORY K BROWN				\$12,085	\$12,085	OTHER PROGRAMS	\$233,218,639
IPA - LAURIE DOWNING	64.U04	IPA LAURIE DOWNING				\$4,463	\$4,463	OTHER PROGRAMS	\$233,218,639
SUICIDE PREVENTION PROGRAMMATIC CONSULTATION	64.U05	IPA SHARI JAGER-HYMAN				\$21,524	\$21,524	OTHER PROGRAMS	\$233,218,639
VA/IPA FOR KEVIN LYNCH	64.U07	IPA - KEVIN LYNCH				\$7,153	\$7,153	OTHER PROGRAMS	\$233,218,639
VA/IPA AGREEMENTS FOR MARY VALIGA, JAMES KEITH AND XIAOWANG QU	64.U13	IPA MARY VALIGA				\$87,306	\$87,306	OTHER PROGRAMS	\$233,218,639
IPA - LAURIE DOWNING	64.U14	IPA LAURIE DOWNING				\$9,478	\$9,478	OTHER PROGRAMS	\$233,218,639
VA IPA FOR KEVIN LYNCH	64.U16	IPA - KEVIN LYNCH				\$11,620	\$11,620	OTHER PROGRAMS	\$233,218,639
TOTAL DEPARTMENT OF VETERANS AFFAIRS							\$3,750,129		
ENVIRONMENTAL PROTECTION AGENCY									
OFFICE OF RESEARCH AND DEVELOPMENT CONSOLIDATED RESEARCH/TRAINING/FELLOWSHIPS	66.511		VIRGINIA POLYTECHNIC INSTITUTE & STATE UNIVERSITY	451533-19314		\$57,290	\$57,290	RESEARCH AND DEVELOPMENT	\$780,703,439
TOTAL ENVIRONMENTAL PROTECTION AGENCY							\$57,290		
DEPARTMENT OF ENERGY									
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0012486				-\$14,100	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0016421				-\$7,839	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049		UNIVERSITY OF DELAWARE	37849		-\$4,397	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049		TEMPLE UNIVERSITY	254998		-\$2,165	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0019781				-\$736	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-84ER45118				\$1,212	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0007901				\$2,350	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0017259				\$6,626	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049		STONY BROOK	63761/1108376/2		\$9,971	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-84ER45118				\$13,810	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0007063				\$15,246	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-84ER45118				\$18,307	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049		UNIVERSITY OF TEXAS AT ARLINGTON	2019GC4293		\$32,173	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0019282				\$44,761	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-91ER20052				\$62,173	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0020963				\$62,595	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0021484				\$64,000	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	ADVANCE ACCOUNT				\$70,945	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0018057				\$76,552	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049		FLORIDA STATE UNIVERSITY	R01865		\$79,007	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049		JOHNS HOPKINS UNIVERSITY	2004571414		\$82,039	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0021066				\$86,539	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-05ER46199				\$87,195	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049		UNIVERSITY OF DELAWARE	58370		\$87,543	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0021241				\$116,307	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-87ER13792				\$119,502	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049		CORNELL UNIVERSITY	85989-11289		\$124,826	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-87ER13792				\$141,442	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0009440				\$148,615	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	ADVANCE ACCOUNT				\$150,897	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0020360				\$151,338	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0017259				\$153,425	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0016043				\$157,965	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0019397				\$164,100	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	ADVANCE ACCOUNT				\$193,750	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0019781				\$201,146	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-07ER46431				\$213,247	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0019116				\$213,560	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0019281				\$237,504	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0007063				\$260,227	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0016421				\$300,375	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5118794		\$342,764	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0013528				\$346,942	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-88ER40479				\$738,232	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0007901				\$2,180,443	\$7,923,538	RESEARCH AND DEVELOPMENT	\$780,703,439
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0020169				\$108,974	\$393,124	RESEARCH AND DEVELOPMENT	\$780,703,439
CONSERVATION RESEARCH AND DEVELOPMENT	81.086		UNITED STATES AUTOMOTIVE MATERIALS PARTNERSHIP, LLC	AMP803		\$28,181	\$480,801	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CONSERVATION RESEARCH AND DEVELOPMENT	81.086		PIXELLIGENT TECHNOLOGIES	SUB TO DE-EE0009120		\$166,489	\$480,801	RESEARCH AND DEVELOPMENT	\$780,703,439
CONSERVATION RESEARCH AND DEVELOPMENT	81.086	DE-FE0008314			\$178,941	\$286,131	\$480,801	RESEARCH AND DEVELOPMENT	\$780,703,439
FOSSIL ENERGY RESEARCH AND DEVELOPMENT	81.089	DE-FE0031252				-\$7,313	\$197,727	RESEARCH AND DEVELOPMENT	\$780,703,439
FOSSIL ENERGY RESEARCH AND DEVELOPMENT	81.089	DE-FE0031673			\$16,905	\$205,040	\$197,727	RESEARCH AND DEVELOPMENT	\$780,703,439
ADVANCED RESEARCH PROJECTS AGENCY - ENERGY	81.135		COMMUNITY ENERGY VENTURES	SUB TO DE-AR0001237		\$39,379	\$39,379	RESEARCH AND DEVELOPMENT	\$780,703,439
ADVANCED ELECTRO-CATALYSTS THROUGH CRYSTALLOGRAPHIC ENHANCEMENT	81.RD	420085				-\$11,917	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
LHC ATLAS OPERATIONS SUPER PROGRAM	81.RD	382260				\$3,900	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
ANALYSIS OF THE MAGNETIC PROPERTIES OF NEW SPIN-CROSSOVER COMPLEXES	81.RD	472000				\$6,217	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
DEEP UNDERGROUND NEUTRINO EXPERIMENT (DUNE)	81.RD	668259				\$18,511	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
LLNL: SHAPE CHANGING OF RESPONSIVE ELASTOMER STRUCTURES (SCORES)	81.RD	DE-AC52-07NA27344	LAWRENCE LIVERMORE NATIONAL LABORATORY	B642549		\$20,000	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
TAILORING PHOTOPHYSICAL ENERGY TRANSFER FOR SELECTIVE SEPARATIONS OF C	81.RD	DE-AC36-08GO28308	NATIONAL RENEWABLE ENERGY LABORATORY	SUB-2021-10494		\$29,137	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
DESIGN OF A TARGET AND DICHOICRON FOR PHOTON SORTING AT CHESS PIPELINE INFRASTRUCTURE OPERATIONS PERSONNEL EFFORT FOR THE LSST DARK	81.RD	7528806	STANFORD LINEAR ACCELERATOR CENTER	SUB TO DE-AC02-76SF00515		\$54,991	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
PIPELINE INFRASTRUCTURE OPERATIONS PERSONNEL EFFORT FOR THE LSST DARK	81.RD	DE-AC02-76SF00515				\$79,505	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
CENTER FOR 3D FERROELECTRIC MICROELECTRONICS	81.RD	DE-SC0021118	PENNSYLVANIA STATE UNIVERSITY	5001327-USDOE		\$84,195	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
WFIRST SCIENCE INVESTIGATION TEAMS AND ADJUTANT SCIENTISTS	81.RD	7372918				\$86,987	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
MULTI-SOURCE LEARNING-ACCELERATED DESIGN OF HIGH-EFFICIENCY MULTI-STAG	81.RD	DE-AR0001201	UNITED TECHNOLOGIES RESEARCH CENTER	1256545		\$101,097	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
HIGH-PERFORMANCE COMPUTING MODEL OF POWDER-SCALE MELTING AND SOLIDIFIC	81.RD	DE-AC05-00OR22725	UT-BATTELLE, LLC	4000171342		\$106,557	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
DEEP UNDERGROUND NEUTRINO EXPERIMENT (DUNE)	81.RD	670531				\$116,440	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
HIGH PERFORMANCE ELECTROMECHANICAL FILTERS REALIZED IN HIGHLY DOPED AL	81.RD	(BLANK)	SANDIA NATIONAL LABORATORY	2093801		\$130,139	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
HYBRID QUANTUM/CLASSICAL ALGORITHMS FOR PHOTOCHEMISTRY AND NONADIABATI	81.RD	DE-AC02-76SF00515	STANFORD LINEAR ACCELERATOR CENTER	200073		\$185,531	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH FOR ATLAS EXPERIMENT	81.RD	80472				\$343,217	\$1,568,684	RESEARCH AND DEVELOPMENT	\$780,703,439
WATCHMAN PDR EFFORT	81.RD	DE-AC52-07NA27344	LAWRENCE LIVERMORE NATIONAL LABORATORY	B634739		\$45,063	\$214,177	RESEARCH AND DEVELOPMENT	\$780,703,439
TOTAL DEPARTMENT OF ENERGY						\$349,883	\$10,210,129		
DEPARTMENT OF EDUCATION									
FEDERAL SUPPLEMENTAL EDUCATIONAL OPPORTUNITY GRANTS (FSEOG)	84.007	P007A193720				\$813,862	\$4,488,905	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
FEDERAL SUPPLEMENTAL EDUCATIONAL OPPORTUNITY GRANTS (FSEOG)	84.007	P007A203720				\$3,675,043	\$4,488,905	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
NATIONAL RESOURCE CENTERS PROGRAM FOR FOREIGN LANGUAGE AND AREA STUDIES OR FOREIGN LANGUAGE AND INTERNATIONAL STUDIES PROGRAM AND FOREIGN LANGUAGE AND AREA STUDIES FELLOWSHIP PROGRAM	84.015	P015A140143				-\$342	\$1,394,289	OTHER PROGRAMS	\$233,218,639
NATIONAL RESOURCE CENTERS PROGRAM FOR FOREIGN LANGUAGE AND AREA STUDIES OR FOREIGN LANGUAGE AND INTERNATIONAL STUDIES PROGRAM AND FOREIGN LANGUAGE AND AREA STUDIES FELLOWSHIP PROGRAM	84.015	P015A140137				\$205	\$1,394,289	OTHER PROGRAMS	\$233,218,639
NATIONAL RESOURCE CENTERS PROGRAM FOR FOREIGN LANGUAGE AND AREA STUDIES OR FOREIGN LANGUAGE AND INTERNATIONAL STUDIES PROGRAM AND FOREIGN LANGUAGE AND AREA STUDIES FELLOWSHIP PROGRAM	84.015	P015B180147				\$243,660	\$1,394,289	OTHER PROGRAMS	\$233,218,639
NATIONAL RESOURCE CENTERS PROGRAM FOR FOREIGN LANGUAGE AND AREA STUDIES OR FOREIGN LANGUAGE AND INTERNATIONAL STUDIES PROGRAM AND FOREIGN LANGUAGE AND AREA STUDIES FELLOWSHIP PROGRAM	84.015	P015A180144/P015B180144				\$370,887	\$1,394,289	OTHER PROGRAMS	\$233,218,639
NATIONAL RESOURCE CENTERS PROGRAM FOR FOREIGN LANGUAGE AND AREA STUDIES OR FOREIGN LANGUAGE AND INTERNATIONAL STUDIES PROGRAM AND FOREIGN LANGUAGE AND AREA STUDIES FELLOWSHIP PROGRAM	84.015	P015A180141			\$2,071	\$383,111	\$1,394,289	OTHER PROGRAMS	\$233,218,639
NATIONAL RESOURCE CENTERS PROGRAM FOR FOREIGN LANGUAGE AND AREA STUDIES OR FOREIGN LANGUAGE AND INTERNATIONAL STUDIES PROGRAM AND FOREIGN LANGUAGE AND AREA STUDIES FELLOWSHIP PROGRAM	84.015	P015A180057/P015B180057			\$9,661	\$396,768	\$1,394,289	OTHER PROGRAMS	\$233,218,639
OVERSEAS PROGRAMS - DOCTORAL DISSERTATION RESEARCH ABROAD	84.022	P022A190008				\$2,207	\$2,207	RESEARCH AND DEVELOPMENT	\$780,703,439
SPECIAL EDUCATION GRANTS TO STATES	84.027		SCHOOL DISTRICT OF PHILADELPHIA	2335/F20		\$447,796	\$447,796	OTHER PROGRAMS	\$233,218,639
FEDERAL WORK-STUDY PROGRAM (FWS)	84.033	P033A193720				\$213,084	\$2,639,216	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
FEDERAL WORK-STUDY PROGRAM (FWS)	84.033	P033A203720				\$2,426,132	\$2,639,216	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
PERKINS LOAN OUTSTANDING LOANS ISSUED AS JULY 1, 2020	84.038					\$27,312,446	\$27,312,446	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
TRIO STUDENT SUPPORT SERVICES	84.042	P042A150394				\$68,773	\$348,981	TRIO CLUSTER	\$1,467,628
TRIO STUDENT SUPPORT SERVICES	84.042	P042A200318				\$280,208	\$348,981	TRIO CLUSTER	\$1,467,628

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
TRIO TALENT SEARCH	84.044	P044A160227				\$240,218	\$240,218	TRIO CLUSTER	\$1,467,628
TRIO UPWARD BOUND	84.047	P047V170188				\$198,681	\$878,429	TRIO CLUSTER	\$1,467,628
TRIO UPWARD BOUND	84.047	P047M180267				\$229,533	\$878,429	TRIO CLUSTER	\$1,467,628
TRIO UPWARD BOUND	84.047	P047A180557				\$450,215	\$878,429	TRIO CLUSTER	\$1,467,628
FEDERAL PELL GRANT PROGRAM	84.063	P063P20192158				\$219,324	\$8,164,981	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
FEDERAL PELL GRANT PROGRAM	84.063	P063P202158				\$7,945,657	\$8,164,981	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
SCHOOL SAFETY NATIONAL ACTIVITIES (FORMERLY, SAFE AND DRUG-FREE SCHOOLS AND COMMUNITIES-NATIONAL PROGRAMS)									
	84.184		SCHOOL DISTRICT OF PHILADELPHIA	2290/F20		\$48,547	\$48,547	RESEARCH AND DEVELOPMENT	\$780,703,439
GRADUATE ASSISTANCE IN AREAS OF NATIONAL NEED	84.200	P200A160282				\$85,563	\$85,563	OTHER PROGRAMS	\$233,218,639
FEDERAL DIRECT LOANS	84.268					\$182,112,903	\$182,112,903	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
PENNSYLVANIA DEPARTMENT OF EDUCATION									
TWENTY-FIRST CENTURY COMMUNITY LEARNING CENTERS	84.287			4100068078	\$9,750	\$172,901	\$1,398,948	OTHER PROGRAMS	\$233,218,639
TWENTY-FIRST CENTURY COMMUNITY LEARNING CENTERS	84.287			FC4100053524	\$14,750	\$407,062	\$1,398,948	OTHER PROGRAMS	\$233,218,639
TWENTY-FIRST CENTURY COMMUNITY LEARNING CENTERS	84.287			FC #4100071658	\$19,000	\$388,036	\$1,398,948	OTHER PROGRAMS	\$233,218,639
TWENTY-FIRST CENTURY COMMUNITY LEARNING CENTERS	84.287			SUB TO S287C170038	\$34,500	\$430,949	\$1,398,948	OTHER PROGRAMS	\$233,218,639
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3272530622		\$10,379	\$1,790,594	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	20093819-RSUB		\$17,318	\$1,790,594	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305		AMERICAN INSTITUTE FOR RESEARCH	0440200001		\$39,963	\$1,790,594	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305		FLORIDA STATE UNIVERSITY	R011963		\$53,298	\$1,790,594	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305	R305B200035				\$313,156	\$1,790,594	RESEARCH AND DEVELOPMENT	\$780,703,439
DOES APPLIED STEM CTE STRENGTHEN THE COLLEGE AND CAREER PIPELINE FOR L	84.305	R305A190523			\$9,860	\$101,260	\$1,790,594	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305	R305A160109				\$22,277	\$595,276	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305	R305B200034				\$44,169	\$134,618	RESEARCH AND DEVELOPMENT	\$780,703,439
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305	R305C150007			\$343,788	\$525,326	\$1,790,594	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH IN SPECIAL EDUCATION	84.324	R324A200233				\$1,134	\$97,474	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH IN SPECIAL EDUCATION	84.324	R324B180017				\$96,340	\$97,474	RESEARCH AND DEVELOPMENT	\$780,703,439
GAINING EARLY AWARENESS AND READINESS FOR UNDERGRADUATE PROGRAMS									
	84.334		SCHOOL DISTRICT OF PHILADELPHIA	005/F16	\$131,605	\$220,233	\$220,233	OTHER PROGRAMS	\$233,218,639
SUPPORTING EFFECTIVE INSTRUCTION STATE GRANTS (FORMERLY IMPROVING TEACHER QUALITY STATE GRANTS)									
	84.367		SCHOOL DISTRICT OF PHILADELPHIA	582910		\$56,574	\$117,032	OTHER PROGRAMS	\$233,218,639
SUPPORTING EFFECTIVE INSTRUCTION STATE GRANTS (FORMERLY IMPROVING TEACHER QUALITY STATE GRANTS)									
	84.367		PENNSYLVANIA DEPARTMENT OF EDUCATION	4100084635		\$60,458	\$117,032	OTHER PROGRAMS	\$233,218,639
TEACHER EDUCATION ASSISTANCE FOR COLLEGE AND HIGHER EDUCATION GRANTS (TEACH GRANTS)	84.379	P379T202158				\$3,764	\$13,128	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
TEACHER EDUCATION ASSISTANCE FOR COLLEGE AND HIGHER EDUCATION GRANTS (TEACH GRANTS)	84.379	9379T212158				\$9,364	\$13,128	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
COVID-19 - EDUCATION STABILIZATION FUND									
	84.425		CARING PEOPLE ALLIANCE	CRSA CHILDCARE PROVIDER FUNDING		\$91,300	\$91,300	OTHER PROGRAMS	\$233,218,639
COVID-19 - IMPACT OF COVID-19 ON PENNSYLVANIA CHILD CARE PROVIDERS									
	84.RD	232752	PENNSYLVANIA STATE UNIVERSITY	S000645-BCUI		\$22,477	\$22,477	RESEARCH AND DEVELOPMENT	\$780,703,439
GREEN STEM	84.U17	(BLANK)	WEST CHESTER UNIVERSITY	ADVANCE ACCOUNT		\$4,782	\$4,782	OTHER PROGRAMS	\$233,218,639
TOTAL DEPARTMENT OF EDUCATION						\$641,431	\$231,920,449		
DEPARTMENT OF HEALTH AND HUMAN SERVICES									
TRAINING IN GENERAL, PEDIATRIC, AND PUBLIC HEALTH DENTISTRY	93.059	1 D87HP321430100				\$94,160	\$786,310	RESEARCH AND DEVELOPMENT	\$780,703,439
TRAINING IN GENERAL, PEDIATRIC, AND PUBLIC HEALTH DENTISTRY	93.059	1 D85HP30830-01-00				\$300,002	\$786,310	RESEARCH AND DEVELOPMENT	\$780,703,439
TRAINING IN GENERAL, PEDIATRIC, AND PUBLIC HEALTH DENTISTRY	93.059	1 D88HP390330100				\$392,148	\$786,310	RESEARCH AND DEVELOPMENT	\$780,703,439
GLOBAL AIDS	93.067	1-U2G-GH-001498-01				\$483,029	\$483,029	RESEARCH AND DEVELOPMENT	\$780,703,439
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	1-R01-DA-036028-01				-\$3,086	\$6,032,988	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH									
	93.077		WAKE FOREST UNIVERSITY	WFUHS 119379		\$389	\$6,032,988	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	1-U54-CA-229973-01				\$564	\$6,032,988	RESEARCH AND DEVELOPMENT	\$780,703,439
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	1-R21-HL-144673-01A1				\$112,976	\$6,032,988	RESEARCH AND DEVELOPMENT	\$780,703,439
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	1R21DA052421-01				\$136,891	\$6,032,988	RESEARCH AND DEVELOPMENT	\$780,703,439
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH									
	93.077		WAKE FOREST UNIVERSITY	WFUHS 119379		\$246,936	\$6,032,988	RESEARCH AND DEVELOPMENT	\$780,703,439
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	1-R01-DA-047743-01A1			\$127,018	\$519,190	\$6,032,988	RESEARCH AND DEVELOPMENT	\$780,703,439
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	1-U54-CA-229973-01			\$3,083,921	\$5,019,128	\$6,032,988	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH									
	93.080		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	8901210000		\$22,898	\$22,898	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.084		WASHINGTON UNIVERSITY IN ST. LOUIS	WU-17-159		-\$8,353	\$1,532,212	RESEARCH AND DEVELOPMENT	\$780,703,439
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.084		DUKE UNIVERSITY MEDICAL CENTER	2035586		\$5,465	\$1,532,212	RESEARCH AND DEVELOPMENT	\$780,703,439
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.084		RUSH UNIVERSITY	15122902-SUB02		\$5,471	\$1,532,212	RESEARCH AND DEVELOPMENT	\$780,703,439
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.084	1 U54CK000610-01-00				\$16,652	\$1,532,212	RESEARCH AND DEVELOPMENT	\$780,703,439
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.084	1-U54-CK-000485-01			\$93,367	\$1,512,977	\$1,532,212	RESEARCH AND DEVELOPMENT	\$780,703,439
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006450-01				-\$2,269	\$274,016	RESEARCH AND DEVELOPMENT	\$780,703,439
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006660-01				-\$451	\$274,016	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1U18FD006669-01				\$327	\$274,016	RESEARCH AND DEVELOPMENT	\$780,703,439
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006661-01				\$394	\$274,016	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006158-01				\$1,128	\$274,016	RESEARCH AND DEVELOPMENT	\$780,703,439
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103		BRIGHAM AND WOMEN'S HOSPITAL	124939		\$3,833	\$274,016	RESEARCH AND DEVELOPMENT	\$780,703,439
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006855-01				\$7,849	\$274,016	RESEARCH AND DEVELOPMENT	\$780,703,439
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1U18FD007245-01				\$15,076	\$274,016	RESEARCH AND DEVELOPMENT	\$780,703,439
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006985-01				\$17,995	\$274,016	RESEARCH AND DEVELOPMENT	\$780,703,439
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006856-01				\$35,016	\$274,016	RESEARCH AND DEVELOPMENT	\$780,703,439
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1U18FD006669-01				\$40,622	\$274,016	RESEARCH AND DEVELOPMENT	\$780,703,439
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1U18FD006984-01				\$42,093	\$274,016	RESEARCH AND DEVELOPMENT	\$780,703,439
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	FP23610_SU_B01_01		\$44,655	\$274,016	RESEARCH AND DEVELOPMENT	\$780,703,439
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006158-01				\$67,748	\$274,016	RESEARCH AND DEVELOPMENT	\$780,703,439
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		FLORIDA ASSOCIATION OF HEALTHY START COALITIONS, INC.	16-08-2019		-\$400	\$261,210	RESEARCH AND DEVELOPMENT	\$780,703,439
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3258990618		\$10,913	\$261,210	RESEARCH AND DEVELOPMENT	\$780,703,439
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		NORTHWELL HEALTH CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	510109UPENN		\$20,317	\$261,210	RESEARCH AND DEVELOPMENT	\$780,703,439
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3258990618		\$25,359	\$261,210	RESEARCH AND DEVELOPMENT	\$780,703,439
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3210800519		\$34,755	\$261,210	RESEARCH AND DEVELOPMENT	\$780,703,439
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	320961-06-01		\$37,318	\$261,210	RESEARCH AND DEVELOPMENT	\$780,703,439
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201890820		\$37,512	\$261,210	RESEARCH AND DEVELOPMENT	\$780,703,439
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		UNIVERSITY OF CALIFORNIA, LOS ANGELES	2000 G TC248		\$95,436	\$261,210	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113	2-P30-ES-013508-10				-\$9,503	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113		UNIVERSITY OF CINCINNATI	011720-002		\$13,990	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113		CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	137605		\$17,405	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113		UNIVERSITY OF LOUISVILLE	ULRF_18-015251-01		\$29,326	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113		JT-MESH DIAGNOSTICS	SUB TO R41ES031778		\$67,444	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113	2R25ES021649-06				\$79,139	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113		UNIVERSITY OF CINCINNATI	011150-007		\$82,313	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113	1-R01-ES-026023-01				\$93,466	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113	1-R21-ES-031243-01A1				\$109,049	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113		RUTGERS UNIVERSITY	1398		\$156,882	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113		DUKE UNIVERSITY	A03-3948		\$175,000	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113	7-R01-ES-028277-04				\$265,887	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113	1-R01-ES-028206-01				\$303,333	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113	2-T32-ES-019851-06				\$416,386	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113	1-R01-ES-028114-01A1				\$424,931	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113	2-P30-ES-013508-15				\$1,578,938	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
ENVIRONMENTAL HEALTH	93.113	1-R01-ES-029294-01A1			\$141,799	\$510,599	\$4,314,585	RESEARCH AND DEVELOPMENT	\$780,703,439
PREVENTIVE MEDICINE RESIDENCY	93.117	1 D33HP31673-01-00				\$412,922	\$412,922	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R56-DE-024749-01				-\$7,202	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-024716-01				\$5	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R37-DE-026152-01				\$5	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-024153-01A1				\$5	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121		LANKENAU INSTITUTE FOR MEDICAL RESEARCH	06297-0793		\$5	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-028561-01A1				\$5	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1R01DE029436-01				\$5	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-017732-07A1				\$19	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-021921-06				\$19	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-019108-06A1				\$48	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	7-R01-DE-025037-06				\$461	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	7R01DE027374-03				\$508	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-018023-07A1				\$527	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-025848-01A1				\$567	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-025220-01				\$1,025	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121		LOUISIANA STATE UNIVERSITY	SOD-20-136-002		\$3,504	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	7-U01-DE-027637-02				\$3,520	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121		VIRGINIA COMMONWEALTH UNIVERSITY	FP00010440_SA002		\$17,418	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121		DREXEL UNIVERSITY	900101		\$20,055	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121		UNIVERSITY OF ROCHESTER			\$20,146	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121		MEDICAL CENTER	417864-G / UR FAO GR511139		\$26,591	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121		UNIVERSITY OF FLORIDA	UFDS00012134		\$27,039	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-030415-01				\$33,204	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-F31-DE-029361-01				\$39,615	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1F31DE030365-01				\$50,346	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7-R01-DE-025037-06	NEW YORK UNIVERSITY	F1433-01		\$64,930	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-F32-DE-029407-01				\$74,816	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121		NEW YORK UNIVERSITY	F0671-01		\$76,822	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-K08-DE-027129-01				\$104,315	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-024716-01				\$104,403	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121		CAROLINAS HEALTH CARE SYSTEM	3000301222 (A18-0261-S007)		\$114,814	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R21-DE-028417-01				\$122,522	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1R21DE029926-01				\$123,789	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R03-DE-028026-01A1				\$127,926	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121		LANKENAU INSTITUTE FOR MEDICAL RESEARCH	06297-0793		\$165,208	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-021921-06				\$227,277	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-017732-07A1				\$236,731	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	4-R00-DE-025915-03				\$242,552	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-025848-01A1				\$284,691	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-024160-01A1				\$290,380	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-027970-01				\$366,193	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-023071-06A1				\$368,047	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-024153-01A1				\$388,430	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	4-R00-DE-026807-02				\$398,018	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1R01DE029436-01				\$410,758	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7R01DE027374-03				\$441,886	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-027185-01A1				\$468,471	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-006014-34A1				\$511,372	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-029648-01				\$552,649	\$11,038,937	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7-R01-DE-026772-05				\$7,836	\$283,436	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7-R01-DE-026279-05				\$12,548	\$238,545	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-019108-06A1				\$19,486	\$344,668	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-024749-01				\$24,339	\$74,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7-R01-DE-024982-04				\$32,421	\$86,050	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-025220-01				\$33,707	\$210,236	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-018023-07A1				\$68,920	\$193,630	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-027901-01				\$74,877	\$335,861	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R37-DE-026152-01				\$87,466	\$384,484	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-028561-01A1				\$121,864	\$366,761	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7-U01-DE-027637-02				\$280,669	\$1,505,398	RESEARCH AND DEVELOPMENT	\$780,703,439
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-026603-01A1				\$382,493	\$511,145	RESEARCH AND DEVELOPMENT	\$780,703,439
GRANTS TO INCREASE ORGAN DONATIONS	93.134		JOHNS HOPKINS UNIVERSITY	2003709181		\$1,030	\$1,030	RESEARCH AND DEVELOPMENT	\$780,703,439
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136		UNIVERSITY OF MICHIGAN	SUBK00013120		\$1,648	\$1,754,650	RESEARCH AND DEVELOPMENT	\$780,703,439
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1-R49-CE-002474-01				\$14,471	\$1,754,650	RESEARCH AND DEVELOPMENT	\$780,703,439
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1 R49CE003083-01-00				\$634,285	\$1,754,650	RESEARCH AND DEVELOPMENT	\$780,703,439
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1 R01CE003143-01-00				\$2,427	\$423,069	RESEARCH AND DEVELOPMENT	\$780,703,439
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1 R01CE003049-01-00				\$341,366	\$681,177	RESEARCH AND DEVELOPMENT	\$780,703,439
COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM	93.137		PHILADELPHIA YOUTH SPORTS COLLABORATIVE	SUMMER CAMP 2020		\$2,000	\$2,000	OTHER PROGRAMS	\$233,218,639
HUMAN GENOME RESEARCH	93.172	1-U01-HG-006398-01				\$-78,796	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172		COLUMBIA UNIVERSITY	1 (GG012559)		\$-858	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	960033RUSB		\$-78	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172		STANFORD UNIVERSITY	60247895-50011-A		\$630	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172		BIOSPYDER	SUB TO R41HG010638		\$12,178	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1-F30-HG-010442-01				\$15,709	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172		ALTIUS INSTITUTE FOR BIOMEDICAL SCIENCES	PF4172		\$21,533	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1-F30-HG-010822-01A1				\$30,525	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1-F30-HG-010986-01A1				\$32,856	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172		GEISINGER HEALTH SYSTEM	646017UP		\$38,989	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
HUMAN GENOME RESEARCH	93.172	1-F30-HG-011578-01				\$42,590	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1-F31-HG-011185-01				\$45,509	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1-F31-HG-011429-01				\$47,662	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1K99HG010905-01A1				\$62,542	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172		BROAD INSTITUTE OF MIT AND HARVARD	5000950-5500001052		\$82,396	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172		STANFORD UNIVERSITY	R01 HG010476 62166731-137013		\$97,314	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1K01HG010903-01A1				\$107,809	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	R25-HG-010323				\$117,306	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172		UNIVERSITY OF CHICAGO	FP061089-01-C		\$121,420	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1-T32-HG-009495-01				\$180,981	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1-T32-HG-009496-01				\$243,412	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1-R21-HG-010536-01				\$304,589	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	2-T32-HG-000046-21				\$346,653	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1-R01-HG-009655-01				\$511,750	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	2-R01-HG-006137-07			\$44,993	\$53,707	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	2-R01-HG-006137-10			\$113,436	\$240,858	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1-R01-HG-010646-01			\$156,344	\$659,775	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1-R01-HG-010067-01			\$220,535	\$396,132	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1-U24-HG-010862-01A1			\$322,175	\$576,464	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
HUMAN GENOME RESEARCH	93.172	1-RM1-HG-010023-01			\$628,189	\$2,510,407	\$6,821,964	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	7-R01-DC-010014-10				-\$31,517	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-013961-01A1				-\$18,084	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-014479-01				-\$3,678	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-017144-01A1				\$70	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-F31-DC-016192-01A1				\$1,763	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-F31-DC-016524-01				\$4,136	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2-R13-DC-010549-11				\$5,571	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		MONELL CHEMICAL SENSES CENTER	NIH033B06MENNE		\$12,067	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000478		\$25,870	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	108585C		\$27,744	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-F31-DC-017054-01A1				\$37,629	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		NORTHWESTERN UNIVERSITY	60044484 PENN		\$39,780	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-F31-DC-018473-01A1				\$41,274	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		NORTHWESTERN UNIVERSITY	60049678 UP		\$42,091	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-014464-01				\$63,876	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R21-DC-019193-01				\$66,383	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2-R01-DC-009209-11				\$87,554	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		MEDICAL COLLEGE OF WISCONSIN	SUB TO R01DC016622		\$128,166	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-T32-DC-016903-01				\$143,615	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		TEMPLE UNIVERSITY	262389 UPENN		\$179,963	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		NORTHWESTERN UNIVERSITY	SP0028600-PROJ0014095		\$206,379	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1R01DC018525-01				\$311,142	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-015527-01A1				\$320,910	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2-R01-DC-014479-06A1				\$354,406	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2-R01-DC-006213-16A1				\$380,749	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-018278-01A1				\$401,147	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-016309-01A1				\$421,591	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2-R01-DC-006254-16A1				\$456,728	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1R01DC017690-01A1				\$537,214	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-017144-01A1				\$588,951	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2-R01-DC-012854-06				\$643,497	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-016800-01A1				\$685,472	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-018075-01A1			\$14,099	\$510,922	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2-R01-DC-006213-11A1			\$30,523	\$45,502	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-015359-01A1			\$39,933	\$301,923	\$7,020,806	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL RESEARCH SERVICE AWARD IN PRIMARY CARE MEDICINE	93.186	6 T32HP10026-23-01				\$411,394	\$411,394	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213		NEW YORK UNIVERSITY	17-AO-00-008501		\$40,615	\$459,931	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	1-UH2-AT-007797-01				\$165,880	\$459,931	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213		UNIVERSITY OF MINNESOTA	A0006743902		\$253,436	\$459,931	RESEARCH AND DEVELOPMENT	\$780,703,439
FAMILY PLANNING SERVICE	93.217	FHPA036160				\$73,026	\$73,026	OTHER PROGRAMS	\$233,218,639
NATIONAL RESEARCH SERVICE AWARDS HEALTH SERVICES RESEARCH TRAINING	93.225	1-T32-HS-026116-01				\$543,263	\$543,263	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		CORNELL UNIVERSITY	83742-11053		-\$15,344	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-K02-HS-022124-01				-\$8,958	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R01-HS-023615-01				-\$3,713	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R01-HS-024106-01				-\$3,554	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R36-HS-027142-01				-\$2,872	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		VISITING NURSE SERVICE OF NEW YORK	4629_2020_PENN		\$6,623	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		ARBOR RESEARCH COLLABORATIVE FOR HEALTH	SUB TO R01-HS025756		\$21,284	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES	51981 - UPENN		\$23,798	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		EMORY UNIVERSITY	A015673		\$29,985	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		COLUMBIA UNIVERSITY	1(GG014621-01)		\$39,834	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000523		\$46,639	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	ACTIVITY#320133072		\$47,607	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		YALE UNIVERSITY	GR107704 (CON-80001950		\$55,075	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		EMORY UNIVERSITY	A242409		\$58,435	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		JOHNS HOPKINS UNIVERSITY	2004496574		\$62,427	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		UNIVERSITY OF IOWA	500848-01		\$64,867	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201800422		\$71,146	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R01-HS-025184-01				\$116,218	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-K12-HS-026372-01				\$581,374	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R18-HS-026862-01A1			\$8,397	\$327,559	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	7-R01-HS-021491-04			\$9,607	\$46,505	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R01-HS-024918-01			\$31,571	\$122,834	\$1,687,769	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	2-P01-HL-094307-06A1				\$38	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-U01-HL-125388-01A1				\$2,378	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1F31HL154855-01				\$38,875	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-R01-HL-123331-01A1				\$42,252	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201930820		\$82,821	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233		UNIVERSITY OF NEVADA, LAS VEGAS	GR09951		\$91,084	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-K99-HL-147212-01				\$112,437	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-R01-HL-122754-01A1				\$121,278	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	2-T32-HL-007953-19				\$240,114	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1R01HL149133-01				\$502,773	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-R01-HL-142981-01A1				\$512,455	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	2-T32-HL-007713-26A1				\$763,628	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-R25-HL-120874-01			\$10,797	\$49,998	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-R01-HL-134015-01			\$224,323	\$494,195	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	2-T32-HL-110952-06			\$288,852	\$288,852	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	2-P01-HL-094307-06A1			\$516,386	\$2,700,177	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-R01-HL-143790-01			\$786,098	\$981,503	\$7,024,858	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		ARIZONA STATE UNIVERSITY	SUB TO U01MH121260		-\$140,112	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	7-R01-MH-105128				-\$627	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F32-MH-117924-01A1				-\$148	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R34-MH-108437-01A1	UNIVERSITY OF CALIFORNIA, LOS ANGELES	1580 G WB602		-\$143	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242					-\$23	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	2-T32-MH-065218-11				-\$1	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	7-R01-MH-103910-06				-\$1	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-106967-01A1				\$41	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-109382-01A1				\$41	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - MENTAL HEALTH RESEARCH GRANTS	93.242	2-R01-MH-098742-06A1				\$41	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - MENTAL HEALTH RESEARCH GRANTS	93.242	1UF1MH121944-01				\$94	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		YALE UNIVERSITY	GR104299 (CON-80001421)		\$311	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201070320		\$718	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	2-T32-MH-019112-24				\$1,073	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3209760321		\$2,925	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		VANDERBILT UNIVERSITY	VUMC86227		\$4,098	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		CHILD MIND INSTITUTE BIOBANK	1R21MH118556 SUB1		\$4,964	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F31-MH-126569-01				\$6,459	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F31-MH-124372-01A1				\$6,459	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		MASSACHUSETTS GENERAL HOSPITAL	227381		\$6,596	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF ALABAMA AT BIRMINGHAM	000518108-003		\$8,447	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F31-MH-125542-01A1				\$8,569	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		TEMPLE UNIVERSITY	260864-PENN		\$9,870	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F31-MH-123063-01A1				\$10,765	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		ACLARIS MEDICAL, LLC	R43MH107089-S1		\$12,100	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		VALA SCIENCES, INC.	SUB TO R44MH119621		\$12,395	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5111526		\$16,631	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		BOISE STATE UNIVERSITY	8424-PO133997		\$17,250	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF WASHINGTON	UWSC10849		\$18,094	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		HENRY FORD HEALTH SYSTEM	B11175_UPENN		\$18,103	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		PROMPTWORKS	SUB TO R32MH121205		\$18,962	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201571123		\$18,999	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-K99-MH-126427-01				\$20,006	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		THOMAS JEFFERSON UNIVERSITY	080-19250-S36601		\$20,183	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3210640821		\$21,266	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F31-MH-125539-01				\$22,910	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000301		\$24,207	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		OHIO STATE UNIVERSITY	GR122043/ SPC-1000004737		\$26,603	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F31-MH-120925-01A1				\$28,353	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF CALIFORNIA, LOS ANGELES	2000 G VA473		\$28,426	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-124897-01				\$28,647	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		COLUMBIA UNIVERSITY	1(GG011930)		\$31,384	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F30-MH-118871-01				\$33,236	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		NOUS IMAGING, INC.	R44MH121276_SUB3		\$33,887	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F32-MH-115661-01A1				\$36,488	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F32-MH-125600-01				\$38,892	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F30-MH-122076-01				\$39,286	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200290221		\$41,572	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		NOUS IMAGING, INC.	R44MH124567_SUB3		\$45,183	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F31-MH-123033-01				\$45,286	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F32-MH-115434-01				\$46,470	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-K01-MH-125144-01				\$47,844	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		COLUMBIA UNIVERSITY	1(GG014372-01)		\$49,902	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-123841-01A1				\$50,326	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-126773-01				\$52,566	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	102885C		\$53,578	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1F32MH113334-01A1				\$54,094	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201740321-S1		\$54,824	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201790521		\$55,300	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-125544-01				\$56,312	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F32-MH-123002-01				\$61,066	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F32-MH-120890-01				\$61,867	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.	26657		\$62,060	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF WASHINGTON	UWSC9095		\$63,581	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned by Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	116965C		\$63,756	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF MARYLAND	3001271		\$66,934	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF FLORIDA	SUB0002369		\$67,838	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		ARIZONA STATE UNIVERSITY	18-285		\$74,817	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	4-R01-MH-098260-03				\$84,295	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF CALIFORNIA, SAN DIEGO	118744601		\$84,479	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-123888-01A1				\$86,883	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		RUTGERS UNIVERSITY	SUB TO R01MH109520		\$87,215	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		DREXEL UNIVERSITY	800172		\$93,953	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		NORTHWESTERN UNIVERSITY	60047194 UP		\$99,885	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		WASHINGTON UNIVERSITY IN ST. LOUIS	WU-20-422		\$103,334	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-118037-01				\$105,306	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-108996-01A1				\$106,004	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.	149042		\$143,127	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	4-R00-MH-111836-03				\$145,807	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		COLUMBIA UNIVERSITY	1(GG011969-01)		\$148,439	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1R21MH12239-01				\$149,409	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-K01-MH-120509-01A1				\$156,248	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-107571-01A1				\$156,506	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-K01-MH-121777-01				\$167,313	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1R21MH12121-01				\$167,783	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-118489-01A1				\$170,850	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-K23-MH-118580-01A1				\$180,044	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		ALLEN INSTITUTE FOR BRAIN SCIENCE	2017-0567		\$181,793	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		YALE UNIVERSITY	GR110979 (CON-80002775)		\$182,877	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-111886-01				\$184,347	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R25-MH-119043-01				\$191,798	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-T32-MH-106442-01A1				\$211,982	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		PALO ALTO VETERANS INSTITUTE FOR RESEARCH	WIS0003-05		\$213,789	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	2-R01-MH-087950-06A1				\$228,879	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	2-T32-MH-019112-29A1				\$241,748	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	2-T32-MH014654-40				\$249,692	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - MENTAL HEALTH RESEARCH GRANTS	93.242	7-K08-MH-112120-04				\$264,947	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-U01-MH-109991-01				\$272,465	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-118170-01				\$275,150	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1RF1MH123979-01				\$305,573	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-115030-01				\$311,802	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		EMORY UNIVERSITY	A051228		\$314,320	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-T32-MH-109433-01A1				\$331,772	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	2-R01-MH-055687-21				\$353,265	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-109260-01A1				\$355,797	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		NEW YORK UNIVERSITY GROSSMAN SCHOOL OF MEDICINE	19-A0-00-1003623		\$417,119	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-112847-01				\$435,169	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-120174-01A1				\$452,557	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-111719-01A1				\$453,432	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-110939-01A1				\$453,739	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF WASHINGTON	UWSC11446		\$468,629	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-110180-01A1				\$509,185	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-109498-01				\$517,417	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-123550-01				\$530,151	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-U01-MH-119738-01				\$546,166	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-120811-01				\$550,850	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242		YALE UNIVERSITY	GR107872 (CON-80002099)		\$600,232	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-117014-01A1				\$667,430	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-120269-01				\$683,640	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-113550-01A1				\$701,097	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-113565-01A1				\$705,839	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-RF1-MH-116920-01				\$778,035	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-123491-01				\$2,037	\$169,575	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-116362-01				\$2,330	\$85,419	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-116884-01A1				\$6,995	\$468,595	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-120739-01				\$20,488	\$148,676	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-119219-01A1				\$23,907	\$719,284	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-112070-01A1				\$25,000	\$462,811	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	2-R01-MH-075916-05A1				\$39,022	\$39,022	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R37-MH-109728-01				\$39,064	\$628,421	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-108551-01				\$41,401	\$298,041	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-106967-01A1				\$47,710	\$93,093	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MENTAL HEALTH RESEARCH GRANTS	93.242	1UF1MH121944-01			\$53,518	\$2,063,381	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-118369-01A1			\$56,756	\$615,138	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-P50-MH-113840-01			\$66,088	\$1,202,452	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1R01MH118203-01A1			\$75,702	\$389,016	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-109382-01A1			\$95,111	\$379,769	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R56-MH-118550-01			\$100,426	\$150,598	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-119185-01A1			\$108,826	\$468,671	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	2-P30-MH-097488-06			\$118,910	\$1,676,868	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-117807-01A1			\$197,617	\$825,345	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-115557-01			\$201,578	\$368,067	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	R01MH111602			\$205,104	\$393,800	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-108627-01			\$214,299	\$283,175	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-107452-01A1			\$217,182	\$567,879	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-111389-01			\$220,248	\$585,700	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-U01-MH-107276-01A1			\$233,083	\$665,171	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	2-R01-MH-098742-06A1			\$390,601	\$941,135	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-120482-01			\$425,360	\$776,812	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL HEALTH RESEARCH GRANTS	93.242	7-U19-MH-106434-02			\$1,784,206	\$2,427,176	\$36,144,553	RESEARCH AND DEVELOPMENT	\$780,703,439
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243		DELAWARE, STATE OF	0417124		\$3,950	\$1,219,139	OTHER PROGRAMS	\$233,218,639
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243		CITY OF PHILADELPHIA	1720535		\$68,518	\$1,219,139	OTHER PROGRAMS	\$233,218,639
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243		ADAMS COUNTY, PENNSYLVANIA	SUB TO 1H795M081196-01		\$106,871	\$1,219,139	OTHER PROGRAMS	\$233,218,639
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243		CITY OF PHILADELPHIA	2120005-00		\$145,702	\$1,219,139	OTHER PROGRAMS	\$233,218,639
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243		CITY OF PHILADELPHIA	SUB TO SAMHSA		\$166,066	\$1,219,139	OTHER PROGRAMS	\$233,218,639
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243	1H795PO080317-01				\$261,196	\$1,219,139	OTHER PROGRAMS	\$233,218,639
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243	1H791O81596-01				\$466,836	\$1,219,139	OTHER PROGRAMS	\$233,218,639
ADVANCED NURSING EDUCATION WORKFORCE GRANT PROGRAM	93.247	1T94HP30898-0-100				\$-51	\$-51	RESEARCH AND DEVELOPMENT	\$780,703,439
OCCUPATIONAL SAFETY AND HEALTH PROGRAM	93.262	2T03OH008628-15-00				\$161,322	\$161,322	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSE FACULTY LOAN PROGRAM ISSUED DURING FY21	93.264					\$172,018	\$2,384,906	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
NURSE FACULTY LOAN PROGRAM OUTSTANDING AS OF 07/01/21	93.264					\$2,212,888	\$2,384,906	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
HEALTH SYSTEMS STRENGTHENING AND HIV/AIDS PREVENTION, CARE AND TREATMENT UNDER THE PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF	93.266		BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	60648.2005114.669202		\$1,305	\$239,266	RESEARCH AND DEVELOPMENT	\$780,703,439
HEALTH SYSTEMS STRENGTHENING AND HIV/AIDS PREVENTION, CARE AND TREATMENT UNDER THE PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF	93.266	1-R01-HS-027595-01A1				\$38,237	\$239,266	RESEARCH AND DEVELOPMENT	\$780,703,439
HEALTH SYSTEMS STRENGTHENING AND HIV/AIDS PREVENTION, CARE AND TREATMENT UNDER THE PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF	93.266	7-R01-EB-022574-03			\$183,018	\$199,724	\$239,266	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273	1-R01-AA-022595-01A1				\$2,654	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273		COLUMBIA UNIVERSITY	2(GG014243-01)		\$5,103	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273		PUBLIC HEALTH MANAGEMENT CORPORATION	7617061803		\$7,232	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273	1-R01-AA-023192-01				\$12,276	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273		UNIVERSITY OF ROCHESTER	417591G / URFAO: GR510935		\$20,284	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	105095C		\$23,728	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273	1-K01-AA-028292-01A1				\$26,805	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273		RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.	PO# 140111		\$41,884	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273	1-K23-AA-023894-01				\$97,787	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273		UNIVERSITY OF NEW MEXICO	028372-874D		\$103,069	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273		YALE UNIVERSITY	GR104469 (CON-80001475)		\$156,219	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273	4-R00-AA-026892-02				\$176,147	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273		STONY BROOK	88624/2/1162469		\$245,517	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273	1-R01-AA-026302-01				\$284,791	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273	1-R01-AA-027202-01A1				\$370,346	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273	1-U01-AA-025931-01A1				\$385,096	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273	1-R01-AA-026267-01A1				\$652,338	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273	1-DP1-AA-028409-01				\$1,441,174	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
ALCOHOL RESEARCH PROGRAMS	93.273	1-R01-AA-024941-01			\$240,092	\$535,833	\$4,588,283	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2-R01-DA-033641-06				-\$7,010	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1R21DA044017-01A1				-\$1,874	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-046619-01				-\$1,725	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R21-DA-043983-01A1				-\$398	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	4-R01-DA-033670-05				-\$31	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-049514-01				\$41	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1R21DA049572-01				\$459	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		YALE UNIVERSITY	GR105496 (CON-80001678)		\$3,223	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		YALE UNIVERSITY	CON-80002920 (GR111857)		\$14,337	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		UNIVERSITY OF MICHIGAN	3003985347		\$16,058	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		NEW YORK UNIVERSITY	19-A0-00-1002274		\$16,997	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-F32-DA-053099-01				\$18,781	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		WEILL CORNELL MEDICAL COLLEGE	201209-5		\$19,800	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-K01-DA-051709-01A1				\$22,145	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		UNIVERSITY OF CONNECTICUT	420072		\$22,252	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		TEMPLE UNIVERSITY	264420-UPENN		\$23,091	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		UNIVERSITY OF ROCHESTER	417660G / URFAO:GR510990		\$23,393	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		UNIVERSITY OF WASHINGTON	UWSC11619		\$32,704	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		CORNELL UNIVERSITY	183469-2		\$49,798	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R36-DA-050877-01				\$50,761	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
ALTERED MIDBRAIN GABAERGIC CIRCUITRY DRIVES GREATER COCAINE SELF-ADMIN	93.279	1-R01-DA-053296-01				\$51,403	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		WISTAR INSTITUTE	25631-02-324		\$59,300	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		COLUMBIA UNIVERSITY	12(GG015428-03)		\$59,965	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	7-K01-DA-049900-02				\$69,192	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5-U34-DA-045177-01A1				\$173,340	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		SOBER GRID, INC.	SUB TO 5R44DA044062-03		\$80,874	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		SIMON FRASER UNIVERSITY	SUB TO 3R01DA041747		\$84,129	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	7-K99-DA-048748-03				\$94,842	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-K01-DA-040023-01A1				\$104,292	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		DUKE UNIVERSITY	A033335		\$107,591	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		EMBERA NEURO THERAPEUTICS, INC.	SUB TO U01DA038879		\$111,816	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		UNIVERSITY OF MICHIGAN	SUBK00011012		\$115,083	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		EMORY UNIVERSITY	A305847		\$122,467	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-U18-DA-052399-01				\$122,630	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1K01DA051348-01				\$136,504	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2-K24-DA-029062-06				\$137,461	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		WISTAR INSTITUTE	25621-02-324		\$137,583	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		UNIVERSITY OF FLORIDA	SUB00002214		\$138,233	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R21-DA-045792-01A1				\$148,648	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-K24-DA-045244-01A1				\$149,763	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-K23-DA-038726-01A1				\$154,518	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		GEISINGER HEALTH SYSTEM	626510UP01		\$158,182	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R34-DA-050297-01				\$159,961	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-K01-AD04717-01A1				\$183,023	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R21-DA-046364-01A1				\$188,147	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	4-R00-DA-043609-03				\$189,580	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-K23-DA-048167-01				\$195,861	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R21-DA-050761-01				\$209,727	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		WEILL CORNELL MEDICAL COLLEGE	SUB TO NIH ADV ACCT		\$220,950	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		SUNNYBROOK RESEARCH INSTITUTE	2017-1218		\$245,098	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-041402-01				\$288,695	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-040670-01A1				\$301,829	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		YALE UNIVERSITY	GR109740 (CON-80002398)		\$315,032	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-039215-01A1				\$345,775	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2-T32-DA-028874-08				\$389,026	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2-R01-DA-037897-05A1				\$411,784	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-UG1-DA-050209-01				\$425,555	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-044205-01A1				\$426,297	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-041409-01A1				\$445,278	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-044906-01				\$449,635	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1DP1DA051620-01				\$494,722	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-0P1-DA-044250-01				\$504,753	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-042682-01				\$519,390	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-U18-DA-052513-01			\$3,671	\$156,924	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1R01DA045604-01A1			\$15,984	\$551,888	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-040972-01A1			\$16,662	\$423,667	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-049514-01			\$25,214	\$672,712	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-041180-01A1			\$33,422	\$182,589	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2-R01-DA-029840-06A1			\$122,503	\$360,745	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-048001-01			\$186,048	\$630,238	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-037289-01A1			\$204,039	\$233,509	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2-R01-DA-035868-04A1			\$217,114	\$455,275	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-049545-01			\$228,869	\$660,934	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-P30-DA-046345-01A1			\$401,619	\$1,831,430	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-UG3-DA-049694-01			\$482,622	\$1,244,217	\$17,032,864	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2-R01-EB-008722-05A1				-\$15,712	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-F31-EB-024378-01A1				-\$52	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
COVID-19 - DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		ALPHATHERA	SUB TO R44 EB023750-02		\$66	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1U24EB028941-01				\$82	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-026892-01				\$233	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		BOSTON UNIVERSITY	4500002478		\$4,987	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		UNIVERSITY OF MIAMI	SPC-000724		\$14,114	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2-T32-EB-020087-06				\$15,418	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2-T32-EB-004311-11				\$16,159	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R21-EB-029556-01A1	UNIVERSITY OF CONNECTICUT HEALTH CENTER	UCHC7-117331099		\$18,000	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286					\$27,168	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R21-EB-023989-01A1				\$41,231	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-F31-EB-029309-01				\$44,327	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		INDIANA UNIVERSITY	8165-UP		\$47,740	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-017255-01A1	CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200920521/PO 962704-RSUB		\$55,840	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		UNIVERSITY OF CHICAGO	AWD100072 (SUB00000207)		\$56,474	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286					\$56,955	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1K99EB028838-01A1				\$77,435	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-026988-01				\$107,999	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		ALPHATHERA	SUB TO 3R44EB023750-0351		\$144,291	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		DARTMOUTH COLLEGE	R1035		\$146,956	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-021293-01A1				\$173,077	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-022612-01				\$180,125	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-T32-EB-020087-01A1				\$200,605	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2-T32-EB-004311-16				\$201,305	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		ALPHATHERA	SUB TO R44 EB023750-02		\$213,422	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2-T32-EB-009384-11				\$237,629	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-029363-01				\$264,086	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-026945-01				\$274,452	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-022573-03				\$283,428	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R21-EB-027407-01				\$323,850	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-029767-01				\$344,535	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-028162-01				\$357,292	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-029238-01A1				\$375,150	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-026892-01				\$488,393	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-023274-01				\$519,171	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-028320-01				\$534,593	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2-P41-EB-015893-31				\$590,703	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2-R01-EB-017753-05				\$675,097	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned by Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-028764-01				\$705,194	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1R01EB030876-01A1			\$45,118	\$197,469	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R21-EB-027397-01			\$60,089	\$202,748	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1U24EB028941-01			\$105,091	\$418,526	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-028778-01A1			\$151,570	\$392,027	\$9,012,588	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	0008663BN		\$11,406	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		UNIVERSITY OF PITTSBURGH	CNVA00047269 (127145-6)		\$14,127	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		MEDICAL UNIVERSITY OF SOUTH CAROLINA	A00-2768-5004		\$14,949	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-7401-4609		\$20,696	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201001122		\$33,953	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		WASHINGTON UNIVERSITY IN ST. LOUIS	WU-20-107		\$41,392	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		MEDICAL UNIVERSITY OF SOUTH CAROLINA	MUSC16-081-8C186		\$119,194	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		RAND CORPORATION	9920170019		\$227,630	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1-R01-MD-011518-01A1			\$20,485	\$331,612	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1R01MD016029-01			\$20,785	\$69,618	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1-R01-MD-013859-01			\$191,404	\$577,592	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1-R01-MD-011679-01			\$197,822	\$742,532	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1-R01-MD-013623-01			\$307,049	\$839,341	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	7-R01-MD-013558-03			\$317,509	\$582,645	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1-U01-MD-011274-01			\$878,692	\$1,553,048	\$5,179,735	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310	1-DP2-OD-007288-01				-\$18,333	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310	1-DP2-MH-110247-01				-\$4,296	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310	1-DP2-GM-105444-01				-\$8	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310		DREXEL UNIVERSITY	800134		\$2,402	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310		NEW YORK UNIVERSITY	15-AD-00-004321-01		\$5,076	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - TRANS-NIH RESEARCH SUPPORT	93.310		UNIVERSITY OF CALIFORNIA, SANTA BARBARA	SUB TO R01DK130067		\$7,197	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000614		\$14,821	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310		COLUMBIA UNIVERSITY	1(GG013725-01)		\$20,565	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - TRANS-NIH RESEARCH SUPPORT	93.310		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	124865C		\$20,696	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310		UNIVERSITY OF CALIFORNIA, DAVIS	20150115-01		\$95,079	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310	7-OT3-OD-025347-02				\$96,950	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310	1-R03-TR-003299-01				\$112,539	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310	1-DP5-OD-021391-01				\$144,230	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310	1DP2TR002776-01				\$155,708	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201240619		\$169,580	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310	1U01DA052715-01				\$271,024	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310	1-DP5-OD-026420-01				\$392,512	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310	1DP5OD028144-01				\$418,330	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310	1-DP5-OD-026386-01				\$473,408	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310	1-R01-AR-075337-01				\$895,247	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310	1-R01-GM-137425-01				\$1,103,092	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - TRANS-NIH RESEARCH SUPPORT	93.310	1U18TR003775-01			\$1,640	\$239,997	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANS-NIH RESEARCH SUPPORT	93.310	1U01DK127405-01			\$248,703	\$771,701	\$5,387,517	RESEARCH AND DEVELOPMENT	\$780,703,439
LDS DENTAL OUTSTANDING AS OF 07/01/2020	93.342					\$3,243	\$16,638,403	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
HPL MEDICAL OUTSTANDING AS OF 07/01/2020	93.342					\$165,278	\$16,638,403	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
LDS MEDICAL ISSUED AFTER 07/01/2020	93.342					\$384,464	\$16,638,403	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
HPL VET ISSUED AFTER 07/01/2020	93.342					\$530,000	\$16,638,403	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
HPL DENTAL ISSUED AFTER 07/01/2020	93.342					\$1,315,000	\$16,638,403	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
LDS MEDICAL OUTSTANDING AS OF 07/01/2020	93.342					\$2,145,750	\$16,638,403	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
HPL VET OUTSTANDING AS OF 07/01/2020	93.342					\$2,775,204	\$16,638,403	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
HPL DENTAL OUTSTANDING AS OF 07/01/2020	93.342					\$9,319,464	\$16,638,403	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350		DYSTONIA MED RES FD	SUB TO U54TR001456		\$2,400	\$14,768,384	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350		UNIVERSITY OF PITTSBURGH	AWD00001775 (134056-1)		\$9,944	\$14,768,384	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350		UNIVERSITY OF WISCONSIN-MADISON	0000000860		\$65,623	\$14,768,384	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350		UNIVERSITY OF WISCONSIN-MADISON	0000000859		\$77,156	\$14,768,384	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned by Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201810721		\$152,511	\$14,768,384	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350		BOSTON UNIVERSITY CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	4500002228		\$157,570	\$14,768,384	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200680218		\$388,359	\$14,768,384	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	2-UL1-TR-001878-06				\$454,171	\$14,768,384	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	1-UL1-TR-001879-01				\$592,828	\$14,768,384	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5-TL1-TR-001880-02				\$1,022,007	\$14,768,384	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	1-U01-TR-003734-01			\$84,199	\$349,247	\$14,768,384	RESEARCH AND DEVELOPMENT	\$780,703,439
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	1-UL1-TR-001879-01			\$3,405,360	\$11,496,568	\$14,768,384	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	7-K01-OD-019729-06				-\$222	\$1,448,199	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	1-S10-OD-023465-01A1				\$4,577	\$1,448,199	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH INFRASTRUCTURE PROGRAMS	93.351		COLUMBIA UNIVERSITY	1(GG012813)		\$13,703	\$1,448,199	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	7-R03-OD-026599-02				\$26,144	\$1,448,199	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	1-S10-OD-026986-01A1				\$31,406	\$1,448,199	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	1S100D030413-01				\$445,032	\$1,448,199	RESEARCH AND DEVELOPMENT	\$780,703,439
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	2-P40-OD-010939-34A1			\$48,400	\$927,559	\$1,448,199	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		MORRIS ANIMAL FOUNDATION	D17CA-501		\$2,408	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - 21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-P01-CA-214278-01				\$26,867	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		WISTAR INSTITUTE	25451-06-314; NATHANSON		\$43,127	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		JOHNS HOPKINS UNIVERSITY	2004621711		\$44,009	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201380619		\$71,968	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		WISTAR INSTITUTE	25451-05-314; XU		\$79,809	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201460819-XX		\$155,818	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0000921427		\$158,935	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-R33-CA-225310-01			-\$312	\$210,290	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	SUB TO 1U01CA232563-01		\$303,090	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201460819-XX / PO 20028898-RSUB		\$403,803	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-U24-CA-224122-01				\$531,584	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-U01-CA-232836-01A1				\$626,938	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-P01-CA-210944-01			\$4,622	\$2,265,603	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-P50-CA-244690-01			\$20,245	\$834,421	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-U01-CA-243702-01A1			\$41,610	\$288,954	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-U54-CA-244711-01			\$148,428	\$1,469,189	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-P01-CA-214278-01			\$364,200	\$3,673,105	\$11,189,918	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	1-F31-NR-018097-01A1				-\$458	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	1-F31-NR-018374-01				-\$5	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - NURSING RESEARCH	93.361	2-T32-NR-007104-21				\$1,779	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	1-F31-NR-017554-01A1				\$2,110	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	1-F31-NR-018104-01				\$3,596	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	1-F31-NR-019925-01				\$4,306	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361		JOHNS HOPKINS UNIVERSITY	2004317284		\$8,493	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361		UNIVERSITY OF CALIFORNIA, IRVINE	2019-3728		\$14,943	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	1-K23-NR-017663-01A1				\$16,321	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201511123		\$19,694	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361		UNIVERSITY OF WASHINGTON	UWSC10149		\$20,197	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5111361		\$20,585	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361		BRIGHAM AND WOMEN'S HOSPITAL	117914		\$20,697	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361		DREXEL UNIVERSITY	800066		\$24,119	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361		RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK	1163840-89250		\$29,002	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361		COLUMBIA UNIVERSITY	2(GG014705-01)		\$39,618	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	1-F31-NR-019527-01A1				\$40,316	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361		UNIVERSITY OF COLORADO DENVER	FY18.105.016		\$46,162	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	2-R01-NR-016014-03				\$56,017	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	1R21NR019047-01A1				\$102,606	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	1-K23-NR-018487-01				\$135,971	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	1-K23-NR-017209-01A1				\$163,225	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	1-R01-NR-019753-01				\$205,836	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	1R01NR018836-01				\$389,525	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	2-T32-NR-009356-11				\$412,860	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING RESEARCH	93.361	2-T32-NR-007104-21				\$434,166	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total	
NURSING RESEARCH	93.361	1-R01-NR-017853-01A1				\$477,007	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439	
NURSING RESEARCH	93.361	1-R01-NR-015226-01A1				\$607,687	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439	
NURSING RESEARCH	93.361	1-R01-NR-018196-01				\$954,145	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439	
NURSING RESEARCH	93.361	1-R01-NR-018455-01			\$43,388	\$59,989	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439	
NURSING RESEARCH	93.361	7-R01-NR-012213-05				\$55,197	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439	
NURSING RESEARCH	93.361	2R01NR014784-06				\$112,942	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439	
NURSING RESEARCH	93.361	1-R01-NR-018425-01A1				\$117,566	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439	
NURSING RESEARCH	93.361	2-R01-NR-015639-04				\$178,485	\$532,613	\$6,234,719	RESEARCH AND DEVELOPMENT	\$780,703,439
NURSING STUDENT LOAN GRADUATE OUTSTANDING NEW LOANS ISSUED DURING 2021	93.364						\$122,568	\$4,104,398	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
NURSING STUDENT LOAN GRADUATE OUTSTANDING LOANS ISSUED AS OF 07/01/2020	93.364						\$417,050	\$4,104,398	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
NURSING STUDENT LOAN UNDERGRADUATE NEW LOANS ISSUED DURING 2021	93.364						\$794,532	\$4,104,398	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
NURSING STUDENT LOAN UNDERGRADUATE OUTSTANDING LOANS ISSUED AS OF 07/01/2020	93.364						\$2,770,248	\$4,104,398	STUDENT FINANCIAL ASSISTANCE	\$247,859,286
NATIONAL AND STATE TOBACCO CONTROL PROGRAM	93.387	2-R01-HL-063954-14A1				-\$595,172	-\$595,172	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	4-P01-CA-174439-04				-\$37,515	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF SOUTHERN CALIFORNIA	120627049		-\$14,008	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2-R01-CA-138835-06A1				-\$224	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
COVID-19 - CANCER CAUSE AND PREVENTION RESEARCH	93.393		ROCKEFELLER UNIVERSITY	1-P01-CA-196539-01		\$568	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK	SUB TO 1R01CA206193		\$2,786	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-F99-CA-234842-01				\$4,095	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		MAYO CLINIC ROCHESTER	63846738		\$5,273	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		OHIO STATE UNIVERSITY	60064995		\$7,506	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		THOMAS JEFFERSON UNIVERSITY	080-03800-S27301		\$16,688	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF SOUTHERN CALIFORNIA	125902890		\$17,216	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF MICHIGAN	3004298102		\$20,047	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-187718-01A1				\$25,153	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF MISSOURI-COLUMBIA	C00053910-3		\$28,900	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		HARVARD UNIVERSITY	115005-5117695		\$38,083	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		HARVARD UNIVERSITY	117202-5111676		\$39,304	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-190871-01				\$41,503	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF CALIFORNIA, DAVIS	201603696-14/A18-0177-5014		\$42,108	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-189743-01A1				\$43,211	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF CALIFORNIA, LOS ANGELES	1647 G CA089		\$53,861	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-184315-01				\$61,221	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		QUANTITATIVE RADIOLOGY SOLUTIONS, LLC	SUB TO CA199735		\$64,771	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		FOX CHASE CANCER CENTER	FCCC 15086-01		\$74,807	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		NORTHWESTERN UNIVERSITY	60038259 UP		\$78,075	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		ROCKEFELLER UNIVERSITY	1-P01-CA-196539-01		\$81,024	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-190415-01				\$86,132	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF UTAH	10044180-01		\$99,638	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		YALE UNIVERSITY	GR108743(CON-80002262)		\$101,571	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF SOUTHERN CALIFORNIA	135979558		\$112,537	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	7-R01-CA-178744-06				\$123,901	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		ROCKEFELLER UNIVERSITY	SUB00000171		\$139,118	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-202699-01A1				-\$59,809	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2-R01-CA-092900-15				\$176,516	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF CHICAGO	AWD101267 (SUB00000394)		\$180,634	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		HARVARD MEDICAL SCHOOL	1057501		\$188,749	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		YALE UNIVERSITY	M17A12539(A10702)		\$232,715	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393		MAYO CLINIC ROCHESTER	UOP-225625		\$239,167	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-230800-01A1				\$310,464	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2U01CA164947-05A1				\$320,545	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2-R01-CA-078831-20				\$348,650	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2-R01-CA-174904-06A1				\$362,610	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-215518-01A1				\$375,984	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1R01CA215587-01				\$449,341	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-249210-01				\$451,241	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-UM1-CA-239745-01				\$873,701	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	4-P01-CA-174439-04			\$14,720	\$14,720	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-196131-01A1			\$17,869	\$29,712	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2R01CA138835-11			\$21,029	\$278,574	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-207513-01			\$26,770	\$501,222	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-202262-01A1			\$34,720	\$289,773	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-206058-01			\$36,682	\$308,016	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R21-CA-227613-01A1			\$39,601	\$195,329	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439	

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-U05-CA-246744-01			\$49,850	\$208,736	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-227188-01A1			\$55,827	\$337,541	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CAUSE AND PREVENTION RESEARCH	93.393	7R01CA237670-02			\$306,808	\$744,788	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-243914-01			\$344,682	\$665,733	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-204193-01A1			\$397,160	\$667,294	\$10,279,446	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		UNIVERSITY OF MASSACHUSETTS	WA00397956/OSP2016156		-\$44,156	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-238552-01A1				\$39	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-251764-01				\$124	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		CASE WESTERN RESERVE UNIVERSITY	SUB TO RES510429		\$1,855	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U24CA196172-03-UPA3		\$4,146	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		MD ANDERSON CANCER CENTER	SUB TO UH2CA207101		\$5,192	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	60723.2006384.669301		\$5,432	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	2U24CA196172-06-UPA1		\$5,968	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R21-CA-223358-01			\$7,671	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		UNIVERSITY OF MARYLAND	1903275 REQUEST: 2658		\$7,758	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-229502-01				\$870	\$13,235,315	RESEARCH AND DEVELOPMENT	780703439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	2U24CA196172-06-UPA2		\$11,708	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R21-CA-27056-01				\$13,528	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	IDGRT-00000367		\$18,648	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		RUTGERS UNIVERSITY	0347		\$20,588	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-258717-01				\$24,615	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		CASE WESTERN RESERVE UNIVERSITY	RES514087		\$25,345	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		CASE WESTERN RESERVE UNIVERSITY	RES511172		\$30,853	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		UNIVERSITY OF CONNECTICUT HEALTH CENTER	UHC7-118312410		\$37,307	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-191207-01A1				\$38,328	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5114713		\$38,584	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		BRIGHAM AND WOMEN'S HOSPITAL	114835		\$39,908	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		AMERICAN COLLEGE OF RADIOLOGY UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	1672		\$40,832	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394			107245C		\$43,595	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2-R01-CA-113941-10				\$44,007	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		JOHNS HOPKINS UNIVERSITY	SUB TO U01CA210170		\$48,498	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-201328-01A1				\$55,794	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		THOMAS JEFFERSON UNIVERSITY	080-30000-S22601		\$74,160	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		UNIVERSITY OF TEXAS						
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		SOUTHWESTERN MEDICAL CENTER	GMO200103		\$90,466	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		JBS SCIENCE, INC.	R44CA165312-UP		\$94,969	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1R21CA236653-01A1				\$117,304	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-U24-CA-189523-01A1				\$127,276	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		UNIVERSITY OF KANSAS MEDICAL CENTER	GR15769		\$154,463	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R33-CA-206907-01A1				\$176,225	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		MAYO CLINIC ROCHESTER	THE-216870		\$193,599	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-255655-01				\$270,455	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-226412-01				\$304,002	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-211337-01				\$350,083	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-193050-01				\$420,479	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-207643-01				\$428,653	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-250102-01				\$447,780	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-251764-01				\$521,830	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-236362-01				\$527,747	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-204446-01A1				\$561,214	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-U24-CA-231858-01				\$667,608	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-225874-01A1				\$676,700	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-223816-01A1				\$702,143	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-238552-01A1				\$757,315	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-196528-01A1				\$412,511	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-204261-01A1				\$23,979	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-U01-CA-242871-01				\$39,847	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-193556-01A1				\$44,322	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-229502-01				\$58,809	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-197000-01A1				\$106,788	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-227142-01				\$110,573	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1R01CA228457-01A1	(UNASSIGNABLE) MOUNT SINAI MEDICAL CENTER	0254-3503-4605	\$141,409	\$540,575	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2-R01-CA-161749-05	JOHNS HOPKINS UNIVERSITY	ABTC 1501 (BMS# CA209-596)	\$161,992	\$594,267	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-227485-01A1	JOHNS HOPKINS UNIVERSITY	ABTC1801	\$427,616	\$596,611	\$13,235,315	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-181429-01A1	JOHNS HOPKINS UNIVERSITY	ABTC1603		-\$3,585	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-02-UPA10		\$275	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		JOHNS HOPKINS UNIVERSITY	ABTC 1202		\$1,168	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CANCER TREATMENT RESEARCH	93.395	1-P01-CA-217805-01A1	UNIVERSITY OF SOUTHERN CALIFORNIA	107587057		\$2,665	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		JOHNS HOPKINS UNIVERSITY	ABTC 1801		\$2,860	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		JOHNS HOPKINS UNIVERSITY	ABTC1603		\$3,254	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		BRIGHAM AND WOMEN'S HOSPITAL	121298		\$4,322	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U-10-CA-180820-06UPA5C		\$5,249	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		HARVARD MEDICAL SCHOOL	235481		\$6,579	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		NRG ONCOLOGY	NRG-XIAO-GY6		\$7,000	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	SUB TO UG1CA233249		\$7,328	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	9500130220-XX		\$9,304	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-06UPA6C		\$10,000	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-244845-01A1	NRG ONCOLOGY	NRG-LANGER-GY6		\$10,721	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		NRG ONCOLOGY	NRG-PRYMA-GY6		\$15,000	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		INDIANA UNIVERSITY	IN-4687956-UP		\$17,211	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-06-UPA2C		\$17,970	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		UNIVERSITY OF CALIFORNIA, LOS ANGELES	1568 G WA742		\$18,742	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000465		\$18,856	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-06-UPA2A		\$21,653	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-174976-01A1	ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-06UPA1C		\$23,183	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		WISTAR INSTITUTE	24672-02-366		\$23,992	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R21-CA-223366-01A1	CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3208130624		\$27,641	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3208130624		\$27,664	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R21-CA-216552-01A1	UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER	3RFW6		\$38,797	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		UNIVERSITY OF CALIFORNIA, LOS ANGELES	1568 G TA812		\$41,943	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		UNIVERSITY OF CALIFORNIA, LOS ANGELES	1568 G TA812		\$57,679	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-182747-01A1	CUREBIOTECH, INC.	SUB TO 2R44CA217489		\$59,295	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1R21CA238108-01A1	UNIVERSITY OF CALIFORNIA, LOS ANGELES	1670 G WC216		\$60,755	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		UNIVERSITY OF CALIFORNIA, LOS ANGELES	1670 G WC216		\$61,320	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R21-CA-224267-01A1	UNIVERSITY OF NEBRASKA FRONTIER SCIENCE & TECHNOLOGY	34-2005-2096-001		\$65,804	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		FRONTIER SCIENCE & TECHNOLOGY RESEARCH FDN	ECOG PURCHASE SERVICE AGREEMENT		\$96,430	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		LINNAEUS THERAPEUTICS	SUB TO 2R44CA228695		\$102,682	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-06-U PA3A		\$112,427	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		NRG ONCOLOGY	04-225-0712		\$115,935	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-06UPA1A		\$116,193	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-06UPA1A		\$126,316	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-06UPA1A		\$143,951	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1R21CA252558-01	MASSACHUSETTS GENERAL HOSPITAL	231928		\$157,458	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R21-CA-239127-01A1	CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	SUB TO 2U10CA180886		\$161,601	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	SUB TO 2U10CA180886		\$172,252	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-198015-01	WISTAR INSTITUTE	SUB TO P01CA114046		\$180,733	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		WISTAR INSTITUTE	SUB TO P01CA114046		\$189,533	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		WISTAR INSTITUTE	24926-13-314		\$214,462	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		WISTAR INSTITUTE	24926-13-314		\$215,580	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		RTOG FOUNDATION, INC.	UPENN-NCTN-YR6-11		\$215,674	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	4-R00-CA-226399-03				\$25,773	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	2-R01-CA-019033-41				\$344,415	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-219034-01A1				\$344,661	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	7R01CA102613-12				\$372,770	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	R37-CA-215436				\$408,876	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		WISTAR INSTITUTE	24926-04-314		\$423,734	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-201071-01A1				\$462,646	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-247803-01				\$516,063	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395		AMERICAN COLLEGE OF RADIOLOGY	1823		\$535,722	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-208273-01A1				\$541,867	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	9-R01-CA-249929-06A1				\$617,345	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-229803-01				\$737,112	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-241762-01				\$780,048	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-P01-CA-217805-01A1				\$2,491,441	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	2-P01-CA-087971-11A1				\$2,004	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-229305-01A1				\$13,366	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-197332-01				\$79,293	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-219871-01A1				\$92,891	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-219006-01A1				\$188,866	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-238237-01A1				\$296,383	\$14,928,922	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-181633-01A1				-\$1,842	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-237243-01A1				\$154	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CANCER BIOLOGY RESEARCH	93.396	2-P01-CA-165997-06A1				\$154	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-182675-01A1				\$2,493	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		AQD LIFE SCIENCES	R41CA221595-UP		\$5,715	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	GMO:200704		\$9,720	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		BRIGHAM AND WOMEN'S HOSPITAL	118360		\$9,796	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		WISTAR INSTITUTE	25820-03-369		\$14,693	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5710004020		\$16,507	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		WISTAR INSTITUTE	25681-02-373		\$22,047	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		WISTAR INSTITUTE	25241-02-370		\$35,166	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		WISTAR INSTITUTE	25651-02-366		\$37,296	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-193602-01A1				\$41,041	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	2-R01-CA-118374-07A1				\$48,922	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1U01CA254886-01				\$81,246	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		UNIVERSITY OF VIRGINIA	GB10749		\$94,724	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R50-CA-221841-01				\$114,933	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE MEMORIAL SLOAN-KETTERING	SUB TO P01CA128814		\$123,057	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		CANCER CENTER	BD526705		\$141,333	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		WISTAR INSTITUTE	25491-02-363		\$156,555	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-187392-01A1				\$157,575	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE	59953-13198-UPENN		\$183,193	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	4-R00-CA-226400-03				\$214,326	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	2R01CA174761-06A1				\$218,197	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1R01CA248315-01				\$236,237	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	4-R00-CA-212302-03				\$263,936	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		WISTAR INSTITUTE	28994-30-359		\$285,521	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-196232-01A1				\$304,970	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	2-R01-CA-168654-06				\$322,932	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-219083-01				\$329,330	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-235760-01A1				\$341,095	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-229688-01A1				\$352,833	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-241501-01A1				\$369,753	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	2-R01-CA-148774-06				\$372,947	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	7-R01-CA-227124-02				\$373,610	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		JOHNS HOPKINS UNIVERSITY	2004720261		\$374,939	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-243520-01A1				\$376,650	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	2-R01-CA-143296-06A1				\$382,710	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R37-CA-234027-01				\$411,787	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-197916-01A1				\$416,228	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	2-R01-CA-098371-11				\$452,970	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-234005-01A1				\$530,002	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-222503-01A1				\$545,772	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-245323-01				\$578,954	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-226983-01				\$621,325	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-231021-01A1				\$640,233	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396		KAISER PERMANENTE	RNG209451-PENN-01		\$745,456	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R35-CA-220483-01				\$1,010,584	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-198089-01			\$6,974	\$231,395	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-228339-01			\$23,424	\$300,372	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-237243-01A1			\$25,594	\$494,764	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	2-P01-CA-104838-11			\$26,502	\$95,484	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-237200-01A1			\$37,321	\$334,867	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-206012-01			\$38,349	\$334,709	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-240814-01A1			\$80,554	\$265,627	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	2-R01-CA-158301-06A1			\$215,041	\$477,204	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-237170-01			\$279,007	\$435,487	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	1-U01-CA-227550-01			\$419,172	\$784,628	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER BIOLOGY RESEARCH	93.396	2-P01-CA-165997-06A1			\$584,281	\$1,261,298	\$17,383,610	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CANCER CENTERS SUPPORT GRANTS	93.397	2-P30-CA-016520-40				-\$4,366	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		WISTAR INSTITUTE	24961-05-314		-\$823	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		WISTAR INSTITUTE	SUB TO 5-P50-CA174523		-\$168	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		WISTAR INSTITUTE	24961-02-314		\$3,365	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		WISTAR INSTITUTE	25501-02-381		\$3,370	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		WISTAR INSTITUTE	24961-10-314		\$9,416	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		COLUMBIA UNIVERSITY	1(GG012789-18) PROJECT 2		\$13,861	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		MD ANDERSON CANCER CENTER	SUB TO P50CA221707		\$20,394	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		MD ANDERSON CANCER CENTER	3001631191		\$20,696	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		WISTAR INSTITUTE	24961-04-314		\$25,652	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		WISTAR INSTITUTE	24961-06-314		\$28,577	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		COLUMBIA UNIVERSITY	2(GG012789-04)		\$38,632	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		COLD SPRING HARBOR LABORATORY	25103074		\$48,113	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		COLUMBIA UNIVERSITY	3(GG012789-03)		\$50,656	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		MOY CLINIC ROCHESTER	UOP-182363		\$97,373	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		JOHNS HOPKINS UNIVERSITY	2003261994		\$132,187	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397	1-U54-CA-190158-01				\$299,185	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397		JOHNS HOPKINS UNIVERSITY	2004131859		\$594,422	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397	1-U54-CA-193417-01			\$54,615	\$800,835	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397	2-P30-CA-016520-40			\$330,486	\$6,439,253	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CENTERS SUPPORT GRANTS	93.397	2-P30-CA-016520-45			\$10,980	\$3,596,470	\$12,217,100	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F32-CA-221093-01				-\$4,492	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CANCER RESEARCH MANPOWER	93.398	2-T32-CA-009615-26				\$430	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-260781-01				\$2,153	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-217070-01				\$4,136	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-243294-01				\$4,220	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F30-CA-236129-01				\$5,267	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1F31CA261124-01				\$6,459	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1 F31 CA261156-01				\$6,459	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	4-K00-CA-245802-03				\$6,563	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	4-K00-CA-212455-03				\$8,215	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-260918-01				\$8,731	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F32-CA-243475-01A1				\$9,473	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1F30CA260944-01				\$10,670	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F30-CA-257287-01				\$10,765	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-236269-01				\$15,173	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-254075-01A1				\$15,283	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F30-CA-236464-01A1				\$17,056	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F30-CA-224970-01				\$24,005	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	2-T32-CA-009615-26				\$29,562	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-225069-01A1				\$29,762	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-232551-01A1				\$29,860	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F30-CA-232388-01				\$32,571	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-232468-01				\$32,670	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F32-CA-250144-01A1				\$38,253	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1F31CA254329-01				\$41,278	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-239428-01				\$41,311	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-239514-01				\$42,770	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-247348-01				\$42,882	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-254244-01				\$43,117	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-250267-01				\$43,592	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-250316-01				\$44,101	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-239424-01A1				\$44,525	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-254405-01				\$45,368	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-194256-01				\$48,258	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F30-CA-253989-01				\$50,251	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-254260-01				\$50,977	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-K23-CA-187185-01A1				\$51,026	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F32-CA-228285-01				\$59,312	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F32-CA-254210-01				\$63,442	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	4-K00-CA-212437-02				\$72,002	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-F32-CA-221010-01A1				\$73,508	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	2-R25-CA-140116-11				\$90,499	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	2-T32-CA-009140-41A1				\$126,413	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER RESEARCH MANPOWER	93.398	1-K07-CA-218366-01A1				\$131,871	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-T32-CA-251063-01				\$137,034	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-K22-CA-214849-01				\$138,744	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-230190-01A1				\$162,464	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-215312-01A1				\$172,290	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-230170-01A1				\$185,794	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-234335-01				\$210,321	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-241084-01				\$216,991	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-234326-01				\$251,996	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-230157-01A1				\$295,230	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	2-T32-CA-115299-11				\$337,129	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	2-T32-CA-009615-31				\$402,760	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	2-T32-CA-009140-46				\$518,897	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	2-T32-CA-009679-26A1				\$631,693	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	2-K12-CA-076931-16A1			\$8,979	\$100,342	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER RESEARCH MANPOWER	93.398	2-K12-CA-076931-21			\$356,624	\$738,879	\$6,050,311	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CANCER CONTROL	93.399	1-R01-CA-244074-01				\$20	\$2,647,213	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CONTROL	93.399		NRG ONCOLOGY	NCORPC003-UPENN-GY6		\$7,444	\$2,647,213	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CONTROL	93.399		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	UG1CA189828-06UPA5		\$14,938	\$2,647,213	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CONTROL	93.399		OREGON HEALTH & SCIENCE UNIVERSITY	1014562_UPENN		\$17,606	\$2,647,213	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CONTROL	93.399		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	UG1CA189828-07-UPA6		\$19,882	\$2,647,213	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CONTROL	93.399		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	UG1CA189828-06-UPA3		\$23,903	\$2,647,213	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CONTROL	93.399		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	UG1CA89828-06-UPA4		\$47,674	\$2,647,213	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CONTROL	93.399		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	UG1CA189828-06-UPA3		\$49,672	\$2,647,213	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CONTROL	93.399	1-R21-CA-239177-01A1				\$86,637	\$2,647,213	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CONTROL	93.399	1-R01-CA-225929-01A1				\$396,550	\$2,647,213	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CONTROL	93.399	1-R01-CA-241661-01				\$405,035	\$2,647,213	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CONTROL	93.399	1-R01-CA-244074-01				\$590,315	\$2,647,213	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CONTROL	93.399	1R01CA236468-01A1			\$98,559	\$313,543	\$2,647,213	RESEARCH AND DEVELOPMENT	\$780,703,439
CANCER CONTROL	93.399	1-R01-CA-226888-01A1			\$220,852	\$673,994	\$2,647,213	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATIONS HEALTH	93.421		UNIVERSITY OF VERMONT & STATE AGRICULTURAL COLLEGE	AWD0000288SU800000140		\$75,269	\$75,269	RESEARCH AND DEVELOPMENT	\$780,703,439
INNOVATIVE STATE AND LOCAL PUBLIC HEALTH STRATEGIES TO PREVENT AND MANAGE DIABETES AND HEART DISEASE AND STROKE-	93.435		CITY OF PHILADELPHIA	2020657		\$23,212	\$23,212	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - HRSA COVID-19 CLAIMS REIMBURSEMENT FOR THE UNINSURED PROGRAM AND THE COVID-19 COVERAGE ASSISTANCE Y FUND	93.461	N/A				\$3,956,928	\$3,956,928	OTHER PROGRAMS	\$233,218,639
AMERICAN INDIAN CHRONIC RENAL INSUFFICIENCY COHORT STUDY AI-CRIC	93.47		UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER	3RGL2		\$232,223	\$232,223	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - PROVIDER RELIEF FUND	93.498	N/A				\$213,160,407	\$213,160,407	OTHER PROGRAMS	\$233,218,639
AFFORDABLE CARE ACT (ACA) MATERNAL, INFANT AND EARLY CHILDHOOD HOME VISITING PROGRAM	93.505		UNITED WAY OF LANCASTER COUNTY	4100070241		\$1,120,932	\$1,120,932	OTHER PROGRAMS	\$233,218,639
COMMUNITY SERVICES BLOCK GRANT (A, B, M)	93.569		COUNTY OF LANCASTER	HAP CV COUNTY		\$194,654	\$194,654	477 CLUSTER	\$213,854
COVID-19 - CHILD CARE AND DEVELOPMENT BLOCK GRANT	93.575		CARING PEOPLE ALLIANCE	CHILD CARE COVID-19 PANDEMIC RELIEF AWARD		\$19,200	\$19,200	477 CLUSTER	\$213,854
SOCIAL SERVICES BLOCK GRANT	93.667		CITY OF PHILADELPHIA	2120005-00		\$51,196	\$51,196	OTHER PROGRAMS	\$233,218,639
COVID-19 TESTING AND MITIGATION FOR RURAL HEALTH CLINICS	93.697	PROJECT# 176545				\$662,894	\$662,894	OTHER PROGRAMS	\$233,218,639
TRANS-NIH RECOVERY ACT RESEARCH SUPPORT	93.701	1-P30-CA-147859-01				\$364	\$364	RESEARCH AND DEVELOPMENT	\$780,703,439
MENTAL AND BEHAVIORAL HEALTH EDUCATION AND TRAINING GRANTS	93.732	1 M01HP31346-01-00				\$313,854	\$313,854	RESEARCH AND DEVELOPMENT	\$780,703,439
MEDICAL ASSISTANCE PROGRAM	93.778		CITY OF PHILADELPHIA	2120440-00		\$170,119	\$170,119	OTHER PROGRAMS	\$233,218,639
OPIOID STR	93.788	1H79TI081692-01				\$400,813	\$821,728	OTHER PROGRAMS	\$233,218,639
OPIOID STR	93.788		PENNSYLVANIA DEPARTMENT OF HEALTH	4100086433		\$420,915	\$821,728	OTHER PROGRAMS	\$233,218,639
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R03-HL-141521-01			\$10,690	\$17,993	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-103723-01A1				-\$267,297	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-A342-4605		-\$143,935	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-113216-01A1				-\$127,812	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	4-R01-HL-113216-01A1				-\$107,137	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-R01-HL-073021-05A2				-\$100,821	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	4-R01-HL-115323-04				-\$70,589	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-115323-01A1				-\$58,623	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-126797-01A1				-\$51,212	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-131626-01				-\$30,908	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-128465-01				-\$18,944	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		PROHIBIX, LLC	SUB TO 1 R41 HL140645-01A1		-\$8,478	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF MINNESOTA	N006187419		-\$8,078	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CARDIOVASCULAR DISEASES RESEARCH	93.837	4-R00-HL-131817-03				-\$7,297	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-T32-HL-098054-096A1				-\$1,560	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-129150-01A1				-\$1,522	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-134325-01				-\$1,450	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		WAKE FOREST UNIVERSITY	WFUHS 116558		-\$857	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF VERMONT & STATE AGRICULTURAL COLLEGE	SUB51510 U OF PENN		-\$408	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		BRIGHAM AND WOMEN'S HOSPITAL	5-R01-HL-117713-02/109135/AS314		-\$364	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	4-R37-HL-055323-18				\$40	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-142153-01				\$123	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-149891-01				\$235	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		GEORGE WASHINGTON UNIVERSITY	SUB TO U24HL140168		\$342	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-A342-4605		\$454	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-140176-01				\$523	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		CARDIOSOLV ABLATION TECHNOLOGIES, INC	SUB TO R44HL124901		\$708	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-A342-4605		\$903	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F32-HL-145923-01A1				\$1,053	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-153224-01				\$1,055	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	7-R01-HL-116280-04				\$1,369	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00001011		\$1,394	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF ROCHESTER	417151G / UR FAO GR500047E		\$1,737	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		LAM FOUNDATION	SUB TO U54HL127672		\$2,811	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF CINCINNATI	010575-002		\$3,144	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		PROHIBIX, LLC	SUB TO R44HL140645		\$3,449	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		THOMAS JEFFERSON UNIVERSITY	080-18007-S24201		\$3,927	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		MCGUIRE RESEARCH INSTITUTE	N/A		\$4,025	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-156431-01				\$4,795	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-141759-01				\$4,934	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837		BRIGHAM AND WOMEN'S HOSPITAL	SUB TO 1U01HL23336/AS332/AS333		\$5,007	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		YALE UNIVERSITY	GR105897 (CON-80001728)		\$5,112	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-152446-01				\$6,185	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-146077-01				\$6,290	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		RESEARCH TRIANGLE INSTITUTE	14-312-0214407-52918L		\$6,437	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-132349-01				\$7,005	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-A342-4605		\$7,063	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-132349-01				\$9,139	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		EMORY UNIVERSITY	A258184		\$9,223	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		PROLIFAGEN, LLC	SUB TO R43HL145845		\$11,962	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-T32-HL-007954-16				\$12,570	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		BRIGHAM AND WOMEN'S HOSPITAL	115809		\$13,164	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-A343-4605		\$13,188	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		OHIO STATE UNIVERSITY	6008444		\$13,947	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF CONNECTICUT	UCHC7-122008437		\$19,248	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF DELAWARE	47649		\$19,296	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201170622		\$19,826	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	320823.1222		\$20,362	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	61695.2007934.669303		\$21,065	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-132999-01				\$23,274	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		INDIANA UNIVERSITY	IN4667766PENN		\$23,477	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		FLOBIO LLC	1276778		\$24,219	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		RESEARCH TRIANGLE INSTITUTE	9-312-0217457-66026L		\$25,661	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	7-R01-HL-058493-21				\$26,482	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-U10-HL-110338-01				\$26,866	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F30-HL-142138-01				\$28,365	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF MICHIGAN	SUBK00012346		\$29,313	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	2101260619-XX		\$29,521	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-142238-01A1				\$29,633	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-142160-01				\$29,894	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-143857-01				\$29,912	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F30-HL-142186-01A1				\$31,191	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-R01-HL-133502-05A1				\$32,422	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-147416-01				\$32,683	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CARDIOVASCULAR DISEASES RESEARCH	93.837		BRIGHAM AND WOMEN'S HOSPITAL CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	SUB TO 1U01HL23336/A5332/A5333		\$35,927	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		PHILADELPHIA (CHOP)	3201690324		\$36,862	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-125723-01A1				\$40,546	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-149162-01				\$41,631	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF KENTUCKY	3200000734-18-040		\$46,561	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-128837-01A1				\$46,620	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R03-HL-154232-01				\$51,875	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		RUTGERS UNIVERSITY	8254		\$54,183	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-118195-01A1				\$54,865	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-0000005		\$57,050	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		DUKE UNIVERSITY	2035542		\$57,776	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		THOMAS JEFFERSON UNIVERSITY	080-18007-536301		\$66,463	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF SOUTH CAROLINA	18-3554		\$67,909	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-155599-01				\$69,342	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-R25-HL-084665-11				\$72,335	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	ACTIVITY #3201170622		\$74,018	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-140176-01				\$81,774	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF TEXAS AT AUSTIN ICAMH SCHOOL OF MEDICINE AT MOUNT SINAI	UTA18-00758		\$91,004	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF FLORIDA	0255-E031-4609		\$91,797	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF MASSACHUSETTS MASSACHUSETTS GENERAL HOSPITAL	SUB TO R01HL141294		\$93,695	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF MASSACHUSETTS MASSACHUSETTS GENERAL HOSPITAL	OSP2017185		\$100,543	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF MASSACHUSETTS MASSACHUSETTS GENERAL HOSPITAL	SUB TO1R01HL130539-01AL		\$101,491	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-133502-01				\$102,678	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K01-HL-141643-01				\$103,111	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		YALE UNIVERSITY	GR102136 (CON-80001158)		\$105,953	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-145121-01A1				\$107,413	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		ROCHESTER INSTITUTE OF TECHNOLOGY	31998-01		\$109,804	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1K23HL153667-01				\$113,271	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2R01HL058493-23				\$116,691	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF ALABAMA AT BIRMINGHAM	000503570-010		\$116,990	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF ILLINOIS	097337-17723		\$119,457	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		MEDICAL COLLEGE OF WISCONSIN COLUMBIA UNIVERSITY	SUB TO R01HL142791		\$120,651	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		MEDICAL COLLEGE OF WISCONSIN COLUMBIA UNIVERSITY	1(GG012810-01)		\$124,549	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		MASSACHUSETTS GENERAL HOSPITAL	234357		\$124,652	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K25-HL-145092-01A1				\$126,565	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R56-HL-136730-01A1				\$129,058	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		COLUMBIA UNIVERSITY	1(GG015877-01)		\$130,034	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K08-HL-138269-01				\$134,031	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1K01HL143153-01				\$136,417	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-134904-01				\$140,418	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-143161-01A1				\$150,753	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-153772-01				\$157,790	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	4-R00-HL-141678-03				\$159,466	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-155106-01				\$162,348	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-153646-01				\$163,434	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-133339-01A1				\$166,516	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-133843-01				\$172,427	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-145437-01				\$172,724	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	FP1897_SUB01_01		\$174,773	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K08-HL-136858-01A1				\$174,960	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF WASHINGTON	UWSC8520		\$196,185	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-131557-01				\$200,695	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K08-HL-132101-01				\$203,906	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-126788-01A1				\$207,031	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K08-HL-136890-01				\$208,974	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-134923-01				\$226,224	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-149801-01A1				\$243,705	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-134853-01				\$277,472	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-DP2-HL-142044-01				\$290,912	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-DP2-HL-147123-01				\$305,136	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-126874-01A1				\$323,467	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-152446-01				\$326,810	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-146662-01A1				\$370,155	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-152086-01				\$371,082	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-T32-HL-007586-31				\$380,062	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-139783-01A1				\$39,295	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-137232-01A1				\$399,143	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-R01-HL-108119-06A1				\$402,124	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-141462-01A1				\$404,003	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-141294-01				\$406,826	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-139358-01				\$436,851	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-133080-01				\$458,963	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-148769-01				\$492,782	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R61-HL-146390-01				\$513,845	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-T32-HL-007891-21A1				\$535,371	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-T32-HL-007843-21				\$543,315	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-147379-01				\$566,753	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-135090-01A1				\$570,172	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL152430-01				\$586,546	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-129805-01A1				\$587,931	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-T32-HL-098054-11				\$602,517	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-141912-01A1				\$668,198	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-141232-01A1				\$702,571	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R35-HL-145203-01				\$744,178	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-149891-01				\$755,096	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R61-HL-141440-01				\$802,618	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837		BOSTON UNIVERSITY	4500003022		\$818,375	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-141759-01				\$824,967	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R35-HL-140018-01				\$1,120,873	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-153224-01			\$3,268	\$376,999	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-138306-01A1			\$4,231	\$136,391	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R21-HL-152148-01			\$4,612	\$111,450	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-121510-01A1			\$5,657	\$210,145	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-141844-01A1			\$8,028	\$735,161	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-P01-HL-059407-16A1			\$8,312	\$362,369	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL152707-01			\$9,862	\$181,327	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-R01-HL-103419-06A1			\$14,140	\$118,987	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R21-HL-150723-01			\$17,634	\$261,002	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-128465-01			\$23,062	\$23,062	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-148103-01A1			\$23,212	\$352,760	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-R01-HL-107904-05			\$25,094	\$93,514	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-148272-01A1			\$28,014	\$278,084	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-131613-01A1			\$33,545	\$436,983	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL151292-01			\$40,690	\$160,191	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R21-HL-141802-01			\$50,464	\$122,307	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	7-R01-HL128349-03			\$53,661	\$151,665	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL151292-01			\$57,044	\$321,872	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-137984-01A1			\$80,000	\$637,008	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-151277-01A1			\$93,829	\$280,240	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R34-HL-146927-01			\$106,640	\$246,239	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-UM1-HL-088957-11			\$128,765	\$533,121	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-136719-01			\$216,266	\$593,500	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-142893-01			\$244,048	\$504,442	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-151345-01			\$267,691	\$595,295	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-133218-01A1			\$281,188	\$506,682	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-R01-HL-073021-10A1			\$337,217	\$773,994	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-147256-01			\$352,369	\$725,262	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-134905-01			\$355,213	\$791,226	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-R01-HL-103723-05			\$424,405	\$596,773	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
CARDIOVASCULAR DISEASES RESEARCH	93.837	7-R01-HL-134647-02			\$508,189	\$676,371	\$35,315,476	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-145408-01A1				\$575,537	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - LUNG DISEASES RESEARCH	93.838	1-U01-HL-148857-01				-\$35,223	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K99-HL-141678-01				-\$778	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - LUNG DISEASES RESEARCH	93.838	1R01HL148821-01				\$241	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - LUNG DISEASES RESEARCH	93.838	1-R01-HL-137006-01				\$243	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000816		\$1,618	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		MEDICAL UNIVERSITY OF SOUTH CAROLINA	MUSC18-066-8D441		\$4,966	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K99-HL-141684-01				\$5,870	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		LURIE CHILDREN'S HOSPITAL OF CHICAGO (ANN & ROBERT H.)	A21-0001-S005-UPENN		\$5,991	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - LUNG DISEASES RESEARCH	93.838	2-R01-HL-087825-11A1				\$6,190	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		NATIONAL JEWISH HEALTH	20120102		\$13,167	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R03-HL-144890-01				\$15,849	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000383		\$18,982	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		CHILDREN'S HOSPITAL OF LOS ANGELES	RGF010323-B		\$20,158	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		UNIVERSITY OF CALIFORNIA, DAVIS	A21-2099-S001		\$21,626	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
LUNG DISEASES RESEARCH	93.838	1-F31-HL-152597-01A1				\$21,643	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		BIOSPUNTIK LLC	SUB TO 1R41HL156767 - 01A1		\$23,050	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-F30-HL-145907-01A1				\$25,989	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	4-R18-HL-116285-04				\$31,594	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		UNIVERSITY OF MICHIGAN	SUBK00010624		\$31,658	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		ALBANY MEDICAL COLLEGE	515502-01		\$32,526	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K24-HL-155804-01				\$33,498	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-F32-HL-154676-01				\$33,498	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		UNIVERSITY OF MICHIGAN	SUBK00012073		\$33,575	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-F32-HL-151114-01				\$37,495	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-F31-HL-149338-01				\$46,668	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - LUNG DISEASES RESEARCH	93.838	1-R01-HL-157189-01				\$52,504	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		BOSTON UNIVERSITY	4500003055		\$53,664	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K23-HL-151879-01A1				\$58,276	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-141992-01				\$63,453	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-F32-HL-152664-01				\$65,102	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - LUNG DISEASES RESEARCH	93.838		RTI INTERNATIONAL	33-312-0217571-66400L		\$66,673	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	7R01HL112987-07				\$69,505	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200850618		\$86,739	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K08-HL-151911-01A1				\$87,817	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	2-K24-HL-103844-06				\$94,749	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	2-K24-HL-115354-06				\$100,489	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1K99HL151670-01				\$105,275	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		BRIGHAM AND WOMEN'S HOSPITAL	122805		\$110,561	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K24-HL-143289-01				\$118,144	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201040419		\$126,445	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		ALBERT EINSTEIN COLLEGE OF MEDICINE, INC	311072		\$128,720	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		PEROXITECH, LLC	SUB TO 1R41HL145848-01A1		\$132,638	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	7-K01-HL-135459-03				\$139,860	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	10253SC		\$142,846	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K01-HL-149851-01				\$146,783	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-152194-01A1				\$150,613	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K08-HL-150226-01				\$154,531	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		THOMAS JEFFERSON UNIVERSITY	080-18007-533801		\$159,756	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K23-HL-143181-01				\$161,715	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K23-HL-146894-01				\$164,390	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K23-HL-132065-01A1				\$173,280	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K08-HL-136698-01A1				\$175,002	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-151153-01A1				\$180,231	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1U01HL152970-01				\$182,939	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-124986-01A1				\$188,421	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-127969-01A1				\$189,863	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K23-HL-141584-01				\$196,723	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1R56HL139559-01A1				\$200,048	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K23-HL-140482-01				\$210,232	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K23-HL-141639-01				\$229,669	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		LIGNAMED	SUB TO R44HL140680		\$283,194	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	2R01HL132999				\$336,495	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-153510-01				\$356,811	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838		CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	137990		\$395,540	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-153539-01				\$423,464	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	2-R01-HL-087825-11A1				\$468,729	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-139066-01				\$500,449	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-141608-01A1				\$505,757	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-137389-01A1				\$653,706	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-143364-01A1				\$656,862	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1R01HL151467-01				\$659,046	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R38-HL-143613-01				\$662,552	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1R01HL148821-01				\$664,110	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-144859-01				\$717,655	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R61-HL-137063-01				\$727,496	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-142258-01A1				\$740,996	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-150147-01				\$741,383	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-U01-HL-148857-01				\$844,625	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1R01HL146386-01A1			\$22,527	\$351,421	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-K23-HL-146970-01			\$24,740	\$180,301	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-137915-01			\$30,436	\$635,081	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-133889-01A1			\$47,195	\$298,685	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-137006-01			\$57,444	\$657,422	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	2-R01-HL-087115-06A1			\$65,411	\$65,411	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
LUNG DISEASES RESEARCH	93.838	1-U03-HL-141736-01			\$71,015	\$950,241	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-142269-01			\$95,698	\$449,750	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-U01-HL-129998-01			\$127,981	\$417,265	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-R01-HL-133433-01A1			\$265,819	\$814,474	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
LUNG DISEASES RESEARCH	93.838	1-U01-HL-145435-01			\$869,703	\$1,366,914	\$22,199,122	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-R25-HL-084665-16				\$22,000	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		RUTGERS UNIVERSITY	SUB0151		-\$7,087	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-P01-HL-040387-26A1				-\$71	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-F31-HL-140774-01				\$48	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BLOOD DISEASES AND RESOURCES RESEARCH	93.839		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200770621/962617-RSUB		\$117	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-P01-HL-146373-01A1				\$1,291	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-F31-HL-139091-01				\$5,058	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		THOMAS JEFFERSON UNIVERSITY	080-18060-S17002		\$5,067	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		TEMPLE UNIVERSITY	267434-PENN		\$5,138	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000690		\$5,324	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		UNIVERSITY OF MICHIGAN	3004935104		\$5,521	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-K99-HL-153696-01A1				\$6,690	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE	1187-SUB		\$8,408	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		DUKE UNIVERSITY	A034441		\$10,779	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		UNIVERSITY OF NEW HAMPSHIRE	18-016		\$24,802	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200650121		\$30,507	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-K99-HL-148646-01				\$31,315	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000690		\$34,511	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		NORTHWESTERN UNIVERSITY	60056523 PENN		\$36,042	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-F31-HL-150952-01				\$45,509	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-F32-HL-154519-01				\$65,167	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R21-HL-144224-01				\$68,453	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000215		\$83,974	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3210081122		\$89,288	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201710624		\$90,005	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200770621/962617-RSUB		\$125,770	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-T32-HL-007775-26				\$152,793	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-UG1-HL-069286-17				\$186,285	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-155144-01				\$194,260	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		INDIANA UNIVERSITY	IN4687667UPENN		\$195,117	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-128895-01				\$210,499	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-148014-01A1				\$319,288	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-R01-HL-111501-06A1				\$329,162	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-139552-01A1				\$343,176	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-T32-HL-007971-16A1				\$346,206	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-139552-01A1				\$358,505	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-135254-01				\$370,326	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-136572-01				\$447,916	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-145754-01				\$462,259	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-R01-HL-124106-05A1				\$507,070	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-U01-HL-131053-01A1				\$510,874	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-T32-HL-007439-41				\$736,892	\$13,182,614	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		RESEARCH TRIANGLE INSTITUTE	MOU SUB TO U24HD095254		\$3,450	\$238,862	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-141408-01				\$3,944	\$575,530	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2R01HL107904-09				\$26,499	\$467,963	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-148227-01A1				\$29,722	\$434,848	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-R01-HL-091724-24				\$43,051	\$539,468	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1R01HL142976-01				\$127,531	\$771,746	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-134839-01				\$140,579	\$475,986	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-142122-01				\$164,977	\$660,743	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-143806-01				\$308,531	\$825,254	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-P01-HL-146373-01A1				\$362,766	\$1,727,960	RESEARCH AND DEVELOPMENT	\$780,703,439
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	1-R01-HL-153735-01				\$119,767	\$478,706	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	4-R00-AR-067283-03				-\$9,698	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R21-AR-070959-01				-\$310	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-F31-AR-069982-01A1				-\$50	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R21-AR-071623-01A1				\$181	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		EMBODY	SUB TO 1R43AR076841		\$595	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		UNIVERSITY OF MICHIGAN	SUBK00010500		\$1,237	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-T32-AR-007465-31				\$2,244	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	7-R01-AR-066101-03			\$3,299	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-F31-AR-073103-01A1			\$3,913	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R03AR077697-01			\$4,303	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	7-R01-AR-066101-03			\$6,749	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-078898-01			\$9,668	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-F31-AR-077395-01A1			\$10,023	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		TEMPLE UNIVERSITY	258416-UP	\$11,276	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200760422	\$11,841	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R21AR077261-01A1			\$13,712	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		UNIVERSITY OF SOUTHERN CALIFORNIA	116442662	\$16,265	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		DREXEL UNIVERSITY	900036	\$17,164	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	7-R01-AR-074079-03			\$17,349	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-K23-AR-068433-01			\$20,254	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-F31-AR-075436-01			\$26,164	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	7-K08-AR-066661-01			\$27,811	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-077094-01A1			\$29,738	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		NEW YORK UNIVERSITY	16-A0-00-005518-01	\$30,079	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		DREXEL UNIVERSITY	900024	\$31,694	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-K23-AR-077629-01A1			\$34,965	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		NEW YORK UNIVERSITY	18-A1-00-1000572	\$36,698	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-066741-01A1			\$36,835	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		UNIVERSITY OF MARYLAND-BALTIMORE COUNTY	1701828-1038	\$45,078	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-068288-01			\$51,649	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R01AR077598-01A1			\$61,302	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-F32-AR-076906-01			\$73,090	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	7-K01-AR-069002-03			\$96,830	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	GMO180506	\$102,559	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-K08-AR-070289-01			\$106,735	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-077435-01A1			\$115,728	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R21-AR-077700-01			\$115,747	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-068057-01A1			\$120,872	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-066098-01A1			\$125,848	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1K01AR077087-01			\$131,003	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		BRIGHAM AND WOMEN'S HOSPITAL	119899	\$132,375	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	7-R01-AR-073022-03			\$132,875	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-K01-AR-075877-01A1			\$136,032	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-K23-AR-073931-01			\$141,880	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-K08-AR-075846-01			\$163,176	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-K23-AR-071514-01			\$167,118	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1T32AR076951-01			\$170,902	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-069546-01			\$180,066	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-T32-AR-007132-42			\$189,101	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-T32-AR-053461-11			\$196,309	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R21-AR-074570-01A1			\$218,433	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		THOMAS JEFFERSON UNIVERSITY	080-23000-527201	\$218,951	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R21AR074073-01A1			\$227,878	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R34-AR-074733-01A1			\$229,150	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000242	\$261,996	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		THOMAS JEFFERSON UNIVERSITY	080-23000-538001	\$279,100	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-075737-01A1			\$285,229	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-071340-01A1			\$302,977	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-077526-01			\$306,762	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R01AR077615-01			\$328,235	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-071399-01A			\$330,622	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-076381-01A1			\$339,354	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-R01-AR-050068-09A1			\$347,457	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-T32-AR-007465-36			\$381,079	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-073809-01A1			\$381,272	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-073231-01			\$404,108	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R01AR075914-01A1			\$409,253	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439	

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-066567-01A1				\$412,374	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	9-R01-AR-077362-09A1				\$423,405	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-077690-01				\$440,434	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-070750-01				\$497,057	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-076766-01A1				\$546,782	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-P30-AR-069589-01				\$829,414	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-071718-01A1			\$6,126	\$261,662	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-072363-01			\$9,198	\$10,227	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-R01-AR-056624-11			\$17,304	\$433,512	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-P30-AR-069619-01			\$18,122	\$739,459	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R21-AR-071559-01A1			\$27,236	\$107,192	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-065995-01			\$36,314	\$36,542	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-071975-01			\$48,499	\$390,821	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-068382-01			\$72,198	\$150,321	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-074948-01			\$91,087	\$450,446	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-069062-01			\$92,782	\$433,513	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-U54-AR-057319-17			\$121,112	\$299,958	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-075418-01			\$156,433	\$512,901	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R01AR076392-01			\$201,969	\$789,700	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-070873-01A1			\$268,125	\$525,994	\$16,693,844	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK045586-24				-\$76,627	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007780-16				-\$39,286	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	4-P01-DK-049210-20				-\$18,963	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		AUGUSTA UNIVERSITY	30835-61		-\$14,691	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-120561-01				-\$14,068	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-106489-01				-\$13,818	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		COLUMBIA UNIVERSITY	1(GGG011642-03)		-\$10,193	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-107453-01A1				-\$9,729	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R37-DK-043806-18				-\$8,188	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-114436-01				-\$4,719	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R21-DK-108045-01A1				-\$3,021	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-110183-01A1				-\$2,648	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-088383-05				-\$2,265	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-060455-11A1				-\$2,189	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007066-41				-\$1,788	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-109492-01A1				-\$1,365	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-U01-DK-103225-01			-\$1,105	-\$1,105	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-UC4-DK-104196-01				-\$1,029	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MICHIGAN	3003289619		-\$943	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-DP3-DK-108220-01				-\$882	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-U01-DK-103225-01				-\$662	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F32-DK-116528-01A1				-\$364	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-106309-01A1				-\$242	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CASE WESTERN RESERVE UNIVERSITY	RESS07516		-\$105	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5-R01-DK-056886-12				-\$45	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-109979-01				-\$34	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-102533-01A1				-\$1	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-106478-01				\$11	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-101478-02				\$77	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K23-DK-116935-01A1				\$135	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-113307-01				\$164	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-123356-01				\$240	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-120982-01				\$241	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		GEORGE WASHINGTON UNIVERSITY	18-M94		\$699	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-114103-01A1				\$1,940	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3258760720		\$2,106	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		DREXEL UNIVERSITY	232664		\$2,130	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-111091-01				\$2,610	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		NORTHWESTERN UNIVERSITY	60052783 UPA		\$2,844	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CASE WESTERN RESERVE UNIVERSITY	RES512826		\$3,067	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		INDIANA UNIVERSITY	8689_PENN		\$3,449	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007006-42				\$4,511	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K01-DK-111715-01				\$4,667	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		MASSACHUSETTS GENERAL HOSPITAL	231761		\$4,741	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		AUGUSTA UNIVERSITY	32307-48		\$5,525	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		MEDICAL COLLEGE OF WISCONSIN	SUB TO 5R01DK083538		\$5,777	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F30-DK-120096-01A1				\$6,330	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-128876-01				\$6,674	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MICHIGAN	SUBK00010724		\$7,952	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		TUFTS UNIVERSITY	101517-00002		\$8,338	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F32-DK-116519-01A1				\$8,669	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ILLINOIS AT CHICAGO	17709		\$9,167	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ALASKA FAIRBANKS	SUB TO R01DK109946		\$10,534	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200530322		\$11,850	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MICHIGAN	SUBK00012114		\$11,875	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF PITTSBURGH	0062023(131994-1)		\$13,153	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01-DK-128861-01				\$16,656	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JOHNS HOPKINS UNIVERSITY	2004016695		\$17,364	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		GEORGE WASHINGTON UNIVERSITY	20-M122		\$17,844	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	107915C		\$18,418	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JOHNS HOPKINS UNIVERSITY	2004065226		\$19,182	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201760420		\$19,765	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL BOSTON	GENFD0001987300		\$20,000	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-127610-01				\$21,643	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		MD ANDERSON CANCER CENTER	3001370497		\$22,692	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		WASHINGTON UNIVERSITY IN ST. LOUIS	WU-20-278		\$24,209	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	61294.2006834.669616		\$25,665	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F30-DK-120135-01				\$25,891	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JAEB CENTER FOR HEALTH RESEARCH	SUB TO R01DK121240		\$25,954	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F30-DK-120062-01				\$26,179	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3209810920		\$26,311	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		BAYLOR COLLEGE OF MEDICINE	SUB TO R01DK101500		\$26,332	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		HARVARD PILGRIM HEALTH CARE	PH000668A		\$27,400	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F32-DK-122684-01A1				\$27,645	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JOHNS HOPKINS UNIVERSITY	2004295590		\$28,593	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		TULANE UNIVERSITY	TUL-HSC-553788-15/16		\$29,178	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		NORTHWESTERN UNIVERSITY	60046420 UPENN		\$29,258	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3210191223		\$29,522	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-117577-01A1				\$30,289	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		BROAD INSTITUTE OF MIT AND HARVARD	5000110-5500000842		\$30,313	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F30-DK-118827-01				\$30,488	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-118816-01				\$30,625	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MICHIGAN	SUBK00010054		\$30,852	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-122677-01				\$32,837	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		PENNSYLVANIA STATE UNIVERSITY	5821-UP-DHHS-4888		\$33,126	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		TEMPLE UNIVERSITY	258377-UPENN		\$33,391	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F32-DK-124971-01				\$33,983	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-087635-06				\$35,630	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF UTAH CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	10030258-00		\$36,554	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847			GRT-00000382		\$36,997	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JOSLIN DIABETES CENTER, INC	100136		\$37,370	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ILLINOIS AT CHICAGO	17647		\$37,551	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF SOUTHERN CALIFORNIA	137014491		\$38,540	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1F31DK124956-01A1				\$38,550	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		COLUMBIA UNIVERSITY	2(GG015836-01)		\$39,034	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		COLUMBIA UNIVERSITY	1(GG011642-01)		\$40,062	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-105689-01A1				\$40,569	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-122649-01				\$41,041	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1F31DK125008-01A1				\$41,289	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-123886-01				\$42,606	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-122683-01				\$42,938	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-120162-01				\$45,173	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MICHIGAN	SUBK00010278		\$45,473	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-126231-01				\$45,496	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1F31DK126404-01				\$45,520	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-128443-01				\$47,031	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JOHNS HOPKINS UNIVERSITY	2004935396		\$51,768	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1F32DK126385-01A1				\$52,239	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-124658-01A1				\$52,332	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F30-DK-126353-01				\$52,362	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000106		\$52,595	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7-R01-DK-119656-03				\$52,665	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		DUKE UNIVERSITY	A032135		\$53,244	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ILLINOIS AT CHICAGO	17483		\$53,815	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F32-DK-118818-01A1				\$56,148	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ALABAMA AT BIRMINGHAM	000524405-SC003		\$57,019	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CORNELL UNIVERSITY	203486		\$58,886	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-045586-28A1				\$59,484	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		NORTHWESTERN UNIVERSITY	60044864		\$60,214	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R03-DK-122191-01				\$60,489	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	50578.914951.6560		\$61,182	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F32-DK-120211-01A1				\$61,308	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MARYLAND, BALTIMORE	3001055		\$62,327	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		MASSACHUSETTS GENERAL HOSPITAL	SUB TO U01DK106981		\$64,843	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F32-DK-123948-01				\$65,673	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R25-DK-066028-16				\$65,996	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R25-DK-108711-01A1				\$66,384	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F32-DK-117568-01A1				\$73,149	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	22107-GRT-00000441		\$74,215	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-125573-01A1				\$74,368	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		SCINTILLON INSTITUTE	22241-209-415		\$80,725	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		EMORY UNIVERSITY	T674972		\$85,292	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	96445C		\$93,258	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-125497-01A1				\$93,301	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		INDIANA UNIVERSITY	IN4689868 PENN		\$95,055	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200040820		\$96,597	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF PITTSBURGH	AWD00001317 (133760-01)		\$99,051	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		SAINT LOUIS UNIVERSITY	ERS #21446-44249		\$100,511	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MIAMI	SPC-001391		\$101,126	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3210191223		\$104,656	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	FP21401_A1_SUB02_01		\$105,370	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000685		\$113,851	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		WASHINGTON UNIVERSITY IN ST. LOUIS	WU-21-140		\$115,113	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200370521 POW 962245 - RSUB		\$117,758	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K01-DK-117970-01				\$118,685	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-120902-01A1				\$119,653	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		VANDERBILT UNIVERSITY	VUMC81957		\$119,861	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K01-DK-116922-01A1				\$120,998	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1K01DK125602-01				\$121,419	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-106457-01A1				\$133,568	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ILLINOIS AT CHICAGO	16587-00		\$142,962	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-125880-01				\$143,802	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000596		\$144,239	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R03DK123543-01				\$144,509	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CASE WESTERN RESERVE UNIVERSITY	RES512857		\$147,842	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-119475-01				\$152,445	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R03-DK-120946-01				\$153,406	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-111547-01A1				\$154,529	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		TULANE UNIVERSITY	TUL-HSC-556923-18/19		\$158,701	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JAEB CENTER FOR HEALTH RESEARCH	SUB TO 1R01DK122603		\$161,295	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	K23-DK118198				\$162,431	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-123316-01A1				\$162,916	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-117013-01				\$167,847	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R56-DK-101478-06				\$174,387	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	107905C		\$178,535	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7-K23-DK-114526-02				\$179,110	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K23-DK-115897-01				\$182,146	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007785-19				\$182,184	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		NEW YORK UNIVERSITY GROSSMAN SCHOOL OF MEDICINE	SUB TO DP3DK114812		\$185,396	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-122099-01				\$205,143	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000106		\$208,805	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K23-DK-116935-01A1				\$217,436	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-104796-01A1				\$220,345	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007780-21				\$241,977	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		WINTHROP-UNIVERSITY HOSPITAL	3500-07429 (PENN)		\$242,419	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1U01DK127768-01				\$245,386	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	4-R37-DK-053839-20				\$252,150	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-U01-DK-057135-17				\$291,539	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007314-36				\$292,227	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-106027-01				\$298,034	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-045416-23A1				\$303,022	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3209810625		\$303,981	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK123624-01A1				\$310,948	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	201010		\$315,385	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-125387-01				\$318,938	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-117124-01A1				\$323,030	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-114104-01				\$324,125	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-121801-01A1				\$328,558	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-120982-01				\$337,682	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK049780-23				\$352,728	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007740-21A1				\$381,375	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-091331-06				\$384,249	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-119314-01				\$386,680	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-105821-01A1				\$389,640	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-114103-01A1				\$393,375	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200400817		\$415,833	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-123356-01				\$433,170	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-122039-01				\$446,667	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-114054-01				-\$31,293	\$448,480	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-107667-01A1				\$464,741	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-119290-01A1				\$474,990	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-125521-01				\$488,469	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-123528-01				\$490,740	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-021397-40A1				\$496,253	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007006-47				\$497,391	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-121175-01				\$510,465	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-076077-10				\$516,040	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-106309-05				\$529,513	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007066-46				\$556,123	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-123252-01				\$573,908	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2R01DK043806-28				\$585,741	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-DP1-DK-126167-01				\$593,718	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-120757-01A1				\$595,266	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-U01-DK-060984-18				\$629,592	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK114291-01A1				\$659,478	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-P30-DK-050306-21				\$992,583	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-U01-DK-123594-01				\$2,974,831	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-U04-DK-112217-01				\$4,113,184	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-U01-DK-126654-01			\$5,080	\$33,320	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-U01-DK-099919-01			\$5,925	\$124,280	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-112812-01			\$10,518	\$415,244	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1U34DK120091-01			\$11,709	\$35,692	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-087635-11A1			\$17,222	\$604,145	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-117208-01A1			\$18,686	\$268,030	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-U24-DK-082316-12			\$25,000	\$1,089,322	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-113307-01			\$25,225	\$361,542	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-U01-DK-123813-01			\$25,690	\$1,065,580	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-106243-01A1			\$27,492	\$382,245	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-105155-01A1			\$31,237	\$31,237	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-098656-06A1			\$38,966	\$767,805	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-115762-01A1			\$46,911	\$622,502	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-U01-DK-106892-01			\$47,973	\$127,867	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R21-DK-117297-01A1			\$85,255	\$265,478	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7-R01-DK-070869-12			\$89,328	\$410,404	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2U01DK106892-06			\$94,740	\$546,682	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-U01-DK-103225-06			\$109,860	\$613,650	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-111558-01A1			\$116,982	\$292,967	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-UG3-DK-122644-01			\$120,456	\$854,675	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-118431-01			\$138,037	\$147,920	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-U04-DK-116271-01			\$138,737	\$376,716	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-083355-06A1			\$147,377	\$309,215	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-UM1-DK-126194-01			\$154,718	\$1,065,987	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-123041-01A1			\$187,258	\$442,383	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-117488-01			\$188,133	\$668,408	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-111638-01A1			\$189,426	\$752,114	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-116005-01A1			\$220,998	\$449,499	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK116199-01			\$263,071	\$438,346	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-P30-DK-019525-41			\$322,421	\$1,418,872	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-U01-DK-100846-07			\$455,316	\$881,555	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-U24-DK-060990-18			\$543,868	\$2,997,631	\$53,374,436	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	8567		-\$38,995	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MIAMI	668005 SPC-000425		-\$31,061	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-088176-01A1				-\$19,320	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-T32-NS-007180-32				-\$5,441	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned by Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	4-R01-NS-055293-09				-\$1,879	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		ASTROCYTE PHARMACEUTICALS, INC.	SUB TO 1R41NS093756		-\$1,322	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U54-NS-115322-01				-\$439	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-104874-01				-\$357	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		DUKE UNIVERSITY	2034906		-\$262	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F30-NS-100595-01				-\$70	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3209700718		-\$49	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		WASHINGTON UNIVERSITY IN ST. LOUIS	SUB TO U54NS116025		\$162	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-113241-01				\$164	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-107550-01A1				\$209	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U01-NS-114140-01				\$292	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-T32-NS-091006-01				\$432	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	012043-135731		\$1,031	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-120960-01				\$1,172	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MICHIGAN STATE UNIVERSITY	RC107677UP		\$1,775	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-101807-01A1				\$2,068	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-121219-01				\$2,070	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF PITTSBURGH	AWD00002964 (135356-1)		\$2,148	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-106754-01				\$2,570	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201060520		\$2,941	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MAYO CLINIC JACKSONVILLE	SUB TO 5-U01NS080168-02		\$3,012	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R56-NS-099348-05A1				\$3,449	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-103445-01A1				\$3,653	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		THE METHODIST HOSPITAL RESEARCH INSTITUTE	AGMT00003622		\$5,297	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		DARTMOUTH COLLEGE	R837		\$7,067	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MASSACHUSETTS GENERAL HOSPITAL	SUB TO U01NS095388 / NN108		\$7,149	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MICHIGAN	SUBK00009898		\$7,404	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	011337-135731		\$11,316	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	012044-135731		\$11,434	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		DUQUESNE UNIVERSITY	G1900015		\$12,040	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	011266-135731		\$12,371	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		TUFTS MEDICAL CENTER	5017157-SERV		\$14,396	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MICHIGAN STATE UNIVERSITY	RC110062UP		\$14,410	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MAYO CLINIC ROCHESTER	THE-214838-04		\$17,593	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201310623		\$18,283	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	GMO 181204		\$19,087	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MOSS REHABILITATION RESEARCH INSTITUTE	491401		\$19,336	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		FOX CHASE CANCER CENTER	FCCC 15099-01		\$19,348	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CLEVELAND CLINIC FOUNDATION	718-SUB		\$20,675	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	RSUB/ACTIVITY NO. 3201700420		\$20,694	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF SOUTHERN CALIFORNIA	109041993		\$21,000	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		DUQUESNE UNIVERSITY	G2000093		\$22,499	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K99-NS-109286-01				\$23,001	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	010785-135731		\$23,153	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-120801-01				\$23,187	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		PENNSYLVANIA STATE UNIVERSITY	5001280-DHHS		\$24,078	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MASSACHUSETTS GENERAL HOSPITAL	226626		\$27,042	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-T32-NS-091008-01				\$27,185	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MASSACHUSETTS GENERAL HOSPITAL	235400		\$27,277	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-111803-01A1				\$29,549	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F32-NS-103219-01				\$30,114	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-113481-01A1				\$30,128	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		NORTHWESTERN UNIVERSITY	SP0046269-PROJ0013110		\$30,831	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F32-NS-108511-01A1				\$31,884	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-108622-01				\$32,396	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201310623		\$32,516	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-111868-01				\$34,279	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-118808-01A1				\$34,588	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-117757-01A1				\$34,995	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF IOWA	S01314-01		\$36,932	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF ALABAMA AT BIRMINGHAM	000510297-006		\$37,067	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K01-NS-119496-01				\$39,194	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-115256-01				\$40,821	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		DUKE UNIVERSITY	A030443		\$42,710	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		JOHNS HOPKINS UNIVERSITY	2003724400		\$43,011	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-100182-01				\$43,068	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-111870-01				\$43,376	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-115345-01				\$44,579	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201190720		\$44,716	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-116999-01				\$44,948	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MASSACHUSETTS GENERAL HOSPITAL	236574		\$46,060	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF QUEENSLAND	RM2019002969		\$46,191	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F32-NS-117672-01				\$46,239	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201620321		\$46,545	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-099348-01				-\$12,993	\$54,404	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F32-NS-117785-01				\$55,472	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF ALABAMA AT BIRMINGHAM	000523825-SC001		\$56,125	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	4-K00-NS-105210-03				\$56,446	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-088322-01A1				\$58,045	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F32-NS-116205-01				\$59,360	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-T32-NS-091008-06				\$59,601	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1K99NS118561-01				\$60,105	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F32-NS-108598-01A1				\$60,187	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R56-NS-109435-01A1				\$62,090	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-117756-01A1				\$68,529	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000086		\$69,053	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-116504-01A1				\$69,145	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	4-R37-NS-047344-14				\$79,367	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R03-NS-116301-01				\$83,863	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-092398-01				\$84,181	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201870620		\$85,326	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-060698-13				\$92,262	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CHICAGO	AWD069821 (SUB00000416)		\$95,606	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-109763-01A1				\$97,754	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K99-NS-111736-01A1				\$99,176	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MIAMI	SPC-00091		\$99,464	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MIAMI	SPC-001451		\$103,421	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-088322-06A1				\$110,612	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K23-NS-114167-01A1				\$110,723	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K23-NS-104239-01				\$114,624	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K08-NS-114106-01A1				\$116,550	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K08-NS-110929-01A1				\$121,837	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K08-NS-120595-01				\$122,921	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	7-R01-NS-063399-09				\$126,777	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MEDICAL UNIVERSITY OF SOUTH CAROLINA	A20-0051-S005		\$127,406	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CALIFORNIA, LOS ANGELES	2301 G WE215		\$128,132	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R25-NS-065745-11				\$134,401	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000131		\$144,984	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF ROCHESTER	1417584G/UR FAQ GR10929		\$151,022	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF IOWA	S01108-01		\$151,913	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-094533-01				\$160,389	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	98195C		\$164,054	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MICHIGAN	SUBK00007465		\$166,072	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-095793-01				\$167,950	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		WEILL CORNELL MEDICAL COLLEGE	194698		\$170,662	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	9-R01-NS-118921-06				\$172,479	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K23-NS-110993-01A1				\$173,239	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201590324		\$176,749	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-112742-01A1				\$185,028	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U24-NS-107199-01				\$191,644	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U24-NS-115691-01				\$194,306	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1R34NS118411-01				\$194,332	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		SECOND SIGHT MEDICAL PRODUCTS, INC.	SUB TO 5UH3NS103442-02		\$203,940	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K08-NS-112576-01				\$204,569	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-101108-01				\$225,140	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-088432-01A1				\$231,252	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1R56NS109144-01A1				\$231,616	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-T32-NS-043126-16				\$233,171	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CLEVELAND CLINIC	1428-SUB		\$243,712	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-097914-01A1				\$254,851	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-100892-01A1				\$256,267	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1R01NS115869-01A1				\$258,573	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CALIFORNIA, LOS ANGELES	2000 G VK 398		\$259,110	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-094533-06A1				\$263,071	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U24-NS-107224-01				\$267,964	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R37-NS-115439-01A1				\$289,990	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-096606-01				\$292,203	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		DUKE UNIVERSITY	A033658		\$303,253	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-081054-06				\$303,355	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-110865-01				\$303,932	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		AXONOVA MEDICAL, LLC	SUB TO R44NS108869		\$305,597	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-T32-NS-061779-11A1				\$315,228	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-T32-NS-091006-06				\$320,564	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-DP1-NS-122038-01				\$321,472	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-021229-33A1				\$333,062	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-101106-01				\$342,215	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R37-NS-048471-10				\$353,869	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-060698-06A1				\$355,050	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-101156-01A1				\$360,337	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-110688-01				\$426,046	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1R61NS111375-01A1				\$426,533	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification (Optional)</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-082265-06A1				\$429,367	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-102435-01A1				\$456,040	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-039421-19				\$462,767	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-113366-01A1				\$469,517	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R35-NS-097340-01				\$473,450	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-103873-01A1				\$503,078	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-110716-01A1				\$506,052	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-106108-01A1				\$515,180	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-DP2-NS-111996-01				\$516,381	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-T32-NS-105607-01				\$550,482	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-115995				\$570,317	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R35-NS-097275-01				\$580,249	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-107550-01A1				\$591,885	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-109260-01A				\$713,901	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R35-NS-116843-01				\$745,778	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	7-R35-NS-097370-02				\$804,351	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1R01NS115139-01				\$867,337	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-113241-01				\$988,370	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K23-NS-092973-01A1			\$24	\$128,879	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-105437-01A1			\$253	\$86,293	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-102838-01			\$2,872	\$78,261	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U01-NS-103799-01			\$7,499	\$16,125	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-102324-01			\$17,394	\$155,946	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-116315-01			\$21,513	\$217,341	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U01-NS-114140-01			\$25,000	\$240,135	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-090998-01A1			\$26,464	\$210,956	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-060653-06			\$32,694	\$384,956	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-112274-01A1			\$36,185	\$435,102	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-099129-01A1			\$38,495	\$701,930	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-038104-15A1			\$39,432	\$393,966	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-096720-01A1			\$63,763	\$242,944	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-083702-06A1			\$68,013	\$386,175	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-096087-01			\$75,002	\$475,288	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-094705-01			\$77,945	\$414,003	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-107969-01A1			\$83,562	\$227,645	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1R01NS114226-01			\$95,100	\$553,708	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2R01NS042645-16A1			\$98,970	\$654,613	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-100949-01			\$107,991	\$343,843	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-029436-26A1			\$121,702	\$454,963	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-094224-01A1			\$152,532	\$468,789	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-111115-01			\$188,407	\$422,847	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-094003-01A1			\$211,957	\$374,499	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	7-P01-NS-097206-02			\$231,101	\$382,348	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1U01NS114143-01			\$259,847	\$764,128	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-106611-01A1			\$259,994	\$769,270	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-102731-01A1			\$300,278	\$528,581	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U54-NS-115322-01			\$520,366	\$1,284,586	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1U01NS113198-01			\$754,524	\$1,248,138	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U19-NS-110456-01A1			\$1,425,523	\$3,879,331	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF COLORADO DENVER	FY19.996.001		\$7,968	\$43,002,801	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		RUTGERS UNIVERSITY	1382		-\$15,174	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		BENAROYA RESEARCH INSTITUTE	FY16ITN191		-\$11,476	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-K08-AI-130365-01A1				-\$9,687	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		NOTA LABORATORIES LLC	SUB TO 2R44AI120443		\$7,546	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	4-R00-AI-125786-03				-\$7,037	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-133998-01				-\$4,363	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	4-R01-AI-097590-05				-\$2,018	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		BENAROYA RESEARCH INSTITUTE	0112701501		\$3,927	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI133261-01				-\$811	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-150606-01				\$2	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-139982-01A1				\$16	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-128530-01				\$21	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-124084-01A1				\$29	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	4-R01-AI-101229-04				\$40	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF COLORADO DENVER	FY17.600.001		\$45	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI139890-01A1				\$45	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139102-01A1				\$47	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI157247-01				\$58	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-136945-01				\$76	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		JOHNS HOPKINS UNIVERSITY	2003649380		\$81	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-144572-01				\$96	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-055428-11A1				\$100	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-138078-01A1				\$123	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI152765-01				\$139	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-055435-11A1				\$199	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-050668-14				\$268	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-125284-01A1				\$271	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F32-AI-154797-01				\$365	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MASSACHUSETTS GENERAL HOSPITAL	234447		\$371	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		EMORY UNIVERSITY	A291031		\$1,591	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		BENAROYA RESEARCH INSTITUTE	FY171TN224		\$1,799	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-134862-01A1				\$2,596	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-122749-01				\$2,602	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI154932-01				\$2,628	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0001034943		\$3,994	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F31-AI-160741-01				\$4,306	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	A033383		\$4,599	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7-R01-AI-113047-04				\$4,782	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CALIFORNIA, SAN DIEGO	114143023		\$6,459	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1F31AI161319-01				\$6,459	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		FHI 360	SUB TO UM1 AI068619		\$7,013	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	127765C		\$7,074	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-129890-01A1				\$7,712	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F30-AI-161873-01				\$8,011	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		PARABON NANOLABS, INC.	20190927-UPENN-SBIR1-MRNA		\$8,450	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	SUB TO R01-AI-145840		\$8,495	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-157147-01A1				\$8,876	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139123-01				\$9,591	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		FHI 360	HPTN 091 PO20001123		\$9,627	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-P01-AI-068730-06				\$9,789	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R03-AI-156551-01				\$9,839	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0000866273		\$10,675	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-118891-01				\$11,959	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-165080-01				\$12,173	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MAGEE-WOMENS RESEARCH INSTITUTE & FOUNDATION UNIVERSITY OF MICHIGAN	9436		\$12,513	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CALIFORNIA, LOS ANGELES	SUBK00012761		\$13,049	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855			1560 G XC165		\$13,499	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DANA-FARBER CANCER INSTITUTE	1280903		\$13,789	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI162646-01A1				\$14,032	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		EMORY UNIVERSITY	98905C		\$14,033	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		YALE UNIVERSITY	M17Q12603 (Q01414)		\$14,096	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		LOYOLA UNIVERSITY OF CHICAGO	1-210155		\$14,300	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0001038749		\$16,095	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0000851168		\$17,174	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		AMERICAN GASTROENTEROLOGICAL ASSOCIATION	2016003		\$17,320	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MASSACHUSETTS GENERAL HOSPITAL	234438		\$18,014	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		FOX CHASE CHEMICAL DIVERSITY CENTER	95-R42AI138630-PENN		\$19,650	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI153815-01A1				\$21,024	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F31-AI-152354-01A1				\$21,385	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-139932-01				\$22,530	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-135421-01A1				\$22,891	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-143564-01A1				\$23,031	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0001053254		\$24,145	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0000852931		\$24,484	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CALIFORNIA, LOS ANGELES	1560 G WA905		\$25,214	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	3021174		\$25,370	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F31-AI-147415-01				\$25,421	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CHILDREN'S HOSPITAL BOSTON	GENFD0001903586		\$25,587	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000464		\$26,393	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		FOX CHASE CHEMICAL DIVERSITY CENTER	57-R41AI162385-PENN		\$26,419	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-135359-01				\$27,233	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		FOX CHASE CHEMICAL DIVERSITY CENTER	R41AI138630-UP		\$28,076	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC78982		\$29,983	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F31-AI-143387-01A1				\$30,357	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F31-AI-150224-01A1				\$30,725	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-114266-01				\$31,776	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF ALABAMA AT BIRMINGHAM	000515868-002		\$32,120	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F31-AI-133871-01A1				\$32,362	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F30-AI-149864-01A1				\$32,496	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MASSACHUSETTS GENERAL HOSPITAL	SUB TO U01AI136816		\$32,682	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WISTAR INSTITUTE	25281-18-324		\$33,222	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE	959-SUB		\$33,315	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-105343-01A1				\$33,742	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CALIFORNIA, LOS ANGELES	1560 G WB030		\$34,667	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0001062692		\$34,695	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-120011-01				\$35,763	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-151476-01A1				\$38,439	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-132971-01A1				\$39,116	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CALIFORNIA, BERKELEY	00010458		\$40,033	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2R01AI091627-12			\$40,560	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-151334-01A1			\$42,508	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F31-AI-140508-01A1			\$43,751	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		BENAROYA RESEARCH INSTITUTE	FY2017N339	\$44,356	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201750624	\$44,630	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-128059-01A1			\$45,101	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CINCINNATI CHILDREN'S HOSPITAL						
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MEDICAL CENTER	309363	\$46,282	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		BENAROYA RESEARCH INSTITUTE	FY2017N348	\$47,822	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	203-9727	\$47,887	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		ROCKEFELLER UNIVERSITY	SU01AI129825-02	\$48,300	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	A033564	\$51,060	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MAGEE-WOMENS RESEARCH INSTITUTE & FOUNDATION	9629	\$51,430	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-129531-01			\$53,160	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF MICHIGAN	SUBK00014269	\$53,246	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WASHINGTON UNIVERSITY IN ST. LOUIS	WU-21-210	\$54,001	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		ARIZONA STATE UNIVERSITY	SUB TO R01AI117011	\$54,974	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		FHI 360	PO21000094	\$57,014	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F32-AI-154666-01			\$59,023	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		ROCKEFELLER UNIVERSITY	1 U01AI145921	\$60,337	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		NATIONAL JEWISH HEALTH	20098204	\$62,671	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F32-AI-154797-01			\$63,813	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		FHI 360	PO20003102	\$64,931	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		LIGNAMED	SUB TO R42AI132012	\$65,632	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WEILL CORNELL MEDICAL COLLEGE	212094-05	\$66,040	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5105566	\$67,885	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		AMERICAN GASTROENTEROLOGICAL ASSOCIATION	2016002	\$71,518	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WEILL CORNELL MEDICAL COLLEGE	183723-13	\$72,990	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-018289-34			\$75,580	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-UM1-AI-144288-01			\$76,590	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-132912-01			\$77,927	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-134594-01A1			\$81,650	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0001029082	\$81,951	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF COLORADO DENVER	FY21.600.003	\$85,174	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF MASSACHUSETTS	OSP30517-01	\$90,016	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		VANDERBILT UNIVERSITY MEDICAL CENTER	SUB TO R01AI077505	\$91,095	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-138078-01A1			\$91,411	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-130665-01A1			\$91,657	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		EMORY UNIVERSITY	T860086	\$96,414	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF HOUSTON	R-17-0049	\$99,014	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201540224	\$99,395	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-138052-01			\$99,468	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-007632-16			\$103,619	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	92605C	\$104,580	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-149771-01A1			\$106,633	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WISTAR INSTITUTE	25281-17-324	\$106,673	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-K01-AI-139284-01A1			\$110,230	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		EMORY UNIVERSITY	A291031	\$117,034	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WISTAR INSTITUTE	252841-16-324	\$117,185	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-K24-AI-146137-01			\$120,851	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-K01-AI-137317-01A1			\$121,122	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI149456-01			\$127,938	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MAGEE-WOMENS RESEARCH INSTITUTE & FOUNDATION	9492	\$130,146	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-139895-01A1			\$132,086	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-144572-01			\$133,804	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1K23AI143925-01A1			\$138,109	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-144838-01			\$138,775	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WEILL CORNELL MEDICAL COLLEGE	183723-13	\$143,188	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-139982-01A1			\$148,312	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI139890-01A1			\$148,824	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-K23-AI-121485-01A1			\$149,114	\$72,847,969		RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF PITTSBURGH	AWD00002849(135384-3)	\$152,158	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		JOHNS HOPKINS UNIVERSITY	2002973536	\$153,672	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-150556-01A1			\$153,908	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-123243-01			\$160,697	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-144732-01			\$163,192	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-153064-01			\$164,485	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-070077-11			\$165,898	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-T32-AI-118684-01A1			\$176,014	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-142162-01A1			\$176,960	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-137283-01			\$187,393	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-158830-01			\$188,743	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC65908	\$189,106	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF PITTSBURGH	AWD00002849(135385-3)	\$198,249	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-160607-01			\$201,412	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI142638-01A1			\$203,628	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-121166-01			\$212,031	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-122749-01			\$213,988	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	A030469	\$216,717	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-125265-01			\$222,309	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-151607-01			\$222,635	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		FHI 360	SUB TO UM1 AI068619	\$229,000	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI148797-01A1			\$229,998	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF COLORADO DENVER	FY17.600.001	\$234,860	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI149761-01A1			\$235,210	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-007532-21			\$243,912	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200280521-FP00019478-SUB01-01	\$246,795	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	A030915	\$254,009	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-007324-26A1			\$254,736	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-125284-01A1			\$257,884	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-055400-16			\$266,972	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC64583	\$267,543	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-124182-01A1			\$269,574	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-079002-06			\$277,806	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	2037104	\$277,932	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7-R01-AI-127798-02			\$278,391	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	0012501A	\$284,563	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-150246-01			\$290,192	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-125563-01			\$294,046	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-UM1-AI-069534-08			\$299,668	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-118861-01A1			\$307,655	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MASSACHUSETTS GENERAL HOSPITAL	234443	\$308,768	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-148431-01A1			\$309,804	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	1UM1-AI144371-01	\$309,827	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-136945-01			\$317,600	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139060-01			\$318,042	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-123173-01A1			\$323,952	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-T32-AI-141393-01			\$329,063	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-155577-01			\$343,211	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WISTAR INSTITUTE	25281-07-324	\$345,137	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-050668-14			\$346,956	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2T32AI007632-21			\$348,747	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-149487-01			\$354,154	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	1UM1-AI144371-01	\$361,292	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	1UM1-AI144371-01	\$361,774	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-055435-16A1			\$364,437	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0001033142	\$369,607	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CALIFORNIA, LOS ANGELES	1560 BWA857	\$373,992	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-151882-01			\$374,354	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R61-AI-147406-01			\$377,662	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-134834-01A1			\$381,805	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-152362-01			\$385,022	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		COLUMBIA UNIVERSITY	3 (GG013567-03)	\$387,455	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-129661-01A1			\$389,214	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-116794-01A1			\$390,812	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	SUB TO 5UM1-AI144371	\$397,668	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7-R01-AI-123738-02			\$400,676	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-152195-01			\$411,642	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-112427-07			\$413,717	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439	

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	2036421		\$414,551	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-U01-AI-125940-01				\$417,666	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CHILDREN'S HOSPITAL BOSTON	GENFD0001487482		\$421,795	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI154932-01				\$431,475	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-143185-01A1				\$435,726	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CALIFORNIA, LOS ANGELES	1560 BWA857		\$444,908	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	SUB TO R01-AI-145840		\$446,346	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WISTAR INSTITUTE	25281-12-324		\$450,157	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-134834-01A1				\$470,174	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0001038427		\$475,337	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-134879-01				\$490,929	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-047833-16A1				\$524,599	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-143676-01A1				\$535,004	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139102-01A1				\$565,263	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-U01-AI-125940-01				\$572,630	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-143790-01				\$595,159	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-150606-01				\$636,946	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI146162-01A1				\$649,901	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MASSACHUSETTS GENERAL HOSPITAL	234447		\$676,028	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0001038383		\$682,314	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-148249-01				\$699,172	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WISTAR INSTITUTE	25281-10-324		\$816,985	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-050529-17				\$829,654	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-131331-01				\$943,008	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-UM1-AI-069534-08				\$1,042,146	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-UM1-AI-069534-15				\$1,787,061	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-138564-01			\$1,611	\$37,846	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-137433-01			\$1,799	\$125,140	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI154022-01			\$3,449	\$110,693	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-128530-01			\$8,143	\$351,553	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-U19-AI-117950-01			\$8,947	\$274,682	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139618-01A1			\$14,340	\$680,928	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-136626-01			\$14,363	\$715,757	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI130115-01A1			\$14,871	\$363,262	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-143564-01A1			\$17,452	\$135,874	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-145905-01			\$19,378	\$254,000	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI157106-01			\$22,281	\$209,570	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-150246-01			\$23,058	\$267,507	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7-R01-AI-091627-08			\$27,674	\$465,384	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-120489-01A1			\$28,189	\$423,146	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI157247-01			\$48,955	\$743,176	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-108686-06			\$49,969	\$327,935	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-150556-01A1			\$56,177	\$461,301	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139240-01			\$56,828	\$689,184	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139123-01			\$57,508	\$671,429	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-137062-01			\$65,918	\$66,863	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R56-AI-150677-01			\$85,677	\$187,995	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139188-01			\$87,612	\$597,831	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI152236-01			\$87,919	\$324,511	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1U01AI152960-01			\$92,415	\$362,305	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-142572-01			\$101,010	\$558,887	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI152765-01			\$102,214	\$368,522	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-120810-01A1			\$108,621	\$496,390	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-118694-01A1			\$123,069	\$217,139	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-118549-01A1			\$124,071	\$642,451	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-120821-01			\$142,102	\$338,027	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-125524-01			\$154,696	\$207,592	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-140442-01			\$164,170	\$520,367	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-140539-01			\$226,904	\$429,998	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-091595-04A1			\$228,661	\$416,809	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-146129-01			\$233,280	\$618,081	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-138782-01			\$257,865	\$507,445	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI144522-01A1			\$270,216	\$538,725	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7-R01-AI-127271-03			\$303,037	\$578,527	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-150590-01			\$313,999	\$1,025,871	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-123539-01A1			\$331,324	\$653,494	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-146101-01			\$332,387	\$638,622	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-104887-06A1			\$398,553	\$802,927	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-124429-01			\$478,936	\$510,825	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-P30-AI-045008-21			\$561,029	\$3,327,441	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R61-AI-133696-01			\$585,647	\$917,792	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-U19-AI-131130-01			\$651,120	\$1,054,125	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-U19-AI-149680-01			\$686,570	\$1,826,259	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-P01-AI-131138-01			\$1,025,840	\$1,741,419	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-P01-AI-131251-01			\$1,871,125	\$3,121,898	\$72,847,969	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-052302-21				-\$24,027	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-034883-27A1				-\$783	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-097478-05				-\$59	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	7-K08-GM-106144-04				-\$59	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-108744-01				\$3	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-133842-01A1				\$44	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-P01-GM-087253-11				\$77	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		NORTHWESTERN UNIVERSITY	60051124 UPENN		\$85	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1RM1GM136511-01				\$125	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-085207-09				\$178	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R37-GM-057247-18				\$209	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-118139-01				\$247	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-133721-01				\$252	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		SAINT LOUIS UNIVERSITY	ERS #21441-43869		\$272	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-121375-01				\$446	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM087605-04A1				\$683	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-114042-01A1				\$733	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		TUFTS UNIVERSITY	NH9022_UPENN		\$1,107	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	4-R37-GM-056328-18				\$1,203	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-111942-01A1				\$4,131	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-036477-33				\$7,163	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-139211-01A1				\$7,873	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		PARADIGM SURGICAL, LLC	SUB TO R44GM123789		\$8,087	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F32-GM-125123-01A1				\$11,485	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R35-GM-119735-06				\$13,780	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-125959-01A1				\$14,453	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1F31GM140978-01A1				\$15,398	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		RUTGERS UNIVERSITY	1702		\$16,425	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F32-GM-137461-01A1				\$21,269	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-138908-01A1				\$24,525	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		UNIVERSITY OF COLORADO DENVER	FY18.575.005		\$26,392	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-108751-05A1				\$28,965	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		UNIVERSITY OF MICHIGAN	SUBK00012742		\$29,209	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F31-GM-133161-01				\$32,980	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		PENNSYLVANIA STATE UNIVERSITY	6093-UP-DHHS-2653		\$33,923	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-139541-01				\$34,083	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		CARNEGIE MELLON UNIVERSITY	1090631-432700		\$34,151	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	128895C		\$34,754	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-111421-01				\$37,916	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-K99-GM-131028-01				\$40,213	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F31-GM-134591-01A1				\$40,795	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F31-GM-139325-01				\$40,966	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-T32-GM-133398-01A1				\$41,836	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F31-GM-136073-01				\$42,813	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-141747-01				\$46,802	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-038237-27A1				\$52,168	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		UNIVERSITY OF MIAMI	SPC-000658		\$52,776	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		DUKE UNIVERSITY	A03-3177		\$52,882	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R21-GM-132831-01				\$60,349	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F32-GM-126639-01				\$62,925	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-051893-24				\$64,240	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2R35GM118048-06				\$66,042	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-116876-01A1				\$71,317	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F32-GM-133162-01				\$74,398	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-100366-05				\$86,414	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		UNIVERSITY OF CALIFORNIA, LOS ANGELES	0830 G UA376		\$91,882	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		SAINT LOUIS UNIVERSITY	ERS#2288-45656		\$98,394	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-112596-06				\$108,396	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-099836-05				\$109,145	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-K08-GM-139031-01				\$109,237	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-141832-01				\$128,091	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-060804-17				\$130,291	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R21-GM-133060-01				\$141,276	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-115517-01A1				\$147,772	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-097552-06				\$157,932	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-K23-GM-120630-01A1				\$159,472	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-055560-18A1				\$161,389	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-123783-01A1				\$174,518	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-118501-01A1				\$189,419	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-K08-GM-123317-01				\$203,821	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-133172-01				\$226,185	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1R01GM139970-01				\$243,569	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-138201-01				\$243,778	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-087253-11				\$254,312	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-123019-01				\$265,388	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-101149-05				\$275,140	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-138788-01				\$277,085	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-116876-05				\$278,339	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-124143-01				\$295,943	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-051893-20				\$296,817	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM080279-09				\$297,441	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-056838-21				\$298,314	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-129781-01				\$298,768	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1R35GM134957-01				\$300,972	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-123512-01A1				\$302,051	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-127408-01				\$303,877	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-131902-01				\$304,467	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-125811-01A1				\$309,482	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-127593-01				\$317,604	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1R35GM136270-01				\$325,083	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-128794-01				\$325,493	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-121375-01				\$327,413	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-097552-10				\$329,429	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		NORTHWESTERN UNIVERSITY	60051124 UPENN		\$334,040	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1R35GM136259-01				\$335,462	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-124023-01A1				\$336,734	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R25-GM-071745-14A1				\$341,056	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-119735-01				\$342,421	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-118510-01				\$350,533	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-095977-05				\$351,321	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-133154-01				\$352,930	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-008216-33				\$358,747	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-127374-01				\$364,968	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-123233-01				\$366,597	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1R01GM138597-01				\$367,258	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-128748-01				\$369,495	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-138035-01				\$374,025	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-123056-01A1				\$378,787	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-073791-14				\$379,087	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-124684-01				\$382,800	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1DP2GM140923-01				\$387,233	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-085146-09A1				\$394,443	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1R35GM138211-01				\$397,903	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-T32-GM-132039-01				\$399,459	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-133708-01				\$400,543	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-133425-01				\$405,110	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-128096-01				\$410,276	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	4-R37-GM-051279-23				\$431,516	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-124091-01A1				\$439,961	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-115420-05				\$450,668	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-133380-01				\$453,005	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		UNIVERSITY OF CALIFORNIA, LOS ANGELES	1445 G UE023		\$464,813	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-118090-01				\$466,677	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-007229-43				\$479,802	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-118052-01				\$493,319	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-075766-11				\$500,154	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-098389-06				\$508,012	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1R35GM136315-01				\$518,751	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-131907-01				\$534,752	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-127093-01				\$550,417	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-122475-01				\$560,010	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-133721-01				\$560,537	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-008076-35				\$563,079	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-124749-01				\$574,272	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-111128-05				\$577,912	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-122505-01				\$588,053	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-131908-01				\$589,609	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-133842-01A1				\$602,255	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	4-R37-GM-056328-18				\$607,725	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-131680-01				\$650,272	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-118048-01				\$660,801	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-126950-01				\$665,607	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-128903-01				\$671,280	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-036477-37				\$765,351	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-118139-01				\$846,853	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-130302-01				\$892,606	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-088156-06				\$924,948	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1RM1GM136511-01				\$1,050,687	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-007170-44				\$2,621,684	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		ANDAMIO GAMES	7006-001-001-004	\$125	\$122,920	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-071339-11			\$7,682	\$219,454	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1R01GM125301-01			\$8,093	\$357,600	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-049758-24			\$17,774	\$190,050	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-085207-09			\$33,762	\$315,580	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R37-GM-057247-18			\$42,318	\$411,120	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-137430-01A1			\$47,798	\$167,687	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-103899-07			\$65,845	\$613,972	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1R01GM135633-01			\$67,511	\$348,810	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-K12-GM-081259			\$89,314	\$1,288,217	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-129357-01			\$101,127	\$425,357	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-124111-01			\$288,883	\$627,805	\$45,356,807	RESEARCH AND DEVELOPMENT	\$780,703,439
TREATMENT OF HYPERANDROGENISM VS. INSULIN RESISTANCE IN INFERTILE PCOS	93.864		PENNSYLVANIA STATE UNIVERSITY	UPA HD056510		\$13	\$13	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		MEDICAL UNIVERSITY OF SOUTH CAROLINA	A00-2240-S004		-\$14,436	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3258700718		-\$1,755	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-086888-01				-\$1,120	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-T32-HD-040135-11				-\$17	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-076279-01A1				-\$17	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-T32-HD-083185-06A1				\$11	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	58055C		\$236	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	K12-HD-001265				\$954	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		GEORGE WASHINGTON UNIVERSITY	SUB TO U10HD036801/MFMU40C PROSPECT		\$1,109	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		GEORGE WASHINGTON UNIVERSITY	SUB TO U10HD036801/MFMU TOPS		\$1,556	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R21-HD087674-01				\$4,478	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	321098 PO #961914RSUB		\$4,667	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		GEORGE WASHINGTON UNIVERSITY	SUB TO U10HD036801		\$6,940	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000601		\$7,867	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		GEORGE WASHINGTON UNIVERSITY	SUB TO U10HD036801 (CMV)/MFMU		\$8,292	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		GEORGE WASHINGTON UNIVERSITY	SUB TO U10HD036801		\$8,891	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF MICHIGAN	SUBK00011494		\$10,195	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F30-HD-104360-01				\$10,765	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000147		\$11,229	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		TEMPLE UNIVERSITY	264697-UPENN		\$12,216	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		OHIO STATE UNIVERSITY	60079099		\$12,529	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		EMORY UNIVERSITY	A403216		\$12,718	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF MICHIGAN	SUBK00010144		\$19,747	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		NORTHWESTERN UNIVERSITY	60046347 PENN		\$19,763	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		JOHNS HOPKINS UNIVERSITY	2004462188		\$19,888	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF TEXAS AT AUSTIN	UTA20-000200		\$21,239	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201440523		\$21,863	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5106229		\$25,736	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	ACTIVITY 321098 (PO#961915RSUB		\$27,875	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R21-HD-088941-01A1				\$29,936	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	203661015-S1		\$30,144	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201990721	\$34,515	\$30,515	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F30-HD-098015-01			\$32,437	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		COLUMBIA UNIVERSITY	4(GG011848-01)		\$33,051	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF MICHIGAN	SUBK00012813	\$33,553	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F32-HD-089623-01A1			\$33,837	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		MOSS REHABILITATION RESEARCH INSTITUTE	4934	\$33,930	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F31-HD-100171-01A1			\$36,002	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF DELAWARE	44252	\$36,752	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F31-HD-098764-01			\$37,237	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-075869-01A1			\$38,457	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1F31HD103375-01			\$38,550	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1F31HD101346-01A1			\$40,403	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201340523	\$43,308	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F31-HD-102121-01			\$45,138	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F31-HD-102084-01			\$45,507	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F30-HD-098803-01			\$45,753	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1F30HD103378-01			\$46,158	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-102013-01A1			\$47,605	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1F31HD102165-01			\$49,127	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F32-HD-101230-01A1			\$50,886	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F32-HD-103448-01			\$51,665	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	8233030620	\$53,896	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		YALE UNIVERSITY	GR107889 (CON-80002064)	\$54,038	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	GRT-00000289	\$56,417	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R21-HD-101792-01			\$58,189	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5113142	\$58,221	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-T32-HD-083185-01			\$64,068	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200880522	\$65,091	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-UG1-HD-087192-06			\$74,608	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		GEORGE WASHINGTON UNIVERSITY	SUB TO U10HD036801	\$80,600	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R03-HD-099667-01A1			\$85,721	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-K99-HD-098329-01			\$85,951	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF MISSOURI-COLUMBIA	C00069141-1	\$107,308	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-K23-HD-084727-01A1			\$107,399	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CENTRAL MICHIGAN UNIVERSITY	F63374	\$117,960	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1K23HD102523-01			\$121,019	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201250522	\$131,204	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R21HD102801-01			\$132,186	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF ALABAMA AT BIRMINGHAM	000527889-SC002-MCD	\$132,270	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		RESEARCH TRIANGLE INSTITUTE	PFDN CAPITATION FUNDING	\$141,125	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		JOHNS HOPKINS UNIVERSITY	2004123438	\$162,477	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201860524	\$170,076	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-K23-HD-090272-01A1			\$172,986	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF PITTSBURGH	0061510 (131226-1)	\$175,313	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-R01-HD-058730-06A1			\$185,902	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-K12-HD-001265-21			\$192,128	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5106045	\$209,463	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200830522	\$213,102	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-UG1-HD-069010-06			\$242,194	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-UG1-HD-087192-01			\$251,710	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-T32-HD-007242-36A1			\$254,270	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R61-HD-101937-01A1			\$321,034	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-R01-HD-069592-06A1			\$337,074	\$14,264,529		RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-092266-01				\$354,844	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R01HD102318-01				\$386,295	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	T32-HD-007440				\$410,417	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-P2C-HD-049464-16				\$468,401	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1U54HD104392-01				\$481,034	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R01HD098867-01A1			\$5,708	\$462,921	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-U01-HD-087180-01			\$6,628	\$119,406	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R21-HD-091330-01A1			\$8,904	\$73,877	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R21-HD-093369-01			\$24,653	\$24,653	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R21HD097576-01A1			\$48,337	\$93,442	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-087391-01A1			\$59,292	\$212,245	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-089390-01A1			\$75,026	\$369,309	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-K12-HD-085848-01			\$90,466	\$231,023	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-P50-HD-068157-06A1			\$96,485	\$1,379,271	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-091350-0			\$105,467	\$415,464	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-087485-01A1			\$140,001	\$378,053	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-098269-01A1			\$147,824	\$354,877	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-UG1-HD-068244-06			\$204,133	\$204,133	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-097686-01A1			\$212,876	\$608,059	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-090082-01	STATE UNIVERSITY OF NEW YORK	77545-1138238-2	\$276,264	\$356,679	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-090082-01	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5116605	\$324,934	\$585,137	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5-U01-AG-032984-07			\$332,679	\$516,619	\$14,264,529	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R56-AG-061867-01				-\$74,814	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-RF1-AG-053951				-\$23,754	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-K24-AG-047908-01				-\$10,082	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	7-R01-AG-048388-03				-\$7,776	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R21-AG-053638-01A1	MAYO CLINIC ROCHESTER	PO #63788299		-\$6,315	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	2-P30-AG-012836-21				-\$4,168	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	4-K24-AG-042765-03				-\$2,523	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R56-AG-061867-01				-\$1,520	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	2-P01-AG-017586-16				-\$531	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - AGING RESEARCH	93.866	1-R01-AG-054435-01A1				-\$179	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - AGING RESEARCH	93.866	1-R01-AG-054435-01A1				\$103	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		BRIGHAM AND WOMEN'S HOSPITAL	113049		\$132	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		NATIONAL BUREAU OF ECONOMIC RESEARCH, INC.	P01-AG-005842		\$179	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	122133383		\$575	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	OS00000589		\$1,056	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - AGING RESEARCH	93.866	1-U54-AG-052427-01				\$2,666	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-F31-AG-057171-01				\$2,979	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		WAKE FOREST UNIVERSITY	101720-114751		\$3,150	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	OS00000155		\$3,217	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - AGING RESEARCH	93.866	2-U24-AG-041689-06				\$3,668	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		DUKE UNIVERSITY	1 (GG012937-01)		\$3,999	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-F31-AG-072777-01				\$4,306	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001049		\$5,306	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		JOHNS HOPKINS UNIVERSITY	2004442257		\$6,661	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1R01AG070944-01				\$7,087	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R01-AG-069401-01A1				\$7,338	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF FLORIDA	SUB00002681		\$7,419	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	120113669		\$8,094	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF WISCONSIN-MADISON	0000000888		\$9,009	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R01-AG-071818-01				\$9,598	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		SEATTLE CHILDREN'S HOSPITAL RESEARCH INSTITUTE	12330SUB		\$9,637	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-F32-AG-054032-01A1				\$10,270	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MICHIGAN	SUBK00009919		\$10,319	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	NIH-022 A4 75697387		\$11,158	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	110645C		\$11,396	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	OS00000157		\$12,262	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION	STE2196-18		\$13,757	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	129134561		\$13,807	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	129204282		\$14,282	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	1-F31-AG-069441-01				\$14,770	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		SYRACUSE UNIV	30917-05467-505		\$14,998	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF ROCHESTER	417733G/URFAO:GR510940		\$15,919	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R21-AG-052905-01				\$15,947	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		BROWN UNIVERSITY	00001588		\$16,069	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		BOSTON UNIVERSITY	4500003659		\$16,108	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE	69990-13315-UPENN		\$16,126	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	0500000158		\$16,155	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-F30-AG-058317-01				\$17,704	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		DTX PHARMA	SUB TO R43AG065066		\$18,754	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	105710197		\$20,554	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		COLUMBIA UNIVERSITY	3(GG017449-01)		\$21,032	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1F31AG060672-01				\$21,127	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		JOHNS HOPKINS UNIVERSITY	2004835051		\$22,586	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		JOHNS HOPKINS UNIVERSITY	2004105740		\$23,593	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF TEXAS AT AUSTIN	UTA17-000231		\$24,232	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		STANFORD UNIVERSITY	61927487-133778		\$24,241	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		WAKE FOREST UNIVERSITY HEALTH SCIENCES	WFUHS 551083		\$24,750	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF WISCONSIN-MADISON	0000000888		\$24,955	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF WASHINGTON	762205		\$25,151	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	117340690		\$28,091	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		BROWN UNIVERSITY	00001384		\$29,118	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001376		\$29,453	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R13-AG-069597-01				\$30,668	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		INDIANA UNIVERSITY	8545		\$32,889	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF WASHINGTON	UWSC10653/BPO33606		\$32,939	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R03-AG-069817-01				\$33,122	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		ADVANCED MEDICAL ELECTRONICS	SUB TO 1R32AG049524		\$33,791	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		ALBERT EINSTEIN COLLEGE OF MEDICINE, INC	SUB TO R01AG055527		\$33,872	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF COLORADO	FY21.1105.001		\$33,972	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R56-AG-071177-01				\$34,204	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R01-AG-066650-01A1				\$34,462	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		BRIGHAM AND WOMEN'S HOSPITAL	121337		\$35,081	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001337		\$36,191	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		DUKE UNIVERSITY	A030456		\$36,617	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF CHICAGO	AWD101518		\$36,640	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-T32-AG-051090-01				\$37,339	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		BOSTON UNIVERSITY	4500003187		\$37,448	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		BROWN UNIVERSITY	00001589		\$37,776	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1R03AG069793-01				\$38,599	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF CALIFORNIA, SAN DIEGO	47180199		\$39,218	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R56-AG-050620-01A1				\$39,449	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MICHIGAN	SUBK00007532		\$39,978	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-K99-AG-066947-01A1				\$40,290	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	107890382		\$40,292	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-U01-AG-066100-01				\$40,997	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1F31AG069390-01				\$41,239	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R03-AG-053277-01				\$42,387	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MARYLAND, BALTIMORE	1200011D REQUEST:2765		\$42,473	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-RF1-AG-069474-01A1				\$42,546	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001173		\$44,032	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		JOHNS HOPKINS UNIVERSITY	2003755014		\$44,188	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		WAKE FOREST UNIVERSITY	WFUHS 552702		\$45,244	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		COLUMBIA UNIVERSITY	1(GG015275-01)		\$45,302	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R21-AG-055142-01A1				\$45,666	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF WISCONSIN-MADISON	785K492		\$45,800	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-F31-AG-063470-01A1				\$45,931	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF PITTSBURGH	AWD00001198 (133499-1)		\$49,235	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		WAKE FOREST UNIVERSITY HEALTH SCIENCES	101720-114750		\$51,065	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3200890622		\$52,447	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF WASHINGTON	UWSC10710		\$53,076	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1R21AG070434-01				\$53,173	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned by Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866		STANFORD UNIVERSITY	61927487-133778		\$53,530	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF PITTSBURGH	0058745131435-2		\$54,625	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		EMORY UNIVERSITY	A175663		\$56,144	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-K24-AG-070459-01				\$56,419	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-F32-AG-060630-01A1				\$57,538	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-K08-AG-065444-01A1				\$58,275	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	107888795		\$68,034	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R03-AG-063213-01				\$69,768	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		DUKE UNIVERSITY	2034990		\$71,914	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		BANNER HEALTH	0435-02-71562		\$72,748	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R21-AG-051981-01A1				\$75,451	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		BRIGHAM AND WOMEN'S HOSPITAL	115388		\$77,556	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-K99-AG-065500-01A1				\$80,083	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION	WEI-2015-17		\$86,672	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001233		\$89,783	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	138398230		\$94,607	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-K01-AG-061277-01				\$95,620	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1K23AG065442-01				\$97,374	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MISSOURI-COLUMBIA	C00065785-1		\$101,422	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1K23AG065499-01A1				\$102,200	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		CASE WESTERN RESERVE UNIVERSITY	RES514121		\$104,969	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R21-AG-065816-01A1				\$109,520	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-K01-AG-064123-01				\$110,539	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1R21AG069805-01				\$118,176	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1R01AG068577-01				\$119,012	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		VANDERBILT UNIVERSITY	VUMC71547		\$122,994	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-K08-AG-052572-01				\$123,186	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		BOSTON MEDICAL CENTER	7653		\$123,322	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R56-AG-066656-01				\$126,369	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-K01-AG-055691-01A1				\$129,305	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	79634962		\$132,019	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	2-K24-AG-042765-06				\$134,554	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R56-AG-062293-01				\$137,936	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		CASE WESTERN RESERVE UNIVERSITY	RES514122		\$138,792	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-K24-AG-055602-01				\$143,360	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	105710197		\$150,844	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R21-AG-061784-01A1				\$152,183	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		WAKE FOREST UNIVERSITY	WFUHS-551083		\$157,540	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R21-AG-047915-01A1				\$158,408	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		COLUMBIA UNIVERSITY	2(GG013395-01)		\$162,994	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		COGNITION THERAPEUTICS, INC.	SUB TO R42AG052249		\$165,488	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-UH2-AG-050311-01				\$166,818	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		BANNER HEALTH	0435-06-102819		\$167,590	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R21-AG-064618-01				\$177,692	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R01-AG-070351-01				\$183,023	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	2-K24-AG-047908-06				\$184,062	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		JOHNS HOPKINS UNIVERSITY	2004028077		\$187,762	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		WAKE FOREST UNIVERSITY	WFUHS 112971		\$191,603	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-000516		\$194,716	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R21-AG-065854-01				\$196,012	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		NATIONAL BUREAU OF ECONOMIC RESEARCH, INC.	4121C-PILOT 2.2-PENN		\$198,181	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		BOSTON UNIVERSITY	4500003108		\$218,688	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	4-R00-AG-056054-03				\$226,459	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1R01AG064231-01A1				\$227,069	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC001222		\$229,063	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001347		\$239,287	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	103875C		\$241,595	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1R01AG063869-01A1				\$241,990	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R56-AG-062665-01				\$242,749	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	SUB TO U01AG068057		\$246,354	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		MAYO CLINIC ROCHESTER	UOP-263134		\$249,628	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001202		\$253,036	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R01-AG-066841-01A1				\$258,545	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total	
AGING RESEARCH	93.866		UNIVERSITY OF WASHINGTON	UWSC10172		\$269,601	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866		JOHNS HOPKINS UNIVERSITY	2003994874		\$278,349	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	94095C		\$280,094	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866		CASE WESTERN RESERVE UNIVERSITY	RES514120		\$284,972	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	7-K76-AG-057016-02				\$285,758	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866		BROWN UNIVERSITY	00001361		\$288,714	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866		INDIANA UNIVERSITY	IN4683234UPEN CS		\$291,341	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	137298061		\$293,471	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1R01AG066569-01				\$315,599	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R56-AG-058732-01A1				\$317,312	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001223		\$320,837	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	2-U54-AG-052427-06				\$329,719	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-RF1-AG-057197-01A1				\$372,145	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1RF1AG066905-01A1				\$374,800	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1R01AG061447-01				\$375,248	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-062140-01A1				\$378,811	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-055570-01				\$394,452	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	2-R01-AG-041099-04				\$396,931	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R56-AG-061057-01				\$414,969	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R21-AG-057380-01				\$429,659	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-060975-01				\$454,977	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866		NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION	WEI2015-14		\$484,580	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	2-T32-AG-000255-21				\$520,598	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-060612-01A1				\$534,024	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	2-P30-AG-012836-26				\$567,007	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-DP2-AG-067492-01				\$599,253	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-RF1-AG-055477-01				\$624,320	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-DP2-AG-067511-01				\$691,471	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-066152-01				\$714,788	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-054519-01A1				\$733,982	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-RF1-AG-058065-01				\$755,520	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-000472		\$795,087	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-RF1-AG-054409-01				\$829,572	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-055005-01				\$857,627	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-P01-AG-066597-01				\$919,542	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-RF1-AG-054104-01				\$993,491	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1U19AG062418-01A1				\$3,530,690	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	P30-AG-010124				\$3,776,638	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	2-P30-AG-034546-06			\$1,139	\$2,298	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-065276-01			\$1,297	\$174,257	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	5-U01-AG-032984-07			\$3,316	\$3,316	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R56-AG-063344-01			\$7,250	\$199,311	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-RF1-AG-063481-01A1			\$10,715	\$570,873	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	7-R01-AG-049815-04			\$12,125	\$12,125	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1R61AG068947-01			\$14,628	\$128,217	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-P30-AG-059302-01			\$15,217	\$603,709	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866		BANNER HEALTH	0435-06-08001		\$17,281	\$181,935	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R01-AG-059763-01A1			\$20,642	\$494,082	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-054521-01A1			\$24,864	\$511,201	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R21-AG-053638-01A1			\$28,833	\$28,833	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1R61AG068945-01			\$37,228	\$168,885	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	2-P01-AG-017586-16			\$53,532	\$1,668,516	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-064589-01			\$54,294	\$414,538	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	2-P30-AG-012836-21			\$63,936	\$63,936	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1R01AG067698-01A1			\$64,497	\$221,928	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	2-R01-AG-025152-11			\$64,990	\$415,642	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-066114-01			\$74,760	\$549,603	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	2-P30-AG-034546-11			\$83,057	\$640,140	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R21-AG-067114-01			\$83,333	\$166,590	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-057501-01			\$127,866	\$582,438	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-062595-01			\$129,768	\$535,288	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	2-U24-AG-041689-06			\$134,581	\$3,069,566	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-060115-01			\$142,940	\$366,584	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-056014-01			\$154,381	\$663,013	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-P30-AG-064105-01			\$162,523	\$790,312	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-054060-01			\$177,211	\$413,123	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-058718-01			\$191,272	\$366,798	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R56-AG-069130-01			\$194,697	\$331,741	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-061945-01			\$228,357	\$428,917	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-R01-AG-062819-01A1			\$242,769	\$479,424	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	
AGING RESEARCH	93.866	1-RF1-AG-053951			\$291,392	\$291,392	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439	

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned by Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	1-U01-AG-061173-01			\$473,637	\$836,187	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-U01-AG-052943-01			\$567,818	\$1,080,051	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	2-P01-AG-031862-11			\$676,742	\$1,733,381	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-U54-AG-052427-01			\$1,016,301	\$1,887,379	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	1-R01-AG-054435-01A1			\$1,127,995	\$2,228,850	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
AGING RESEARCH	93.866	2-U01-AG-032984-11			\$3,968,583	\$5,515,173	\$65,081,562	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		NANOSCOPE TECHNOLOGIES, LLC ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	N/A		-\$20,663	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		UNIVERSITY OF FLORIDA	0255-3312-4605		-\$9,840	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		JAEB CENTER FOR HEALTH RESEARCH	UFDSP00010918		-\$7,416	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867			DRRC.NET		-\$6,947	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R21-EY-027936-01A1				-\$1,982	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - VISION RESEARCH	93.867	2-R01-EY-013434-12A1				\$77	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - VISION RESEARCH	93.867	2-R01-EY-105537-12A1				\$77	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R01-EY-024861-01				\$83	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - VISION RESEARCH	93.867	1-K08-EY-029765-01A1				\$90	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - VISION RESEARCH	93.867	1-R21-EY-029826-01				\$132	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - VISION RESEARCH	93.867		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201360819		\$211	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - VISION RESEARCH	93.867	2-R01-EY-006855-34				\$246	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		JOHNS HOPKINS UNIVERSITY	2004433095		\$427	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-P30-EY-001583-21				\$817	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - VISION RESEARCH	93.867	1-R01-EY-023557-01				\$898	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-K12-EY-015398-16				\$1,104	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		PENNSYLVANIA STATE UNIVERSITY	UPAEY023533		\$4,199	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-K23-EY-025729-01				\$5,071	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		VANDERBILT UNIVERSITY MEDICAL CENTER	SUB TO 1R21EY032592-01		\$5,427	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		JOHNS HOPKINS UNIVERSITY	2002565177		\$8,184	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		UNIVERSITY OF SOUTHERN CALIFORNIA	67228549		\$9,980	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		NEW YORK UNIVERSITY	SUB TO 1U10EY026869		\$14,111	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R21-EY-029091-01				\$17,559	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-K08-EY-025742-01				\$22,332	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-F30-EY-032339-01				\$26,372	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		DUKE UNIVERSITY	A031038		\$27,781	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-F30-EY-029931-01A1				\$29,903	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201580224		\$30,808	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R01-EY-031286-01A1				\$33,032	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		JAEB CENTER FOR HEALTH RESEARCH	EY 14231		\$37,686	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-K12-EY-015398-11A1				\$42,635	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		BRIGHAM AND WOMEN'S HOSPITAL	119243		\$42,652	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-R01-EY-020851-06				\$43,526	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1R21EY031877-01				\$51,152	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R21-EY-032232-01				\$66,699	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R01-EY-024681-01A1				\$93,678	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-T35-OD-010919-21				\$101,144	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R21-EY-028998-01A1				\$101,332	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		UNIVERSITY OF TEXAS AT AUSTIN	UTA17-000180		\$103,030	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		NORTHWESTERN UNIVERSITY	SP0039783-PROJ0013665		\$107,027	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R21-EY-029826-01				\$120,891	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-T32-EY-007035-41				\$121,850	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-R01-EY-022350-04A1				\$130,084	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		FOX CHASE CHEMICAL DIVERSITY CENTER	R41EY030391-UP		\$131,898	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-P30-EY-001583-41				\$133,223	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		MASSACHUSETTS EYE AND EAR INSTITUTE	530636		\$138,401	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		COLUMBIA UNIVERSITY	1(GG013355-01)		\$160,785	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-K08-EY-031754-01				\$174,498	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R21-EY-028273-01A1				\$176,012	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-R01-EY-023557-06				\$176,293	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2R01EY024861-06				\$200,217	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1R21EY031465-01				\$205,767	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		NEW ENGLAND COLLEGE OF OPTOMETRY	3708-07-01-2020UPENN		\$213,154	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R01-EY-028571-01A1				\$221,239	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-R01-EY-019014-06A1				\$238,493	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R01-EY-023557-01				\$248,680	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-K08-EY-030163-01				\$249,380	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1UG1EY030419-01				\$263,964	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
VISION RESEARCH	93.867	1-K08-EY-029765-01A1				\$275,308	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R01-EY-028601-01A1				\$343,425	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R01-EY-025287-01A1				\$351,067	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-R01-EY-022411-05A1				\$358,563	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-R01-EY-013434-12A1				\$368,982	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2R01EY02350-08				\$376,136	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R01-EY-030599-01				\$429,630	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R01-EY-028916-01A1				\$437,154	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R01-EY-027205-01A1				\$524,275	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-R01-EY-105537-12A1				\$635,417	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-R01-EY-015240-13A1				\$652,209	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2P30EY001583-46				\$676,532	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-R01-EY-006855-34				\$880,088	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867		CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	3201360819		\$1,072,194	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1R01EY030227-01A1			\$19,713	\$340,152	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R21-EY-031338-01			\$56,259	\$178,427	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R01-EY-026972-01			\$67,110	\$390,887	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R21-EY-029776-01			\$81,726	\$181,238	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-R01-EY-022070-05A1			\$110,766	\$195,200	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-R01-EY-017549-10			\$148,028	\$767,698	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R01-EY-031209-01A1			\$171,456	\$357,760	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	2-R01-EY-026525-05			\$192,831	\$506,900	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
VISION RESEARCH	93.867	1-R01-EY-030192-01			\$250,247	\$549,181	\$15,135,886	RESEARCH AND DEVELOPMENT	\$780,703,439
AUTISM COLLABORATION, ACCOUNTABILITY, RESEARCH, EDUCATION, AND SUPPORT	93.877		UNIVERSITY OF CALIFORNIA, LOS ANGELES	2000 G YC805		\$179,343	\$179,343	RESEARCH AND DEVELOPMENT	\$780,703,439
MEDICAL LIBRARY ASSISTANCE	93.879		MEDSTAR HEALTH RESEARCH INSTITUTE	5001371840		-\$47	\$2,289,840	RESEARCH AND DEVELOPMENT	\$780,703,439
MEDICAL LIBRARY ASSISTANCE	93.879	1F31LM013403-01				\$46,367	\$2,289,840	RESEARCH AND DEVELOPMENT	\$780,703,439
MEDICAL LIBRARY ASSISTANCE	93.879	1-K99-LM-012926-01A1				\$78,239	\$2,289,840	RESEARCH AND DEVELOPMENT	\$780,703,439
MEDICAL LIBRARY ASSISTANCE	93.879	1-R21-LM-012763-01A1				\$84,617	\$2,289,840	RESEARCH AND DEVELOPMENT	\$780,703,439
MEDICAL LIBRARY ASSISTANCE	93.879		INDIANA UNIVERSITY	IN-4687289-UP		\$107,960	\$2,289,840	RESEARCH AND DEVELOPMENT	\$780,703,439
MEDICAL LIBRARY ASSISTANCE	93.879	1-R01-LM-013437-01				\$226,085	\$2,289,840	RESEARCH AND DEVELOPMENT	\$780,703,439
MEDICAL LIBRARY ASSISTANCE	93.879	1-R01-LM-012607-01			\$5,073	\$317,570	\$2,289,840	RESEARCH AND DEVELOPMENT	\$780,703,439
MEDICAL LIBRARY ASSISTANCE	93.879	1-R01-LM012601-01			\$49,050	\$136,008	\$2,289,840	RESEARCH AND DEVELOPMENT	\$780,703,439
MEDICAL LIBRARY ASSISTANCE	93.879	1R01LM013463-01			\$49,417	\$292,814	\$2,289,840	RESEARCH AND DEVELOPMENT	\$780,703,439
MEDICAL LIBRARY ASSISTANCE	93.879	2-R01-LM-011176-06A1			\$53,814	\$705,569	\$2,289,840	RESEARCH AND DEVELOPMENT	\$780,703,439
MEDICAL LIBRARY ASSISTANCE	93.879	2-R01-LM-010098-10			\$94,619	\$294,658	\$2,289,840	RESEARCH AND DEVELOPMENT	\$780,703,439
GRANTS FOR PRIMARY CARE TRAINING AND ENHANCEMENT	93.884	1 UH1HP29964-01-00				-\$1,346	\$663,750	RESEARCH AND DEVELOPMENT	\$780,703,439
GRANTS FOR PRIMARY CARE TRAINING AND ENHANCEMENT	93.884		MAYO CLINIC ROCHESTER	THE-268163/PO #67322769		\$104,355	\$663,750	RESEARCH AND DEVELOPMENT	\$780,703,439
GRANTS FOR PRIMARY CARE TRAINING AND ENHANCEMENT	93.884	1 T13HP32112-01-00			\$61,600	\$560,741	\$663,750	RESEARCH AND DEVELOPMENT	\$780,703,439
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720667/R7731		-\$1,010	\$1,314,872	OTHER PROGRAMS	\$233,218,639
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	2120575-00		\$23,626	\$1,314,872	OTHER PROGRAMS	\$233,218,639
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	2120578-00		\$35,200	\$1,314,872	OTHER PROGRAMS	\$233,218,639
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720665-03		\$38,161	\$1,314,872	OTHER PROGRAMS	\$233,218,639
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	2120578-00		\$46,365	\$1,314,872	OTHER PROGRAMS	\$233,218,639
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720666-03		\$67,874	\$1,314,872	OTHER PROGRAMS	\$233,218,639
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	RW1731/2120588		\$79,078	\$1,314,872	OTHER PROGRAMS	\$233,218,639
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	2120578-00		\$84,991	\$1,314,872	OTHER PROGRAMS	\$233,218,639
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720668-03		\$94,076	\$1,314,872	OTHER PROGRAMS	\$233,218,639
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720666-03		\$94,334	\$1,314,872	OTHER PROGRAMS	\$233,218,639
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	2120589-00		\$152,366	\$1,314,872	OTHER PROGRAMS	\$233,218,639
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720666-03		\$197,839	\$1,314,872	OTHER PROGRAMS	\$233,218,639
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720668-03		\$199,164	\$1,314,872	OTHER PROGRAMS	\$233,218,639
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720667-03		\$202,808	\$1,314,872	OTHER PROGRAMS	\$233,218,639
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918		DREXEL UNIVERSITY	800100		\$37,795	\$572,284	OTHER PROGRAMS	\$233,218,639
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	H7CHA37319				\$51,348	\$572,284	OTHER PROGRAMS	\$233,218,639
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918		CITY OF PHILADELPHIA	1820058-03		\$75,000	\$572,284	OTHER PROGRAMS	\$233,218,639
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	H76HA00556				\$408,141	\$572,284	OTHER PROGRAMS	\$233,218,639
COOPERATIVE AGREEMENTS FOR STATE-BASED COMPREHENSIVE BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAMS	93.919		FAMILY HEALTH COUNCIL OF CENTRAL PA	4100066441		\$95,373	\$95,373	OTHER PROGRAMS	\$233,218,639
RYAN WHITE HIV/AIDS DENTAL REIMBURSEMENT AND COMMUNITY BASED DENTAL PARTNERSHIP GRANTS	93.924	1 T22HA39649-01-00				\$4,592	\$4,592	RESEARCH AND DEVELOPMENT	\$780,703,439
HIV EMERGENCY RELIEF PROJECT GRANTS	93.940		CITY OF PHILADELPHIA	1820469-02		\$35,261	\$71,125	OTHER PROGRAMS	\$233,218,639
HIV EMERGENCY RELIEF PROJECT GRANTS	93.940		CITY OF PHILADELPHIA	1820469-03		\$35,864	\$71,125	OTHER PROGRAMS	\$233,218,639
ASSISTANCE PROGRAMS FOR CHRONIC DISEASE PREVENTION AND CONTROL	93.945		CROHN'S & COLITIS FOUNDATION OF AMERICA	SUB TO 1-U01-DP-006369-01-00		\$329,222	\$329,222	RESEARCH AND DEVELOPMENT	\$780,703,439
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958		CITY OF PHILADELPHIA	PAC 0100-0294		\$998	\$1,338,023	OTHER PROGRAMS	\$233,218,639
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958		CITY OF PHILADELPHIA	SAMHSA-PERC-FEP		\$222,652	\$1,338,023	OTHER PROGRAMS	\$233,218,639
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958		ADAMS COUNTY, PENNSYLVANIA	SUB TO SAMHSA		\$351,329	\$1,338,023	OTHER PROGRAMS	\$233,218,639
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958		ADAMS COUNTY, PENNSYLVANIA	SUB TO SAMHSA ADV ACCT		\$763,044	\$1,338,023	OTHER PROGRAMS	\$233,218,639

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned by Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
PPHF GERIATRIC EDUCATION CENTERS	93.969	1 U10HP282720-01-00				\$11,690	\$11,690	OTHER PROGRAMS	\$233,218,639
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1-R21-TW-010837-01				\$564	\$882,596	RESEARCH AND DEVELOPMENT	\$780,703,439
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		DUKE UNIVERSITY	3880535		\$10,787	\$882,596	RESEARCH AND DEVELOPMENT	\$780,703,439
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1-D43-TW-011809-01				\$12,346	\$882,596	RESEARCH AND DEVELOPMENT	\$780,703,439
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.	149265		\$14,040	\$882,596	RESEARCH AND DEVELOPMENT	\$780,703,439
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	122725C		\$29,162	\$882,596	RESEARCH AND DEVELOPMENT	\$780,703,439
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		NEW YORK UNIVERSITY	1-R21-TW-011084-01		\$39,570	\$882,596	RESEARCH AND DEVELOPMENT	\$780,703,439
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1-K01-TW-011481-01				\$49,091	\$882,596	RESEARCH AND DEVELOPMENT	\$780,703,439
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1-R21-TW-011496-01A1				\$52,750	\$882,596	RESEARCH AND DEVELOPMENT	\$780,703,439
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		DARTMOUTH-HITCHCOCK MEDICAL CENTER	GC10054-00-02		\$54,742	\$882,596	RESEARCH AND DEVELOPMENT	\$780,703,439
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1-D43-TW-009781-01				\$77,536	\$882,596	RESEARCH AND DEVELOPMENT	\$780,703,439
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1-K01-TW-011190-01A1				\$105,579	\$882,596	RESEARCH AND DEVELOPMENT	\$780,703,439
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1-D43-TW-010448-01				\$13,206	\$882,596	RESEARCH AND DEVELOPMENT	\$780,703,439
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1R21TW011260-01				\$114,894	\$882,596	RESEARCH AND DEVELOPMENT	\$780,703,439
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994		COMMONWEALTH OF PENNSYLVANIA	4100065681		\$174,898	\$423,728	OTHER PROGRAMS	\$233,218,639
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994		PENNSYLVANIA DEPARTMENT OF HEALTH	4100085650	\$72,637	\$248,830	\$423,728	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA FOR WILLIAM LA CAVA	93.RD	IPA AGREEMENT				-\$1,492	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
EVALUATION OF SDG AS COUNTERMEASURE TO RADIATION-INDUCED LUNG DAMAGE	93.RD	HHSN27220150000	LIGNAMED	LGM-2605		\$434	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - REDUCING WEIGHT STIGMA TO IMPROVE LONG-TERM WEIGHT LOSS	93.RD	(BLANK)	UNIVERSITY OF FLORIDA	SUB TO K23-HL-140176-04 ADV ACCT		\$536	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
KENTUCKY HEALTH ANALYSIS	93.RD	FAP111-44-00	COMMONWEALTH OF KENTUCKY	FAP111-44-00		\$657	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
UPCC35419: CLINICAL TRANSPLANT-RELATED LONG-TERM OUTCOMES OF ALTERNATE	93.RD	(BLANK)	TRANSPLANTATION CLINICAL TRIALS NETWORK	PROTOCOL RIDER #1702		\$1,349	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
SECURE DATA MANAGEMENT SYSTEM TO FACILITATE PROSPECTIVE FOLLOW UP OF P	93.RD	HHSN261201400010/HHSN26100006	SOCIAL & SCIENTIFIC SYSTEMS, INC.	PHR-SSS-S-16-004996		\$2,013	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - SECONDARY INFECTIONS AND ANTIBIOTIC RESISTANCE IN POST-ACUTE CARE PATI	93.RD	75D30121C10180				\$3,185	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
GLOBAL INVESTIGATION OF CELL TRAJECTORY AND LINEAGE RELATIONSHIPS IN T	93.RD	R00HD098298				\$3,962	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
CIRCULATING ANTIBODIES TO ORAL MICROBIOTA AND COLON CANCER RISK	93.RD	(BLANK)	TUFTS UNIVERSITY	N/A		\$6,442	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - RAPID AND ULTRA-SENSITIVE SARS-COV-2 ANTIGEN DETECTION FOR ACUTE INFECTION	93.RD	75N92021P00053				\$6,899	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
REDUCING WEIGHT STIGMA TO IMPROVE LONG-TERM WEIGHT LOSS	93.RD	(BLANK)	UNIVERSITY OF FLORIDA	SUB TO K23-HL-140176-04 ADV ACCT		\$7,461	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
ASSESSING AND TRAINING EVERYDAY FUNCTION IN OLDER ADULTS WITH THE VIRT	93.RD	(BLANK)	TEMPLE UNIVERSITY	SUB TO NIH ADV ACCT		\$8,163	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
IPA ASSIGNMENT AGREEMENT	93.RD	IPA AGREEMENT				\$9,162	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
SAFETY AND FEASIBILITY OF CULTIVATED AUTOLOGOUS LIMBAL EPITHELIAL CELL	93.RD	(BLANK)	JAEB CENTER FOR HEALTH RESEARCH	CALEC		\$9,720	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
REGULATION OF AXON GUIDANCE RECEPTOR TRAFFICKING IN THE DEVELOPING MAM	93.RD	R01HD105946				\$9,789	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
TASK ORDER 1 - CONTRACEPTIVE DEVELOPMENT PROGRAM NICHD CONTRACEPTIVE C	93.RD	75N94020D000005				\$10,004	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
BRAIN-ENRICHED MICRORNAS DETECTABLE IN PLASMA AS BIOMARKERS OF ALZHEIM	93.RD	(BLANK)	DIAMIR, LLC	SUB TO NIH ADV ACCT		\$10,100	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
UTILIZATION OF DATA INDICATORS IN THE ESRD SURVEY PROCESS	93.RD	HHSN-500-2016-00085C	UNIVERSITY OF MICHIGAN CASE WESTERN RESERVE UNIVERSITY	SUBK00011951		\$10,533	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
SYSTOLIC BLOOD PRESSURE INTERVENTION TRIAL (SPRINT) DEVELOPMENTAL ORIGIN, INJURY AND EPIGENOMIC REGULATION OF NF1-ASSOCIAT	93.RD	HHSN268200900049C				\$12,917	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - A TEMPORAL CHARACTERIZATION OF SECRETORY POPULATIONS IN THE DEVELOPING	93.RD	(BLANK)	CHILDREN'S RESEARCH INSTITUTE CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	SUB TO NIH ADV ACCT		\$14,011	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - CIVICS COMPONENT A	93.RD	75N93019C00050	DUKE UNIVERSITY	OS0002265 / PROJECT #311013 A032640		\$14,150	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
FLEXIBLE HYBRID CLOUD INFRASTRUCTURE FOR SEAMLESS MANAGEMENT OF HUBMAP	93.RD	(BLANK)	CARNEGIE MELLON UNIVERSITY	ADVANCE ACCOUNT		\$15,000	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
HEALTH AND FINANCIAL IMPLICATIONS OF EARLY-STAGE ALZHEIMER'S DISEASE A	93.RD	(BLANK)	UNIVERSITY OF COLORADO DENVER UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	SUB TO 1RF1AG069922-01		\$15,521	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
THE IMPACT OF DIABETES ON PATIENTS WITH GLOMERULAR DISEASE: CUREGN-DIA	93.RD	(BLANK)	QUANTITATIVE RADIOLOGY SOLUTIONS, LLC	SUB TO R01DK126959		\$16,809	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
DEVELOPMENT OF A PROTOTYPE SOFTWARE FOR AUTOMATED PET/CT INTERPRETATION	93.RD	CA236492				\$17,312	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
EPIGENETIC MECHANISMS OF DRUG RESISTANCE IN RENAL CELL CARCINOMA	93.RD	(BLANK)	UNIVERSITY OF BUFFALO	SUB TO 7R01CA224342-04		\$17,318	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - A MULTICENTER, ADAPTIVE, RANDOMIZED CONTROLLED PLATFORM TRIAL OF THE S	93.RD	0T2HL156812	BLOODCENTER OF WISCONSIN, INC.	SUB TO 0T2HL156812 T051 / SUB TO HHSN-275201000003I		\$18,263	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
PK AND SAFETY OF COMMONLY USED DRUGS IN LACTATING WOMEN AND BREASTFED	93.RD	HHSN-275201000003I	DUKE UNIVERSITY			\$19,215	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned by Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
TREATMENT FOR MIXED URINARY INCONTINENCE: MID-URETHRAL SLING VS. BOTOX	93.RD	U24HD069031	RESEARCH TRIANGLE INSTITUTE	0213574/0213581		\$24,246	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - RAPID AND ULTRA-SENSITIVE SARS-COV-2 ANTIGEN DETECTION FOR ACUTE INFECTION	93.RD	(BLANK)	VENTUREWELL	SARS-COV-2		\$25,000	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - WHOLE-GENOME SEQUENCING TO DEFINE SARS-COV-2 VARIANT POPULATIONS DURING	93.RD	75D30121C10986	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	112106011-7856437		\$28,694	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
PAN-INFLUENZA MRNA VACCINE	93.RD	HHSN272201400006C	UNIVERSITY OF CALIFORNIA, LOS ANGELES	SUB TO 2UM1A1068636		\$29,477	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
POPULATION HEALTH RESEARCH SUPPORT - STUDY OF PREGNANCY AND NEONATAL HEALTH	93.RD	HHSN2752018000121	UNIVERSITY OF CALIFORNIA, LOS ANGELES	SUB TO 2UM1A1068636		\$34,916	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
AIDS CLINICAL TRIALS GROUP (ACTG) LEADERSHIP AND OPERATIONS CENTER (CU)	93.RD	(BLANK)	UNIVERSITY OF CALIFORNIA, LOS ANGELES	SUB TO 2UM1A1068636		\$36,218	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
AGENCY FOR HEALTHCARE RESEARCH AND QUALITY (AHRQ) REQUEST FOR PROPOSAL	93.RD	HHS290201500051	ECRI	SUB TO HHS290201500051		\$36,319	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
EVALUATE THE SAFETY AND QUALITY OF A 3D PRINTED, SINGLE-USE BIOREACTOR	93.RD	75F40119C10158	SOUTHWEST RESEARCH INSTITUTE JAEB CENTER FOR HEALTH RESEARCH	N99005VE2		\$40,076	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
CONTRACTOR SERVICES - FEDERAL	93.RD	N/A	RESEARCH	N/A		\$40,083	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
CENTER FOR ADVANCED METABOLIC IMAGING IN PRECISION MEDICINE (CAMIPM)	93.RD	1-P41-EB-029460-01A1				\$42,977	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
S. AUREUS STRAIN-LEVEL DIVERSITY IN DIABETIC WOUND NEUTROPHIL PHENOTYP	93.RD	(BLANK)	AUGUSTA UNIVERSITY CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)	SUB TO NIH ADV ACCT		\$48,930	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
BACTERIAL INTERFERENCE TO PREVENT STAPHYLOCOCCUS AUREUS INFECTION	93.RD	(BLANK)	PHILADELPHIA (CHOP)	3201270822		\$53,177	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
NIAD CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE	93.RD	75N93021C00015	WASHINGTON UNIVERSITY IN ST. LOUIS	ADVANCE ACCOUNT		\$55,396	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
CAREGIVER SPEAKS: A TECHNOLOGICALLY MEDIATED STORYTELLING INTERVENTION	93.RD	(BLANK)	WASHINGTON UNIVERSITY IN ST. LOUIS	ADVANCE ACCOUNT		\$60,933	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
CLINICAL EVALUATION OF NOVEL PRODUCTS FOR FEMALE CONTRACEPTION (MAIN S)	93.RD	HHSN2752013000201				\$62,949	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
PEDIATRIC SCIENTIST DEVELOPMENT PROGRAM DEVELOPING AN INTERACTIVE BIOINFORMATIC DATA VISUALIZATION PLATFORM	93.RD	K12HD000850	WEILL CORNELL MEDICAL COLLEGE	SUB TO 7K12HD000850-37		\$74,112	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
DEFINING THE CELLULAR CHANGES THAT OCCUR IN CHRONIC OBSTRUCTIVE PULMON	93.RD	(BLANK)	UNIVERSITY OF MARYLAND	SUB TO U24HL134763		\$77,795	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
AIDS MALIGNANCY CONSORTIUM CLINICAL STUDY (AMC)	93.RD	(BLANK)	UNIVERSITY OF MARYLAND	SUB TO U24HL134763		\$80,692	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - MFMU MATERNAL MORBIDITY AND MORTALITY DURING THE COVID-19 PANDEMIC	93.RD	(BLANK)	EMMES CORPORATION	SUB TO UM1CA121947		\$81,000	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
K12 INTERDISCIPLINARY ENGINEERING CAREER DEVELOPMENT CENTER IN MOVEMENT	93.RD	(BLANK)	GEORGE WASHINGTON UNIVERSITY	21050		\$88,042	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
CONTINUED ASSESSMENT OF THE EFFICACY OF CHRONIC OPIOID PAIN TREATMENTS	93.RD	(BLANK)	NORTHWESTERN UNIVERSITY	SUB TO K12 ADV ACCT		\$92,294	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
THE "DYNAMICS OF THE IMMUNE RESPONSES TO REPEAT INFLUENZA VACCINATION	93.RD	(BLANK)	NORTHWESTERN UNIVERSITY	SUB TO K12 ADV ACCT		\$92,294	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
ACCESS (ACCESS FOR CANCER CAREGIVERS TO EDUCATION AND SUPPORT FOR SHAR	93.RD	(BLANK)	WASHINGTON UNIVERSITY IN ST. LOUIS	ADVANCE ACCOUNT		\$114,264	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
CEIRS OPTION 16C EA "HT" (2018-20)	93.RD	HHSN272201400005C	UNIVERSITY OF ROCHESTER	417427G/UR FAO GR510845		\$117,571	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
RACIAL DISPARITIES IN POLICE USE OF DEADLY FORCE AS A CAUSE OF RACIAL	93.RD	(BLANK)	MASSACHUSETTS GENERAL HOSPITAL	SUB TO R01MD014023		\$117,685	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
EVIDENCE-BASED PRACTICE CENTERS - AHRQ EPC VI IDIQ CONTRACT	93.RD	75Q80120D00002	ECRI	SUB TO 75Q80120D00002		\$125,313	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
PROMOTING AND SUPPORTING INNOVATION IN TANF DATA	93.RD	HHS233201500059I	MORC	HHS23337005T		\$137,723	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
CLINICAL AND MOLECULAR DETERMINANTS OF TRANSMISSION OF ESBLs IN THE CO	93.RD	75D30120C09499				\$153,529	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
DEVELOPING ASSAYS TO CHARACTERIZE ANTIBODIES ELICITED BY NEW UNIVERSAL	93.RD	HHSN272201400005C	UNIVERSITY OF ROCHESTER	417638G/UR FAO GR510969		\$153,724	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
CLINICAL EVALUATION OF NESTORONE (NES) AND TESTOSTERONE (T) COMBINATIO	93.RD	HHSN275201300025I/HHSN27500006	UNIVERSITY OF WASHINGTON	UWSC11767		\$159,738	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - MEDICAL IMAGING AND DATA CONSORTIUM: RAPID RESPONSE TO COVID-19 PANDEMIC	93.RD	75N92020D00018	UNIVERSITY OF CHICAGO	AWD101462-0		\$197,855	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
CEIRS OPTION 12 (2018-19)	93.RD	HHSN272201400005C	UNIVERSITY OF ROCHESTER	417427G/UR FAD GR510845		\$221,564	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
CEIRS OPTION 16C EA "HSH7" (2018-20)	93.RD	HHSN272201400005C	UNIVERSITY OF ROCHESTER	417428G/GR510848		\$238,786	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - A MULTICENTER, ADAPTIVE, RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SA	93.RD	75N911019D00024	LEIDOS BIOMEDICAL RESEARCH, INC	20CTA-DM0009		\$318,140	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
QUANTITATIVE ANALYSIS OF LONGITUDINAL MR IMAGES IN BLSA PARTICIPANTS	93.RD	75N95019C00022				\$356,744	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - RAPID VALIDATION AND BEHAVIORAL ECONOMICS TO INCREASE ENROLLMENT AND E	93.RD	6 NUS0CK000527-01-05	PENNSYLVANIA DEPARTMENT OF HEALTH	4400016165		\$428,559	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
A SCALABLE, PATIENT-CENTERED APPROACH FOR "RIGHT-SIZING" OPIOID PRESCR	93.RD	HHSF223201810209C				\$645,341	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
ASSESSMENT OF THE EFFICACY OF ACUTE PAIN TREATMENTS: AN RTC RE-ANALYSI	93.RD	75F40119C10099				\$684,792	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
PRECLINICAL VECTOR PRODUCTION CORE LABORATORY	93.RD	75N92019D00016				\$2,013,023	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
CIVICS COMPONENT A	93.RD	75N93019C00050	DUKE UNIVERSITY	A032640		\$2,030,985	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES	93.RD	HHSN275201300020I			\$4,689	\$138,492	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification (Optional)</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
INHALATION TOXICOLOGY OF CHLORINE GAS-ON-A-CHIP	93.RD	75A50120C00134			\$31,167	\$927,449	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
INTEGRATED INFORMATICS RESOURCES FOR EUKARYOTIC MICROBIAL PATHOGENS AN	93.RD	75N93019C00077			\$2,472,138	\$5,667,717	\$16,556,681	RESEARCH AND DEVELOPMENT	\$780,703,439
<i>PEDIATRIC SCIENTIST DEVELOPMENT PROGRAM</i>	93.U08	N/A	DUKE UNIVERSITY	3993131		\$39,391	\$39,391	RESEARCH AND DEVELOPMENT	\$780,703,439
COVID-19 - QUALTRICS-BASED STUDY OF EFFECT OF COVID-19	93.U11	75N92E20P00102				\$12,994	\$12,994	OTHER PROGRAMS	\$233,218,639
IPA ASSIGNMENT AGREEMENT	93.U15	IPA AGREEMENT				\$31,938	\$31,938	OTHER PROGRAMS	\$233,218,639
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES					\$74,478,710	\$905,394,923			
CORPORATION FOR NATIONAL AND COMMUNITY SERVICE									
<i>AMERICORPS</i>	94.006		COMMONWEALTH OF PENNSYLVANIA	4100084201		\$76,218	\$76,218	OTHER PROGRAMS	\$233,218,639
COVID-19 - VOLUNTEERS IN SERVICE TO AMERICA	94.013	18VSAPA005				\$1,469	\$769,332	OTHER PROGRAMS	\$233,218,639
VOLUNTEERS IN SERVICE TO AMERICA	94.013	18VSAPA005				\$125,595	\$769,332	OTHER PROGRAMS	\$233,218,639
VOLUNTEERS IN SERVICE TO AMERICA	94.013	18VSAPA005				\$234,135	\$769,332	OTHER PROGRAMS	\$233,218,639
VOLUNTEERS IN SERVICE TO AMERICA	94.013	18VSAPA005				\$408,133	\$769,332	OTHER PROGRAMS	\$233,218,639
<i>NEXT STEPS AMERICORPS 2020/2021</i>	94.U09	(BLANK)	COMMONWEALTH OF PENNSYLVANIA	117579-038		\$295,125	\$295,125	OTHER PROGRAMS	\$233,218,639
TOTAL CORPORATION FOR NATIONAL AND COMMUNITY SERVICE							\$1,140,675		
SOCIAL SECURITY ADMINISTRATION									
<i>SOCIAL SECURITY RESEARCH AND DEMONSTRATION</i>	96.007		UNIVERSITY OF WISCONSIN-MADISON	0000000419		\$35,482	\$71,003	RESEARCH AND DEVELOPMENT	\$780,703,439
<i>SOCIAL SECURITY RESEARCH AND DEMONSTRATION</i>	96.007		UNIVERSITY OF MICHIGAN	SUBK00011189		\$35,521	\$71,003	RESEARCH AND DEVELOPMENT	\$780,703,439
TOTAL SOCIAL SECURITY ADMINISTRATION							\$71,003		
DEPARTMENT OF HOMELAND SECURITY									
EVALUATING THE PRIVATE FLOOD INSURANCE MARKET	97.RD	HSHQDC-17-C-B0032				\$8,265	\$8,265	RESEARCH AND DEVELOPMENT	\$780,703,439
TOTAL DEPARTMENT OF HOMELAND SECURITY							\$8,265		
TOTAL EXPENDITURE OF FEDERAL AWARDS					\$93,617,810	\$1,264,816,535			

Please Note:
Italicized award lines indicate pass-through funding

University of Pennsylvania
Notes to Schedule of Expenditures of Federal Awards
June 30, 2021

1. Basis of Presentation

The Schedule of Expenditures of Federal Awards (the “Schedule”) has been prepared to present a summary of those activities of the University of Pennsylvania for the year ended June 30, 2021, which have been financed by the U.S. Government (“Federal awards”) and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance).

For purposes of the Schedule, Federal awards include all Federal assistance entered into directly between the University of Pennsylvania and the Federal government and sub-awards from non-Federal organizations made under federally sponsored agreements. Because the Schedule presents only a selected portion of the activities of the University of Pennsylvania, it is not intended to and does not present the financial position or the revenues, expenses or changes in net assets of the University of Pennsylvania.

The University applies its predetermined approved facilities and administrative rate when charging indirect costs to federal awards rather than the 10% de minimis cost rate as described in Section 200.414 of the Uniform Guidance.

Negative amounts on the schedule represent adjustments in the normal course of business to amounts reported in previous years. Assistance Listing and pass-through award numbers are present where available.

2. Federal Student Financial Assistance

The federal student loan programs included within the Student Financial Aid Cluster on the Schedule of Expenditures of Federal Awards above, with the exception of Federal Direct Loans, are administered directly by the University and balances and transactions relating to these programs are included in the University’s consolidated financial statements. Loans outstanding at the beginning of the year and loans made during the year are included in the federal expenditures presented in the Schedule. The amounts of Federal Loans outstanding as of June 30, 2021 are shown on below.

Federal Grantor/Program	Assistance Listing Number	Outstanding Balance as of 6/30/2021
Department of Education		
Perkins Loan	84.038	20,970,171
Department of Health and Human Services		
Health Professions Student Loans - Dental	93.342	9,134,134
Health Professions Student Loans - Medical	93.342	142,177
Health Professions Student Loans - Vet	93.342	2,722,008
Loans for Disadvantaged Students - Dental	93.342	2,382
Loans for Disadvantaged Students - Medical	93.342	2,394,214
Nursing Student Loan - Graduate	93.364	411,918
Nurse Faculty Loan Program	93.264	2,232,284
Nursing Student Loan - Undergraduate	93.364	3,072,593

II. Internal Control and Compliance



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

To the Trustees of the University of Pennsylvania:

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of the University of Pennsylvania ("the University"), which comprise the consolidated statement of financial position as of June 30, 2021, and the related consolidated statements of activities and of cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated September 23, 2021.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the University's internal control over financial reporting ("internal control") as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

A handwritten signature in cursive script that reads "PricewaterhouseCoopers LLP".

Philadelphia, Pennsylvania
September 23, 2021



**Report of Independent Auditors on Compliance with Requirements
That Could Have a Direct and Material Effect on Each Major Program and on Internal
Control Over Compliance in Accordance with the Uniform Guidance**

To the Trustees of the University of Pennsylvania:

Report on Compliance for Each Major Federal Program

We have audited the University of Pennsylvania’s (the “University”) compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of the University’s major federal programs for the year ended June 30, 2021. The University’s major federal programs are identified in the summary of auditor’s results section of the accompanying schedule of findings and questioned costs.

Management’s Responsibility

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

Auditors’ Responsibility

Our responsibility is to express an opinion on compliance for each of the University’s major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the University’s compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the University’s compliance.

Opinion on Each Major Federal Program

In our opinion, the University complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2021.

Other Matters

As indicated in Part I to the accompanying Schedule of Findings and Questioned Costs, we have audited the Student Financial Assistance cluster as a major program. Also, as indicated in the first paragraph of this report, we performed our audit of compliance using the compliance requirements contained in the



OMB Compliance Supplement, including those contained in Part V 5.3, Compliance Requirement N, Special Tests and Provisions, Section 10 “Gramm-Leach-Bliley Act-Student Information Security.” This section includes three suggested audit procedures with respect to verification that the institution (1) designated an individual to coordinate the information security program, (2) performed a risk assessment that addresses the three required areas in 16 CFR 314.4(b), and (3) documented a safeguard for each risk identified. Our procedures in relation to these three items were limited to inquiry of and obtaining written representation from management and obtaining and reading management’s documentation related to these three items. Our procedures did not include an analysis of the adequacy or completeness of the risk assessment performed or the safeguards for each risk identified by management.

The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with the Uniform Guidance and which are described in the accompanying schedule of findings and questioned costs as items 2021-001, 2021-002, and 2021-003. Our opinion on each major federal program is not modified with respect to these matters.

The University’s response to the noncompliance findings identified in our audit is described in the accompanying Management’s View and Corrective Action Plan. The University’s response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control over Compliance

Management of the University is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the University’s internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the University’s internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Philadelphia, Pennsylvania
March 25, 2022

III. Schedule of Findings and Questioned Costs

University of Pennsylvania
Schedule of Findings and Questioned Costs
June 30, 2021

Section I – Summary of Auditor’s Results

Consolidated Financial Statements

- (i) Type of auditor’s report issued: Unmodified
- (ii) Internal control over financial reporting:
 Material weakness(es) identified? ___ yes X no
 Significant deficiency(ies) identified that are
 not considered to be material weaknesses? ___ yes X none reported
- (iii) Noncompliance material to financial statements
 noted? ___ yes X no

Federal Awards

- (iv) Internal control over major programs:
 Material weakness(es) identified? ___ yes X no
 Significant deficiency(ies) identified that are
 not considered to be material weaknesses? ___ yes X none reported
- (v) Type of auditor’s report issued on compliance
 for major programs: Unmodified
- (vi) Any audit findings disclosed that are required
 to be reported in accordance with
 2 CFR 200.516(a)? X yes ___ no
- (vii) Identification of major programs:

Assistance Listing Number(s)	Name of Federal Program or Cluster
Various	Student Financial Assistance Cluster
93.498	COVID-19 Provider Relief Fund
93.461	COVID-19 HRSA COVID-19 Uninsured Program
Various	TRIO Cluster

- (viii) Dollar threshold used to distinguish between
 Type A and Type B programs: \$3,794,450
- (ix) Auditee qualified as low-risk auditee? X yes ___ no

Section II – Financial Statement Findings

None noted.

University of Pennsylvania
Schedule of Findings and Questioned Costs
June 30, 2021

Section III – Federal Awards Findings and Questioned Costs

Finding 2021-001 Cash Management

Grantor: Centers for Disease Control and Prevention (CDC); Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute/NIH/DHHS; National Eye Institute/NIH/DHHS; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases/NIH/DHHS; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Dental and Craniofacial Research/NIH/DHHS; National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS; National Institute of General Medical Sciences/NIH/DHHS; National Institute of Mental Health/NIH/DHHS; National Institute of Neurological Disorders and Stroke/NIH/DHHS; National Institute on Aging/NIH/DHHS; National Science Foundation; Office of The Director, National Institutes of Health/NIH/DHHS; Department of Education Research and Development Cluster; Trio Cluster

Program:

Assistance Listing#: 47.041; 93.084; 93.121; 93.242; 93.310; 93.353; 93.395; 93.397; 93.838; 93.846; 93.847; 93.853; 93.855; 93.859; 93.865; 93.866; 93.867; 84.042; 84.044; 84.047

Title: Prevention of Disease, Disability, and Death by Infectious Diseases; Child Health and Human Development Extramural Research; 21st Century Cures Act - Beau Biden Cancer Moonshot; Cancer Treatment Research; COVID-19 - Cancer Centers Support Grants; Cancer Treatment Research; Cancer Centers Support Grants; Vision Research; Division of Lung Diseases; Allergy and Infectious Diseases Research; Arthritis, Musculoskeletal and Skin Diseases Research; Oral Diseases and Disorders Research; Diabetes, Digestive, and Kidney Diseases Extramural Research; Biomedical Research and Research Training; Mental Health Research Grants; Extramural Research Programs in the Neurosciences and Neurological Disorders; Aging Research; Engineering; COVID-19 - Engineering; Trans-NIH Research Support; TRIO - Student Support Services; TRIO - Talent Search; TRIO - Upward Bound

Award Year: 07/1/2020 – 06/30/2021

Award Number: 1933400; 1-R01-AR-076381-01A1; 1-R01-HD-102318-01; 1-R21-NS-112742-01A1; 1-R37-NS-115439-01A1; 1-U54-CA-244711-01; 1-U54-CK-000485-01; 2-R01-DE-023071-06A1; 5-P01-CA-217805-03; 5-P30-CA-016520-42; 5-R01-AG-054521-03; 5-R01-AI-091627-11; 5-R01-AI-139102-03; 5-R01-DE-027970-03; 5-R01-DK-106309-04; 5-R01-DK-107667-04; 5-R01-EY-026525-06; 5-R01-EY-027205-04; 5-R01-GM-085207-11; 5-R01-GM-137425-02; 5-R01-MH-118369-02; 5-R01-NS-113241-02; 5-R01-NS-114226-02; 5-R37-CA-215436-04; 5-U01-HL-148857-02; 5-U19-NS-110456-02; 5-U54-CA-193417-05; CMMI-1548571; P042A150394-16; 9044A160227; P047A180557; P047M180267; P047V170188; P042A200318

Passthrough number: Not Applicable

Criteria

2 CFR 200.305 (b3): Reimbursement is the preferred method when the requirements in paragraph (b) cannot be met, when the Federal awarding agency sets a specific condition per §200.207 Specific conditions, or when the non-Federal entity requests payment by reimbursement.

Per the OMB Compliance Supplement, the non-Federal entity must disburse funds for program purposes before requesting payment from the Federal awarding agency or pass-through entity.

University of Pennsylvania
Schedule of Findings and Questioned Costs
June 30, 2021

Condition

In testing compliance with the cash management compliance requirement, specifically the reimbursement-method, 65 individual expenditures were tested to compare the date the University made payment to a vendor for a selected expense transaction to the date the University requested sponsor reimbursement for the same transaction. Thirty-six instances were noted in which the University paid the vendor after requesting and receiving reimbursement from the government, as shown in the chart below.

Assistance Listing Number	Award Number	Expenditure Amount	Date of Payment to Vendor	Date of Government Reimbursement	Days Variance
93.397	5-P30-CA-016520-42	188.43	12/11/2020	12/8/2020	3
93.847	5-R01-DK-106309-04	508.35	8/28/2020	7/15/2020	44
93.847	5-R01-DK-107667-04	249.40	4/13/2021	4/7/2021	6
93.084	1-U54-CK-000485-01	318.90	3/11/2021	3/9/2021	2
47.041	CMMI-1548571	5,200.00	3/26/2021	2/22/2021	32
93.867	5-R01-EY-027205-04	100.64	5/12/2021	4/21/2021	21
93.395	5-R37-CA-215436-04	220.44	9/15/2020	9/14/2020	1
93.855	5-R01-AI-091627-11	1,361.52	2/5/2021	2/4/2021	1
93.121	5-R01-DE-027970-03	715.00	4/22/2021	3/30/2021	23
93.866	5-R01-AG-054521-03	1,200.00	3/26/2021	2/17/2021	37
93.395	5-P01-CA-217805-03	232.89	9/25/2020	9/23/2020	2
93.855	5-R01-AI-139102-03	225.13	11/25/2020	11/2/2020	23
93.859	5-R01-GM-085207-11	13,783.86	7/8/2020	6/29/2020	9
93.397	5-U54-CA-193417-05	5,014.00	3/30/2021	3/4/2021	26
47.041	1933400	149.58	4/29/2021	4/9/2021	20
93.853	5-R01-NS-113241-02	896.40	9/15/2020	8/25/2020	21
93.310	5-R01-GM-137425-02	684.06	5/7/2021	5/3/2021	4
93.353	1-U54-CA-244711-01	163.35	9/18/2020	8/25/2020	24
93.867	5-R01-EY-026525-06	241.20	1/12/2021	12/22/2020	21
93.242	5-R01-MH-118369-02	101.19	8/21/2020	8/19/2020	2
93.853	1-R37-NS-115439-01A1	231.95	4/30/2021	4/29/2021	1
93.853	1-R21-NS-112742-01A1	337.05	12/22/2020	11/18/2020	34
93.121	2-R01-DE-023071-06A1	360.05	2/26/2021	1/20/2021	37
93.838	5-U01-HL-148857-02	130.69	10/9/2020	10/8/2020	1
93.846	1-R01-AR-076381-01A1	247.00	10/15/2020	9/23/2020	22
93.853	5-R01-NS-114226-02	125.00	8/11/2020	8/3/2020	8
93.853	5-U19-NS-110456-02	344.00	9/8/2020	9/3/2020	5
93.853	5-U19-NS-110456-02	203.57	2/1/2021	1/28/2021	4
93.865	1-R01-HD-102318-01	118.31	4/16/2021	3/24/2021	23
84.042	Po42A150394-16	2,100.00	8/6/2020	7/10/2020	27
84.044	9044A160227	3,610.00	4/16/2021	3/10/2021	37
84.047	Po47A180557	224.75	5/21/2021	5/6/2021	15
84.047	Po47M180267	269.79	12/1/2020	11/6/2020	25
84.047	Po47V170188	85.30	5/4/2021	4/8/2021	26
84.044	9044A160227	1,100.00	3/16/2021	3/10/2021	6
84.042	Po42A200318	5,015.24	7/26/2021	7/1/2021	25

This is a repeat of finding 2020-001, 2019-001, 2018-002 and 2017-002 in prior year audit reports.

Cause

Management's current process to ensure that the reimbursement of expenditures occurs only after paying the vendor utilizes the assumption that vendors will be paid within 30 days, on average, of incurring the expense.

University of Pennsylvania
Schedule of Findings and Questioned Costs
June 30, 2021

Effect

The University received Federal reimbursement prior to paying the vendors for the selected expenses. The reliance of the 30 day average time-frame allowed certain expenditures to be included in requests for reimbursement prior to being liquidated.

Questioned Costs

None as reimbursement was requested for allowable costs.

Recommendation

The University should revisit existing internal control procedures to ensure expenditures are paid in compliance with the Federal reimbursement requirements. We also recommend management discuss current cash management requirements with the OMB and the University's cognizant agency to determine a solution that meets the needs of both parties.

Management's View and Corrective Action Plan

Following these findings are management's view and corrective action plan.

University of Pennsylvania
Schedule of Findings and Questioned Costs
June 30, 2021

Finding 2021-002 Enrollment Reporting

Grantor: Department of Education
Program: Student Financial Assistance Cluster
Assistance listing#: 84.063, 84.268
Title: Federal Pell Grant, Federal Direct Loans
Award Year: 07/1/2020 – 06/30/2021
Award Number: P063P202158, P063P20192158
Passthrough number: Not Applicable

Criteria

National Student Loan Data System (NSLDS) Enrollment Reporting Guide 1.1 – The collection of enrollment data is essential to the Department for many reasons:

- It protects the rights of borrowers by ensuring that loan interest subsidies are based on accurate enrollment data.
- It ensures loan repayment dates are accurately based on the last date of attendance.
- It allows in-school deferments to be automatically granted using NSLDS enrollment data.
- It provides vast amounts of critical data about the effectiveness of Title IV aid programs, including completion data.

NSLDS Enrollment Reporting Guide 1.4 – At a minimum, schools are required to certify enrollment every 60 days, and respond within 15 days of the date that NSLDS sends a Roster file to the school or its third-party servicer.

34 CFR 685.309(b) - Unless it expects to submit its next updated enrollment report to the Secretary within the next 60 days, a school must notify the Secretary within 30 days after the date the school discovers that a loan under Title IV of the Act was made to or on behalf of a student who was enrolled or accepted for enrollment at the school, and the student has ceased to be enrolled on at least a half-time basis or failed to enroll on at least a half-time basis for the period for which the loan was intended.

NSLDS Enrollment Reporting Guide 4.3 – As noted previously, there are two categories of enrollment information: “Campus Level” and “Program-Level”, both of which need to be reported and have separate record types.

NSLDS Enrollment Reporting Guide 4.4.3 – It is important to note that, for a student who has graduated, schools who initially report a withdrawn status must subsequently report the student as having graduated by certifying a ‘G’ status at the Campus-Level and/or Program-Level as appropriate. This is true even if the student or the student’s applicable program no longer appears on the school’s Enrollment Reporting Roster because the school has certified the ‘W’ status twice. In this case, the school must add the student and/or program back to the Roster to report the ‘G’. The graduated status may protect the interest subsidy on the student’s current loans.

Condition

Of 25 students selected with changes in enrollment status, two changes in enrollment status were reported to the NSLDS more than 60 days after the student left the University. Additionally, information for 4 students included separation date, campus level, or program level information reported to the third-party service provider and NSLDS that did not agree to the student file. The correct enrollment information was sent to the third-party service provider and NSLDS upon discovery of the errors during the audit.

University of Pennsylvania
Schedule of Findings and Questioned Costs
June 30, 2021

Finding	# of Students	Federal Financial Aid Funds	Exception Noted
1	2	Pell Grant	A
2	1	Direct Loan	B
3	1	Pell Grant	C
4	1	Direct Loan	B
5	1	Direct Loan	B, D

- A** Separation status not reported within 60-day timeframe
- B** Separation start date incorrect
- C** Program-level reporting not updated appropriately
- D** Campus-level status incorrect

Cause

The University’s monitoring process over information reported to the third-party service provider and NSLDS did not ensure the information was transferred timely and agreed to student file information, as is required by the criteria cited above.

Effect

The changes in enrollment status were not reported correctly or timely to the third-party service provider and NSLDS, as required by the criteria cited above.

Questioned Costs

None.

Recommendation

Management should enhance their monitoring controls over student enrollment status changes to ensure that enrollment information is accurate and agrees to student files prior to providing to the third-party servicer and NSLDS. These controls should include ensuring the student information system is properly capturing changes to be sent to NSLDS. Additionally, a detailed review of enrollment changes should occur prior to submission to the third-party service provided and NSLDS to ensure accuracy of the information transmitted.

Management’s View and Corrective Action Plan

Following these findings are management’s view and corrective action plan.

**University of Pennsylvania
Schedule of Findings and Questioned Costs
June 30, 2021**

Finding 2021-003 is an additional finding included in the report based upon the results of the audit of the University of Pennsylvania’s City of Philadelphia Awards. As this program includes Federal funding, it has also been included within this report.

2021-003 Eligibility

Grantor: Department of Health and Human Services, Pass-through City of Philadelphia, AIDS Activity Coordinating Office (AACO)

Program: Ryan White HIV/AIDS

Title: HIV Emergency Relief Project Grants

Assistance Listing #: 93.914

Award Year: 2020-2021, 2021-2022

Award Number: 1720666-03 (RWO968, RWO866, RS0944); 2120578 (RS1944, RW1968, RW1866)

Passthrough number: Not Applicable

Criteria

Per the Ryan White Client Certification Form Instructions provided to management by the AIDS Activity Coordinating Office, “The certification process must begin for all clients upon initial intake for services and final eligibility is determined once all supporting documentation has been received and verified.” Additionally, the form states copies of all documentation are to be retained by the Provider. The City of Philadelphia Audit Guide section 6130.04 provides a list of documents to be maintained and states “case management service providers are required to keep a file on each client served.”

Additionally, per the Universal Monitoring Standards set forth by the Health Resources and Services Administration (HRSA) of the Department of Health and Human Services, the Ryan White HIV/AIDS Program Part A and B Monitoring Standards require service providers who receive Ryan White funding to screen to certify their eligibility for Ryan White-funded services. The guidance states that documentation of eligibility determination is required in client records, as evidenced by copies of documents.

Condition

Health Resources and Services Administration of the Department of Health and Human Services standards require service providers who receive Ryan White funding to screen clients and collect documentation to support the patient’s eligibility for Ryan White funded services, including but not limited to an HIV positive diagnosis, identity, residency, insurance status, and income level. These requirements were sent to the University of Pennsylvania (“the University”) by the City of Philadelphia as part of its contract to provide services.

For the AACO Medical awards, 3 out of a sample of 60 patient files selected for eligibility testing did not contain sufficient evidence of income level to support the Provider’s eligibility determination.

Cause

Management retains income support for patients visiting the clinic that apply for financial assistance to cover the cost of their visit. However, the clinic also serves HIV positive patients that have their own private insurance and do not request financial assistance. For 3 samples selected for eligibility testing, management was unable to provide income support for the patients selected as all the patients were determined to be covered by private insurance. Management provided records to support the other eligibility requirements, including the HIV positive diagnosis of the patient, but was unable to provide income support relating to the eligibility requirement.

Effect

Patient care may be provided to ineligible patients.

University of Pennsylvania
Schedule of Findings and Questioned Costs
June 30, 2021

Questioned Costs

None, as a form of documentation to support eligibility was ultimately provided for each patient and payment was made through private insurance.

Recommendation

The University should ensure proper documentation is retained to support all eligibility requirements, including level of income. Management should implement a periodic review control to detect any patients who are missing eligibility documentation and obtain the missing documentation.

Management's View and Corrective Action Plan

Following these findings are management's view and corrective action plan.

University of Pennsylvania
Summary Schedule of Prior Audit Findings
June 30, 2021

Finding 2020-001 Cash Management

Grantor: National Institute of Aging, National Institute of Health (NIH), Department of Health and Human Services (DHHS); National Institute of Diabetes and Digestive and Kidney Diseases, NIH, DHHS; National Center for Advancing Translational Sciences, NIH, DHHS; National Cancer Institute, NIH, DHHS; National Science Foundation; Department of Education

Program: Research and Development Cluster

Assistance Listing#: 93.866; 93.847; 93.350; 93.397; 47.041; 84.287

Title: Coordinating Center for Genetics and Genomics of Alzheimer's Disease (CGAD); Penn integrated Human Pancreas procurement and Analysis Program; Institutional Clinical and Translational Science Award; Abramson Cancer Center Support Grant; Science and Technology Center for Mechano-Biology; Twenty-First Century Community Learning Centers

Award Year: 07/1/2020 – 06/30/2021

Award Number: 1-U54-AG-052427-01; 1-UC4-DK-112217-01; 1-UL1-TR-001879-01; 2-P30-CA-016520-40; CMMI-1548571; 4100068078; FC #4100071658; SUB TO S287C170038

Summary

Per the OMB Compliance Supplement, the non-Federal entity must disburse funds for program purposes before requesting payment from the Federal awarding agency or pass-through entity. In testing conformity with the cash management reimbursement-method, 40 individual expenditures were tested to compare the date of University payment to the vendor to the date of Government reimbursement to the University. Twenty-six instances were noted in which the University paid the vendor after requesting and receiving reimbursement from the government.

Status Update

See the current year finding and management response for additional information.

Management View and Corrective Action Plan



Office of Research Services

Management View and Corrective Action Plan

Finding 2021-001 Cash Management

Grantor: Centers for Disease Control and Prevention (CDC); Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute/NIH/DHHS; National Eye Institute/NIH/DHHS; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases/NIH/DHHS; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Dental and Craniofacial Research/NIH/DHHS; National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS; National Institute of General Medical Sciences/NIH/DHHS; National Institute of Mental Health/NIH/DHHS; National Institute of Neurological Disorders and Stroke/NIH/DHHS; National Institute on Aging/NIH/DHHS; National Science Foundation; Office of The Director, National Institutes of Health/NIH/DHHS; Department of Education Research and Development Cluster; Trio Cluster

Program:

Assistance Listing#: 47.041; 93.084; 93.121; 93.242; 93.310; 93.353; 93.395; 93.397; 93.838; 93.846; 93.847; 93.853; 93.855; 93.859; 93.865; 93.866; 93.867; 84.042; 84.044; 84.047

Title: Prevention of Disease, Disability, and Death by Infectious Diseases; Child Health and Human Development Extramural Research; 21st Century Cures Act - Beau Biden Cancer Moonshot; Cancer Treatment Research; COVID-19 - Cancer Centers Support Grants; Cancer Treatment Research; Cancer Centers Support Grants; Vision Research; Division of Lung Diseases; Allergy and Infectious Diseases Research; Arthritis, Musculoskeletal and Skin Diseases Research; Oral Diseases and Disorders Research; Diabetes, Digestive, and Kidney Diseases Extramural Research; Biomedical Research and Research Training; Mental Health Research Grants; Extramural Research Programs in the Neurosciences and Neurological Disorders; Aging Research; Engineering; COVID-19 - Engineering; Trans-NIH Research Support; TRIO - Student Support Services; TRIO - Talent Search; TRIO - Upward Bound

Award Year: 07/1/2020 – 06/30/2021

Award Number: 1933400; 1-R01-AR-076381-01A1; 1-R01-HD-102318-01; 1-R21-NS-112742-01A1; 1-R37-NS-115439-01A1; 1-U54-CA-244711-01; 1-U54-CK-000485-01; 2-R01-DE-023071-06A1; 5-P01-CA-217805-03; 5-P30-CA-016520-42; 5-R01-AG-054521-03; 5-R01-AI-091627-11; 5-R01-AI-139102-03; 5-R01-DE-027970-03; 5-R01-DK-106309-04; 5-R01-DK-107667-04; 5-R01-EY-026525-06; 5-R01-EY-027205-04; 5-R01-GM-085207-11; 5-R01-GM-137425-02; 5-R01-MH-118369-02; 5-R01-NS-113241-02; 5-R01-NS-114226-02; 5-R37-CA-215436-04; 5-U01-HL-148857-02; 5-U19-NS-110456-02; 5-U54-CA-193417-05; CMMI-1548571; P042A150394-16; 9044A160227; P047A180557; P047M180267; P047V170188; P042A200318

Passthrough number: Not Applicable

The University is currently following and believes it is in compliance with the cash management regulations as written in 2 CFR Part 200.305(b) which require the organization to minimize the time lapse between request for reimbursement from sponsoring agencies and vendor payment.

We understand that variations remain in the interpretation of the cash management compliance requirement. For example, on October 20, 2017, the Council On Governmental Relations (COGR) wrote a letter to the Office of Financial Management expressing concern that the cash management requirement language in the 2017 Compliance Supplement was not aligned with the requirements for cash management as currently written in 2 CFR Part 200.305(b). COGR's position is that the Compliance Supplement should be revised to conform with the cash management requirements as written in 2 CFR 200.305(b). The University agrees with COGR's position and believes the language in the Compliance supplement leads to an unrealistic and unreasonable administrative burden for universities and possibly a reconfiguration of smoothly running electronic process or a complete replacement of electronic processes with an inefficient, manual one in efforts to ensure each vendor has been paid prior to requesting reimbursement from the sponsoring agency.

The University will continue to monitor the OMB interpretation of the Cash Management requirements.

For FY21, which is consistent since FY17 when the finding was first identified, we note that these exceptions only relate to payables transactions. Payables account for approximately 20% of costs across all federal awards (the other 80% of costs are payroll and fringe, indirect costs, and other internal billings and journals for which cash management is not an issue). Also, the payments identified as exceptions in the audit were all made to vendors within our institutional standard terms of net 45 days.

The Office of Research Services is committed to ensuring that the federal government is not unfairly disadvantaged by our processes. To that end, we are currently exploring several possible process changes to further reduce the time lapse between request for reimbursement from sponsoring agencies and vendor payment or develop a process to mitigate the time lapse effect. Any changes will be decided upon by the end of the current fiscal year.



Elizabeth D. Peloso
Associate Vice President / Associate Vice Provost Research Services
epeloso@upenn.edu
215-898-7293



Management View and Corrective Action Plan

Finding 2021-002 Enrollment Reporting

Grantor: Department of Education
Program: Student Financial Assistance Cluster
Assistance listing#: 84.063, 84.268
Title: Federal Pell Grant, Federal Direct Loans
Award Year: 07/1/2020 – 06/30/2021
Award Number: P063P202158, P063P20192158
Passthrough Number: Not Applicable

Student Registration and Financial Services (SRFS) Management will enhance their monitoring controls over student enrollment status changes to ensure that enrollment information is accurate and agrees to student files prior to providing to the National Student Clearinghouse (NSC) (third-party servicer) and NSLDS.

We are implementing a new Student Information System. The new system will properly capture changes to be sent to NSLDS. Additionally, a detailed review of enrollment changes will take place prior to submission to the NSC (third-party servicer) and NSLDS to ensure accuracy of the information transmitted.

A handwritten signature in black ink, appearing to read "Matthew D. Sessa". The signature is written in a cursive style with a large, stylized "M" and "S".

Matthew D. Sessa

Executive Director, Student Registration and Financial Services

msessa@upenn.edu



Management View and Corrective Action Plan

Finding 2021-003 Eligibility

Grantor: Department of Health and Human Services, Pass-through City of Philadelphia, Aids Activity Coordinating Office (AACO)

Program: Ryan White HIV/AIDS

Title: HIV Emergency Relief Project Grants

Assistance Listing#: 93.914

Award Year: 2020-2021, 2021-2022

Award Number: 1720666-03 (RW0968, RW0866, RS0944); 2120578 (RS1944, RW1968, RW1866)

Passthrough Number: Not Applicable

The Ryan White clinic at the Penn Presbyterian Medical Center experienced some staff performance issues during FY21 which contributed to some patients not being assessed for RW certification. All of these patients received the medical services needed, and none were denied services despite the lack of assessment. During FY22, a new Financial Counselor was hired to do the RW certifications and the Program Manager discussed the results of the audit with the new Financial Counselor to highlight the previous staff member's past shortfalls and stress the need for the clinic to certify Ryan White patients in a timely manner.

Thomas W. Cooper
Vice President / UPHS Corporate Finance
thomas.cooper@uphs.upenn.edu
267-414-2344